0001213900-20-012538.txt : 20200515 0001213900-20-012538.hdr.sgml : 20200515 20200515143823 ACCESSION NUMBER: 0001213900-20-012538 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200515 DATE AS OF CHANGE: 20200515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMAGING DIAGNOSTIC SYSTEMS INC /FL/ CENTRAL INDEX KEY: 0000790652 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 222671269 STATE OF INCORPORATION: FL FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26028 FILM NUMBER: 20884042 BUSINESS ADDRESS: STREET 1: 1291-B NW 65TH PLACE CITY: FORT LAUDERDALE STATE: FL ZIP: 33309 BUSINESS PHONE: 954 581-9800 MAIL ADDRESS: STREET 1: 1291-B NW 65TH PLACE CITY: FORT LAUDERDALE STATE: FL ZIP: 33309 FORMER COMPANY: FORMER CONFORMED NAME: ALKAN CORP DATE OF NAME CHANGE: 19940623 10-Q 1 f10q0320_imagingdiagnos.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[Mark One]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2020

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to______

 

Commission file number: 000-26028

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

 

Florida   22-2671269
(State of
Incorporation)
  (IRS Employer
Ident. No.)
     
1291-B  NW 65th Place, Fort Lauderdale, FL   33309
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number: (954) 581-9800

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
         

  

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer        ☐ Accelerated filer        ☐ Smaller reporting company        ☒
Non-accelerated filer          ☐   Emerging growth company        ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

 

The number of shares outstanding of the issuer’s common stock as of May 15, 2020: 122,876,549 shares of common stock, no par value.

 

 

 

 

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

    Page
     
  Part I - Financial Information  
     
Item 1. Financial Statements  1
     
  Balance Sheets – March 31, 2020 (Unaudited) and June 30, 2019 1
     
  Statements of Operations – (Unaudited) Three and Nine months ended March 31, 2020 and 2019 2
     
  Statements of Changes in Stockholders’ Deficit – (Unaudited) Three and Nine months ended March 31, 2020 and 2019 3
     
  Statements of Cash Flows - (Unaudited) Nine months ended March 31, 2020 and 2019 4
     
  Notes to (Unaudited) Financial Statements 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 23
     
  Financial Condition and Results 23
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 30
     
Item 4. Controls and Procedures 31
     
  Part II - Other Information  
     
Item 1. Legal Proceedings 32
     
Item 1A. Risk Factors 32
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32
     
Item 3. Defaults Upon Senior Securities 32
     
Item 4. (Removed and Reserved) 32
     
Item 5. Other Information 32
     
Item 6. Exhibits 32
     
Signatures 33

 

i

 

 

Item 1. Financial Statements

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Balance Sheets

 

   (unaudited)     
   March 31,
2020
   June 30,
2019
 
Assets
Current assets:        
Cash  $34,743   $44,615 
Accounts receivable, related party, net of allowance   -    7,700 
Due from related party, net of allowance   -    11,965 
Employee advances   5,000    - 
Prepaid expenses   11,226    11,566 
           
Total current assets   50,969    75,846 
           
Property and equipment, net   14,876    19,391 
           
Operating lease right-of-use assets   84,906    - 
           
Total assets  $150,751   $95,237 
           
Liabilities and Stockholders’ Deficit
Current liabilities:          
Accounts payable and accrued expenses  $241,866   $34,943 
Accrued payroll taxes and penalties   314,019    314,019 
Promissory notes, related party   520,000    200,000 
Current portion of operating lease liabilities   73,978    - 
           
Total current liabilities   1,149,863    548,962 
           
Long-term liabilities          
Operating lease liabilities   11,250    - 
           
Total liabilities   1,161,113    548,962 
           
Commitment and Contingencies (Note 16)          
           
Temporary equity          
Convertible Preferred Series L   393,463    379,914 
           
Total temporary equity   393,463    379,914 
           
Stockholders’ Deficit:          
           
Preferred stock, no par, 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 shares issued and outstanding at March 31, 2020 and June 30, 2019   -    - 
Common stock, no par value, 500,000,000 authorized, 122,876,549 and 122,621,646  shares issued and outstanding March 31, 2020 and June 30, 2019, respectively   132,540,145    132,228,967 
Accumulated Deficit   (133,943,970)   (133,062,606)
           
Total stockholders’ deficit   (1,403,825)   (833,639)
           
Total liabilities and stockholders’ deficit  $150,751   $95,237 

 

See accompanying notes to the unaudited financial statements

 

1

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Statements of Operations

(unaudited)

 

   Three Months Ended   Three Months Ended   Nine Months Ended   Nine Months Ended 
   March 31, 2020   March 31, 2019   March 31, 2020   March 31, 2019 
                 
Sales, related party  $-   $12,715   $-   $161,781 
Total Revenue   -    12,715    -    161,781 
                     
Cost of Sales   -    7,442    -    72,176 
                     
Gross Profit   -    5,273    -    89,605 
                     
Operating Expenses:                    
General and administrative   46,395    110,286    214,739    407,030 
Salaries and wages   68,779    141,605    210,781    422,131 
Research and development   6,709    7,595    23,849    57,063 
Sales and marketing   19,776    225    20,081    843 
Depreciation and amortization   621    1,947    4,515    5,840 
Consulting expenses (including share-based compensation)   175,979    125,954    351,678    348,070 
                     
Total Operating Expenses   318,259    387,612    825,643    1,240,977 
                     
Operating Loss   (318,259)   (382,339)   (825,643)   (1,151,372)
                     
Other Income (expense)                    
                     
Interest income   4    77    17    99 
Other Income   -    75    -    27,943 
Interest expense   (17,112)   (14,795)   (42,189)   (31,767)
Total Other Income (Expense)   (17,108)   (14,643)   (42,172)   (3,725)
Net Loss   (335,367)   (396,982)   (867,815)   (1,155,097)
                     
Preferred Stock Dividends   (4,475)   (4,438)   (13,549)   (13,512)
Net Loss Available to Common Stockholders   (339,842)   (401,420)   (881,364)   (1,168,609)
                     
Net Loss per common share:                    
Basic and diluted  $-   $-   $(0.01)  $(0.01)
Weighted average number of common shares outstanding:                    
Basic and diluted   122,758,901    121,964,130    122,732,306    108,930,341 

 

See accompanying notes to the unaudited financial statements

 

2

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Statements of Changes in Stockholders’ Deficit

For the three and nine months ended March 31, 2020 and 2019

(unaudited)

 

   Preferred Stock   Common Stock             
   Number of       Number of       Subscription   Accumulated     
   Shares   Amount   Shares   Amount   Deposits   Deficit   Total 
                             
Balance at June 30, 2019   -   $-    122,621,646   $132,228,967   $-   $(133,062,606)  $(833,639)
                                    
Cummulative Dividend on Series L CV Preferred   -    -    -    -    -    (4,537)   (4,537)
                                    
Net loss   -    -    -    -    -    (255,040)   (255,040)
                                    
Balance at September 30, 2019   -  $-   122,621,646  $132,228,967   $-   $(133,322,183)  $(1,093,216)
                                    
Cummulative Dividend on Series L CV Preferred   -    -    -    -    -    (4,537)   (4,537)
                                    
Shares Issued for Cash   -    -    137,255    70,000    -    -    70,000 
                                    
Stock options expense   -    -    -    60,699    -    -    60,699 
                                    
Net loss   -    -    -    -    -    (277,408)   (277,408)
                                    
Balance at December 31, 2019   -   $-    122,758,901   $132,359,666   $-   $(133,604,128)  $(1,244,462)
                                    
Cummulative Dividend on Series L CV Preferred   -    -    -    -    -    (4,475)   (4,475)
                                    
Shares Issued for Cash   -    -    117,648    60,000    -    -    60,000 
                                    
Stock option expense   -    -    -    120,479    -    -    120,479 
                                    
Net loss   -    -    -    -    -    (335,367)   (335,367)
                                    
Balance at March 31, 2020   -   $-    122,876,549   $132,540,145   $-   $(133,943,970)  $(1,403,825)
                                    
Balance at June 30, 2018   591   $7,589,173    33,597,241   $125,108,179   $-   $(133,064,117)  $(366,765)
                                    
Conversion Viable Series M Cv Preferred to common stock   (591)   (5,910,000)   87,044,089    5,910,000    -    -    - 
                                    
Adjustment to correct number of common shares   -    -    (80)   -    -    -    - 
                                    
Cummulative Dividend on Series M CV Preferred   -    (1,679,173)   -    -    -    1,679,173    - 
                                    
Cummulative Dividend on Series L CV Preferred   -    -    -    -    -    (4,537)   (4,537)
                                    
Net loss   -    -    -    -    -    (401,139)   (401,139)
                                    
Balance at September 30, 2018   -   $-    120,641,250   $131,018,179   $-   $(131,790,620)  $(772,441)
                                    
Cummulative Dividend on Series L CV Preferred   -    -    -    -    -    (4,537)   (4,537)
                                    
Adjustment to correct number of common shares   -    -    6    -    -    -    - 
                                    
Shares Issued for Cash   -    -    294,117    150,000              150,000 
                                    
Subscription Deposit Received   -    -    -    -    50,000    -    50,000 
                                    
Net loss   -    -    -    -    -    (356,976)   (356,976)
                                    
Balance at December 31, 2018   -   $-   120,935,373   $131,168,179   $50,000   $(132,152,133)  $(933,954)
                                    
Cummulative Dividend on Series L CV Preferred   -    -    -    -    -    (4,438)   (4,438)
                                    
Shares Issued for Cash   -    -    1,490,195    760,000    -    -    760,000 
                                    
Subscription deposit converted to common stock   -    -    98,039    50,000    (50,000)   -    - 
                                    
Stock options expense   -    -    -    26,705    -    -    26,705 
                                    
Net loss   -    -    -    -    -    (396,982)   (396,982)
                                    
Balance at March 31, 2019   -   $-    122,523,607   $132,004,884   $-   $(132,553,553)  $(548,669)

 

See accompanying notes to the unaudited financial statements

                                                         

3

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Statements of Cash Flows

(unaudited)

 

   Nine months ended    Nine months ended 
   March 31, 2020   March 31, 2019 
         
Net loss  $(867,815)  $(1,155,097)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   4,515    5,840 
Stock option expense   181,178    26,705 
Bad debt expense   19,665    - 
           
Changes in assets and liabilities and stockholders deficit:          
(Increase) decrease in due from related party, net of allowance   -    27,153 
(Increase) decrease in employee advances   (5,000)   -  
(Increase) decrease in royalty receivable   -    21,753 
(Increase) decrease in other receivables, net of allowance   -    (11,115)
(Increase) decrease in prepaid expenses   340    (4,233)
Increase (decrease) in accounts payable and accrued expenses   206,923    (40,487)
Change in right of use asset/lease obligation, net   322    - 
Total adjustments   407,943    25,616 
           
Net cash used in operating activities   (459,872)   (1,129,481)
           
Cash flows from financing activities:          
Proceeds from promissory notes, related party   320,000    400,000 
Proceeds from issuance of common stock   130,000    960,000 
           
Net cash provided by financing activities   450,000    960,000 
           
Net decrease in cash and cash equivalents   (9,872)   (169,481)
           
Cash and cash equivalents at beginning of period   44,615    271,540 
           
Cash and cash equivalents at end of period  $34,743   $102,059 
           
Supplemental Disclosure of cash flow information:          
Cash paid for interest  $40,068   $31,767 
Cash paid for taxes  $-   $- 

 

See accompanying notes to the unaudited financial statements

 

4

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(1) ORGANIZATION AND NATURE OF BUSINESS

 

Imaging Diagnostic Systems, Inc. (the “Company” or “IDSI”) is a medical technology company that has developed a new, non-invasive CT scanner called CTLM® that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.

 

(2) GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $133,943,970, a stockholders’ deficit of $1,403,825 and a working capital deficiency of $1,098,894. For the nine months ended March 31, 2020, net loss totaled $867,815. The net cash used in operating activities for the nine months ended March 31, 2020 totaled $459,872. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon increasing sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to increase sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received from the Chinese FDA (“CFDA”) marketing clearance for the CTLM® effective November 16, 2018 to November 15, 2023, as disclosed in the Company’s Form 8-K filing on December 11, 2018. However, there can be no assurance that we will obtain U.S. Food and Drug Administration (“FDA”) marketing or other new international marketing clearances, that the CTLM® will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM® in China or elsewhere to allow us to operate profitably. If our majority shareholder Viable International Investments, LLC (“Viable”) fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company’s liquidity profile, and management’s plans in those regards are discussed in the paragraphs that follow.

 

During fiscal year 2020, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities.

 

The Company’s next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval (“PMA”) process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after achieving successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China until the third or fourth quarter of fiscal 2021. No sales in other countries are expected in the near future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance, as to which there can be no assurance.

 

In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company’s Quality Management System, we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. We will maintain our ISO 13485:2016 certification which will allow us to pursue FDA marketing clearance and the CE Mark in the future.

 

5

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(2) GOING CONCERN AND MANAGEMENT’S PLANS (Continued)

 

On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focusing on improving the technical performance and image quality of IDSI’s Computed Tomography Laser Mammography (CTLM®) breast imaging device. The details of the Agreement were disclosed on the Form 8-K filed with the SEC on October 29, 2019. As of the date of this report, Dr. Huabei Jiang has made progress on the image quality, but the efficacy of the improvements will need to be tested once the COVID-19 crisis passes.

 

The Company’s ability to continue as a going concern and its future success is dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. Due to the difficulty of raising additional capital during the current COVID-19 crisis, the Company has been taking aggressive measures to reduce its operating costs in order to preserve cash. The Company has also applied for the Paycheck Protection Program (“PPP”) and the Economic Injury Disaster Loan (“EIDL”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The Company’s ability to meet its cash flow requirements throughout fiscal 2020 and continue its development and commercialization efforts will be dependent on the length and severity of the COVID-19 crisis and the Company’s ability to secure additional funding through the CARES Act. There can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to execute its plan of operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

(a) Basis of presentation and use of estimates

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the year ended June 30, 2019, contained in our General Form for Registration of Securities of Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on September 30, 2019. The results of operations for the nine months ended March 31, 2020, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2020.

 

(b) Revenue recognition

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue

 

6

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

(c) Allowance for doubtful accounts

 

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

 

Our allowance for doubtful accounts was $19,665 as of March 31, 2020 and $0 as of June 30, 2019.

 

(d) Cash and cash equivalents

 

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2020 and June 30, 2019.

 

(e) Concentration of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. At March 31, 2020 and June 30, 2019, the Company had $0 in excess of the federally insured limit.

 

The Company did not have any revenue for the nine months ended March 31, 2020. For the nine months ended March 31, 2019, all of the revenues were from Xi’an IDI Laser Imaging Co. Ltd.

 

(f) Inventory

 

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.

 

(g) Property and equipment

 

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

 

7

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

(h) Research and development

 

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

 

(i) Net loss per share

 

The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

 

The Company had 10,882,662 and 7,717,136 options vested as of March 31, 2020 and June 30, 2019, respectively and 4,213,184 and 5,730,522 options not yet vested as of March 31, 2020 and June 30, 2019, respectively.

 

(j) Stock-based compensation

 

In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard. The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. During the nine months ended March 31, 2020, the Board granted options to purchase 2,098,188 shares with an exercise price of $.51 per share to an employee and a consultant. No stock options were granted to employees and consultants during the nine months ended March 31, 2019. Stock options are being expensed pursuant to ASC 718.

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (15) Stock Options.

 

8

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

  

(k) Long-lived assets

 

The Company relies on the guidance provided by ASC 360 (“Property, Plant & Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

 

The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2020 and 2019.

 

(l) Income taxes

 

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

 

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. 

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2016-2019 are still potentially subject to audit by the taxing authorities.

 

9

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

(m) Warranty reserve

 

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2020 or June 30, 2019.

 

(n) Impact of recently issued accounting pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 and updated in Nov 2018 ASU 2018-19, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”), which requires the immediate recognition of management’s estimates of current and expected credit losses. ASU 2016-13 is effective for fiscal years and interim reporting periods within those years beginning after December 15, 2019. Early adoption is permitted after fiscal years beginning December 15, 2018. The Company is currently evaluating the potential impact of adopting this guidance on our financial statements.

 

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted. The Company is currently assessing the impact of this standard on their financial statements.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

 

(o) Fair Value of Financial Instruments

 

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2020 and June 30, 2019, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities

 

10

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

 

(4) REVENUE

 

The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue. 

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

 

11

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(4) REVENUE (Continued)

 

Information about the Company’s net sales by reporting segment for the nine months ended March 31, 2020 and 2019 is as follows:

 

   For the nine months ended 
   March 31,   March 31, 
   2020   2019 
Sales-parts, related party  $      -   $161,781 
Net sales  $-   $161,781 

 

All sales-parts, related party are sales to a customer located in China.

 

(5) DUE FROM RELATED PARTY

 

On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi’an of China, an affiliated Company of IDSI. The agreements are a Know How Transfer Contract and a CTLM Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi’an will pay IDSI a know how transfer fee of 25% of revenue for CTLM product sales in their territory. The Company also sells inventory parts or acquires parts from third parties on behalf of Xi’an. For the nine months ended March 31, 2020 and 2019, such sales totaled $0 and $161,781, respectively. As of March 31, 2020 and June 30, 2019, the Company has receivables from related parties, net of allowance of $0 and $7,700, respectively as a result of sales of inventory parts or acquisition of parts from third parties on behalf of Xi’an. Xi’an and Viable have common ownership hence these transactions are considered related party transactions. During the three months ended March 31, 2020, the Company decided to reserve the full amount of the receivable of $7,700 due to its age as well as the current COVID-19 crisis.

 

Additionally, as of March 31, 2020 and June 30, 2019, the Company has amounts due from related parties, net of allowance of $0 and $11,965, respectively. The majority of the amount due is $11,115 due from Xi’an. This was for product that was purchased by Xi’an that IDSI paid for. Xi’an will reimburse IDSI for the amounts paid on their behalf. During the three months ended March 31, 2020, the Company decided to reserve the full amount of the amount due from related parties of $11,965 due to its age as well as the current COVID-19 crisis.

 

(6) ROYALTY RECEIVABLE

 

On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the nine months ended March 31, 2020 and 2019, there was no royalty income. As of March 31, 2020 and June 30, 2019, the Company had a royalty receivable balance of $0 and $0, respectively.

 

12

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(7) INVENTORIES

 

Inventories consisted of the following:

 

   March 31,
2020
   June 30,
2019
 
         
Raw materials consisting of purchased parts, components and supplies  $369,452   $369,747 
Work-in process including units undergoing final inspection and testing   52,500    52,500 
Finished goods   15,000    15,000 
Total Inventory  $436,952   $437,247 
Inventory Reserve   (436,952)   (437,247)
Net Inventory  $-   $- 

  

Due to the age of the inventory, lack of demand for parts and lack of sales the Company wrote off all inventory during the year ended June 30, 2017 and has booked a reserve for the entire value of its inventory as of March 31. 2020 and June 30, 2019. For the nine months ended March 31, 2020, reduction of inventory represents physical count adjustments.

 

(8) PROPERTY AND EQUIPMENT

 

The following is a summary of property and equipment, less accumulated depreciation:

 

   March 31,
2020
   June 30,
2019
   Useful life
            
Furniture and Fixtures  $261,011   $261,011   5 years
Computers and Equipment   370,704    370,704   5 years
Third Party Software   10,291    10,291   5 years
Clinical Equipment   15,000    15,000   5 years
Total Property & Equipment  $657,006   $657,006    
Less: accumulated depreciation   (642,130)   (637,615)   
Total Property & Equipment - Net  $14,876   $19,391    

 

Depreciation expense for the nine months ended March 31, 2020 and 2019 was $4,515 and $5,840 respectively.

 

13

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(9) ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

As of March 31, 2020 and June 30, 2019, accounts payable and accrued expenses totaled $241,866 and $34,943, respectively, which consists of accounts payable of $232,970 and $27,912 and other accrued expenses of $8,896 and $7,031, respectively.

 

(10) ACCRUED PAYROLL TAXES AND PENALTIES

 

As of March 31, 2020 and June 30, 2019, the Company owed the IRS $314,019 and $314,019, respectively. Accrued payroll taxes represent outstanding interest and penalties based on prior management’s failure to pay payroll taxes commencing with the quarter ending March 31, 2010. As part of new management’s restructuring plan, the Company received funds from an accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalty and interest abatement. The amount due at March 31, 2020 of $314,019 represents the interest and penalties. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,019. The Company had a telephone conference on April 18, 2019 with the office of appeals and is waiting for further communications from the appeals officer.

 

(11) PROMISSORY NOTES – RELATED PARTY

 

The following table is a summary of the outstanding note balances as of March 31, 2020 and June 30, 2019.

 

 

Noteholder

  Interest
Rate
   Maturity
Date
  March 31,
2020
   June 30,
2019
 
Related Party Notes:               
Erhfort, LLC   15%  9/30/20  $100,000   $100,000 
Erhfort, LLC   15%  9/30/20   100,000    100,000 
JM One Holdings, LLC   15%  8/31/20   20,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Total Related Party Notes          $520,000   $200,000 

 

Each of Erhfort, LLC and JM One Holdings, LLC owns Company common stock directly or indirectly. Hence these debts are considered related party debt.

 

14

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(11) PROMISSORY NOTES – RELATED PARTY (Continued)

 

During the nine months ended March 31, 2020, the Company received loan proceeds of $300,000 from Erhfort, LLC and $20,000 from JM One Holdings, LLC, both of which are related parties. The loans from Erhfort have an annual interest rate of 15% and interest is being accrued and paid monthly. The loan from JM One Holdings, LLC will accrue interest monthly at an annual rate of 15%, but interest will not be paid until maturity. The maturity dates for all loans with original maturity dates prior to September 30, 2020 from Erhfort were extended to September 30, 2020.

 

(12) LEASES

 

In February 2016, the FASB issued Accounting Standards Update 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires lessees to recognize a right-of-use (ROU) asset and lease liability in the balance sheet for all leases, including operating leases, with terms of more than twelve months. Recognition, measurement, and presentation of expenses and cash flows from a lease by a lessee have not significantly changed from previous guidance. The amendments also require qualitative disclosures along with specific quantitative disclosures. We adopted this guidance using the cumulative-effect adjustment method on July 1, 2019, meaning we did not restate prior periods. Current year financial information is presented under the guidance in topic 842, while prior year information will continue to be presented under Topic 840. Adoption of the standard resulted in the recognition of an operating ROU asset and lease liability of approximately $147,000.

 

We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our balance sheets.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, we apply a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

 

15

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(12) LEASES (Continued)

 

Our leases have remaining lease terms of 9 to 22 months as of March 31, 2020.

 

The components of lease expense were as follows:

 

   Nine Months Ended 
   March 31,
2020
 
Operating lease expense  $76,662 
Total lease expense  $76,662 

 

Supplemental cash flow information related to leases was as follows:

 

   Nine Months Ended 
   March 31,
2020
 
Cash paid for amounts included in measurement of lease liabilities    
Operating cash flows from operating leases  $76,339 
      
Right-of-use assets obtained in exchange for new lease obligation     
Operating leases  $147,291 

 

Supplemental balance sheet information related to leases was as follows:

 

   March 31,
2020
 
Operating leases    
Operating lease right-of-use assets  $84,906 
      
Current portion of operating lease liability   73,978 
Operating lease liability, net of current portion   11,250 
Total operating lease liability  $85,228 
      
      
Weighted Average Remaining Lease Term     
Operating leases   1.04 Years 
      
Weighted Average Discount Rate     
Operating leases   15%

 

16

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(12) LEASES (Continued)

 

As of March 31, 2020, maturities of lease liabilities were as follows:

 

   Operating 
Years Ended June 30,  Leases 
2020  $25,661 
2021   58,546 
2022   8,427 
Total minimum lease payments   92,634 
Less: amounts representing interest   (7,406)
Present value of capital lease liabilities  $

85,228

 

 

(13) CONVERTIBLE PREFERRED STOCK

 

The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of March 31, 2020:

 

 

Security

  Date Issued  No. of Shares   Amount   Date of Conversion  No. of Shares Converted   Amount Converted  

Balance

3/31/2020

 
Series M Cv Pfd  8/1/2014   250   $2,500,000   4/18/2017   6   $60,000      
                11/21/2017   3    30,000      
                8/7/2018   241    2,410,000      
Series M Cv Pfd  8/31/2015   200    2,000,000   8/7/2018   200    2,000,000      
Series M Cv Pfd  4/22/2016   150    1,500,000   8/7/2018   150    1,500,000      
Total Series M Cv Pfd      600   $6,000,000       600   $6,000,000   $-0-
Dividends                             -0-
                Total redemption value        $0-
                                
Series L Cv Pfd  2/10/2010   35   $350,000   1/6/2011   15   $150,000   $200,000 
Dividends                             193,463 
                Total redemption value        $393,463 

 

Series L Convertible Preferred Stock

 

On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. At March 31, 2020 and June 30, 2019, the balance of cumulative dividends owed to the investor which is included in redemption value was $193,463 and $179,914, respectively. The total presented on the balance sheet as temporary equity is $393,463 as of March 31, 2020 and $379,914 as of June 30, 2019.

 

17

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(13) CONVERTIBLE PREFERRED STOCK (Continued)

 

Series M Convertible Preferred Stock

 

The Company, during the fiscal year ending June 30, 2015, sold Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, (“Viable”). Each share of the Series M Preferred Stock was convertible into 147,283 shares of Common Stock. In the event of a liquidation, the holders of the Series M Preferred Stock would have been entitled to receive, prior to any distribution of assets to holders of Common Stock or other class of capital stock or other equity securities of the Corporation, $10,000 per share of Series M Preferred Stock held plus accrued but unpaid dividends. The holders of the Series M Preferred Stock would have had identical voting rights as any holder of Common Stock and would have voted together, not as separate classes. The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. The first tranche of the private placement sale of 250 shares of convertible preferred stock was made pursuant to a Securities Purchase Agreement (the “Agreement”) dated June 27, 2014 between the Company and Viable. The Agreement stipulated the payment of a $100,000 non-refundable deposit which was paid on June 27, 2014 and applied to the purchase price on the first closing date, August 4, 2014. At the first closing, $2,400,000 was paid by Viable to purchase 250 shares of convertible preferred stock which provided a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. Because of delays in restructuring the Company and executing its business plan, Viable was unable to convert its Series M Convertible Preferred Stock into Common Stock according to its timeline. On June 1, 2016, Viable presented the Company with a waiver that permanently waived its rights under Section 3 – Redemption at Holder’s Option of the Certificate of Designations of the Series M Preferred Stock. Therefore, the Company reclassified the Series M Preferred Shares to permanent equity from temporary equity on June 1, 2016.

 

Viable, at its option, deviated from the stipulated payment schedules and purchased 200 Series M shares for $2,000,000 on August 31, 2015, and 150 Series M shares for $1,500,000 on April 22, 2016, which completed all of the payments required pursuant to the Agreement. The Series M dividends were payable at the Company’s option in cash or common stock. Accordingly, after the reclassification of Series M from temporary equity to permeant equity the Company has continued to accrue the dividend as a charge to retained earnings and a credit to preferred stock Series M in permanent equity. Upon conversion of the remaining 591 Series M shares to common stock on August 7, 2018, the accrued dividends were forfeited and reversed to retained earnings as the Company does not have any further obligations for payment of such accrued dividends.

 

On November 21, 2017, Viable exercised its right to convert three shares of its Series M Convertible Preferred Stock valued at $30,000 into 441,848 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 392,157 restricted common shares to three accredited investors in China and retained 49,691 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restrictive legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restrictive legend pursuant to Rule 144.

 

On April 18, 2017, Viable exercised its right to convert six shares of its Series M Convertible Preferred Stock valued at $60,000 into 883,696 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 872,787 restricted common shares to three accredited investors in China and retained 10,909 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restricted legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restricted legend pursuant to Rule 144.

 

On August 7, 2018, Viable converted its remaining 591 shares Series M Convertible Preferred Stock into 87,044,089 shares of restricted common stock.

 

18

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(14) COMMON STOCK

 

The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of no par preferred shares authorized.

 

During the nine months ended March 31, 2020, the Company issued 254,903 shares of its common stock to non-affiliated accredited investors pursuant to subscription agreements for $130,000. The price per share was approximately $.51 per share.

 

During the nine months ended March 31, 2019, the Company issued 87,044,089 shares of its common stock as Viable exercised its right to convert the remaining 591 shares of its Series M Convertible Preferred Stock valued at $5,910,000 into 87,044,089 shares of restricted common stock on August 7, 2018. The Company also issued 1,882,351 shares of its common stock to non-affiliated accredited investors pursuant to subscription agreements for $960,000. The price per share was approximately $.51 per share.

 

(15) STOCK OPTIONS

 

On December 4, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

 

On January 1, 2017, the Board granted options to purchase a total of 7,364,136 shares, all with an exercise price and fair value of $0.20 per share. Options were granted to nine employees to purchase 5,498,555 shares and to six consultants to purchase 1,865,581 shares. On January 1, 2018, the Board granted options to purchase 5,000,000 shares all with an exercise price and fair value of $0.20 per share to four consultants. On May 1, 2018, the Board granted an option to purchase 500,000 shares with an exercise price and fair value of $0.20 per share to an additional consultant. On January 1, 2019, the Board granted options to purchase 2,040,000 shares all with an exercise price of $.20 and fair value of $.51 per share to five consultants. On May 1, 2019, the Board granted an option to purchase 360,000 shares with an exercise price of $.20 and fair value of $.51 per share to a consultant. On November 1, 2019, the Board granted an option to purchase 2,000,000 shares with an exercise price of $.51 and fair value of $.51 per share to a consultant. On March 1, 2020, the Board granted an option to purchase 98,188 shares with an exercise price of $.51 and fair value of $.51 to an employee.

 

In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility of a comparable company; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future.

 

In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time.

 

19

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(15) STOCK OPTIONS (Continued)

 

   

As of

March 31,
2020

   

As of

June 30,
2019

 
Expected volatility     23 to 24.00 %     24.00 %
Expected term     4 to 5 Years       5 Years  
Risk-Free interest rate     1.55 to 2.49 %     2.49 %
Forfeiture rate     0.00 %     0.00 %
Expected dividend rate     0.00 %     0.00 %

 

The following table summarizes information about all of the stock options granted, exercised and cancelled under the 2016 Plan at March 31, 2020 and June 30, 2019:

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
 
Outstanding at June 30, 2018   11,636,777   $0.20 
Granted   2,400,000   $0.20 
Exercised   -   $- 
Cancelled   (589,132)  $0.20 
Outstanding at June 30, 2019   13,447,645   $0.20 
Granted   2,098,188   $0.51 
Exercised   -   $- 
Cancelled   (450,000)  $0.20 
Outstanding at March 31, 2020   15,095,833   $0.24 

  

The following table summarizes information about vested and unvested options under the 2016 Plan at March 31, 2020 and June 30, 2019:

 

Employees/Consultants  Unvested   Vested   Total 
Outstanding at June 30, 2018   6,825,181    4,811,596    11,636,777 
Granted   1,800,000    600,000    2,400,000 
Vested   (2,305,527)   2,305,527    - 
Cancelled   (589,132)   -    (589,132)
Outstanding at June 30, 2019   5,730,522    7,717,123    13,447,645 
Granted   1,598,188    500,000    2,098,188 
Vested   (2,665,526)   2,665,526    - 
Cancelled   (450,000)   -    (450,000)
Outstanding at March 31, 2020   4,213,183    10,882,649    15,095,833 

 

Unvested options will be expensed under the Black-Scholes options-pricing model when they vest. As of March 31, 2020, the remaining options to be expensed when vested over the next two and a half years are estimated to be $517,513.

 

At March 31, 2020, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. The previous five plans through and including the 2012 Non-Statutory Plan have a remaining total of options vested and exercisable to purchase 13 shares at exercise prices from a high of $13,500 to a low of $350 per share. The tables below summarize information about these five plans:

 

20

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(15) STOCK OPTIONS (Continued)

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
 
Outstanding at June 30, 2018   13   $1,210 
Granted   -   $- 
Exercised   -   $- 
Cancelled   (.31)  $6,083 
Outstanding at June 30, 2019   13   $976 
           
Granted   -   $- 
Exercised   -   $- 
Cancelled   -   $- 
Outstanding at March 31, 2020   13   $976 

 

Vested & Exercisable Stock Options  March 31, 2020   June 30,
2019
 
Employee 2016 Equity Plan   -    - 
Director 2016 Equity Plan   -    - 
Employee Other Plans   13    13 
Directors and Consultants Other Plans   -    - 
Total   13    13 

 

The Company’s common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI’s registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company’s shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.

 

(16) COMMITMENTS AND CONTINGENCIES

 

The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. Also, due to the lack of sales, there is currently no risk of claims. The Company is now self-insuring the risk of product liability.

 

From May 2010 to June 2012, claims were made by the IRS for payment of the Company’s accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. New management’s tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18th of each month until the balance of payroll taxes, interest and penalties are paid in full.

 

21

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2020

 

(16) COMMITMENTS AND CONTINGENCIES (Continued)

 

During fiscal 2018, as part of new management’s restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019 which is recorded on the balance sheet as of March 31, 2020. The IRS is considering the request.

 

The Company leases a commercial building from Isco Properties, LLC for its offices and warehouse in Fort Lauderdale, FL. The term of the lease is five years beginning February 2014 with a monthly base rent beginning at $6,360 and increasing at a rate of 3% per year. The total rent commitment for the five years is $405,031, which has been fully satisfied as of March 31, 2020. Total rent expense for operating leases for offices and manufacturing facilities amounted to $61,153 and $67,197 for the nine months ended March 31, 2020 and the 2019, respectively. On October 31, 2018, the Company extended the lease for two years from February 1, 2019 to January 31, 2021. The monthly base rent is $7,150 for the 1st year and $7,350 for the 2nd year. The lease agreement was amended on August 1, 2019 which changed the total base rent for year 1 to $76,102 and year 2 to $98,452. This was the result of an agreement to reduce the base rent from August through October of 2019 by $6,650 per month and increasing the base rent from November 2019 through April 2020 by $3,417.38 (which includes imputed interest of $92.38 per month) to make up the deficit. The rent commitment before sales tax for the two years is $174,554. On January 8, 2019, the Company entered into an auto lease agreement. The term of the lease is 3 years beginning January 8, 2019 with a monthly lease payment of $1,204 due on the 7th day of each month. The total lease commitment including sales tax for the 3 years is $43,338.

 

(17) SUBSEQUENT EVENTS

 

Through the date of this report the Company has been taking drastic measures as a response to the global COVID-19 crisis to preserve working capital. These measures include salary reductions and deferral of payments to vendors. The Company is currently in negotiations with its landlord to defer lease payments and has made the decision to furlough all employees from May 1, 2020 until August 1, 2020. The Company has also applied for the Paycheck Protection Program (“PPP”) and the Economic Injury Disaster Loan (“EIDL”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act As of the date of this report, IDSI has received a $4,000 advance from the EIDL and proceeds of $79,600 under the PPP. The Company is seeking total funding of $79,600 under PPP and $200,000 under EIDL. There can be no assurance that the Company will receive this funding

 

22

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

 

This quarterly report on Form 10-Q for the period ended March 31, 2020, contains “forward-looking statements” within the meaning of the federal securities laws and use terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “projects”, “potential,” or “continue,” or the negative or other comparable terminology regarding beliefs, plans, expectations, or intentions regarding the future. These forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially from those discussed and anticipated in such statements. These forward-looking statements include, among others, statements relating to our business strategy, which is based upon our interpretation and analysis of trends in the healthcare treatment industry, especially those related to the diagnosis and treatment of breast cancer, and upon management’s ability to successfully develop and commercialize its principal product, the CTLM®. This strategy assumes that the CTLM® will provide benefits, from both a medical and an economic perspective, to current alternative techniques for diagnosing and managing breast cancer. Factors that could cause actual results to materially differ include, without limitation, the ongoing global COVID-19 pandemic/economic crisis, the timely and successful completion of our clinical trials required by the U.S. Food and Drug Administration (“FDA”) and compliance with the regulations of the FDA and the China Food and Drug Administration (“CFDA”); the timely and successful submission of our FDA application for pre-market approval and our ability to obtain U.S. marketing clearance; manufacturing risks relating to the CTLM®, including our reliance on a single or limited source or sources of supply for some key components of our products as well as the need to comply with especially high standards for those components and in the manufacture of optical imaging products in general; uncertainties inherent in the development of new products and the enhancement of our existing CTLM® product, including technical and regulatory risks, cost overruns and delays; our ability to accurately predict the demand for our CTLM® product as well as future products and to develop strategies to address our markets successfully; the early stage of market development for medical optical imaging products and our ability to gain market acceptance of our CTLM® product by the medical community; our ability to expand our international distributor network for both the near and longer-term to effectively implement our globalization strategy; our dependence on senior management and key personnel and our ability to attract and retain additional qualified personnel; risks relating to financing through private placements or other working capital financing arrangements; technical innovations that could render the CTLM® or other products marketed or under development by us obsolete; competition; risks and uncertainties relating to intellectual property, including claims of infringement and patent litigation; risks relating to future acquisitions and strategic investments and alliances; and reimbursement policies for the use of our CTLM® product and any products we may introduce in the future. There are also many known and unknown risks, uncertainties and other factors, including, but not limited to, technological changes and competition from new diagnostic equipment and techniques, changes in general economic conditions, healthcare reform initiatives, legal claims, regulatory changes and risk factors detailed from time to time in our Securities and Exchange Commission filings that may cause these assumptions to prove incorrect and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, those described above and in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed on September 30, 2019. All forward-looking statements and risk factors included in this Form 10-Q report and in the Form 10-K report are made as of the date of the relevant disclosure document based on information available to us as of the date thereof, and we assume no obligation to update any forward-looking statements or risk factors. The occurrence of any of the events described as risk factors or other future events could have a material adverse effect on our business, results of operations and financial position. Since our common stock is considered a “penny stock,” we are ineligible to rely on the safe harbor for forward-looking statements provided in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). You are cautioned not to place undue reliance on these forward-looking statements.

 

23

 

 

OVERVIEW

 

Our business address is 1291-B NW 65th Place, Fort Lauderdale, FL 33309. Our Internet website address is www.imds.com. The information contained in, or that can be accessed through, our website is not part of this Form 10-Q quarterly report.

 

Imaging Diagnostic Systems, Inc. (“IDSI”) is a late development stage medical technology company that has developed a new, non-invasive CT scanner (“CTLM®”) that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.

 

Since inception in December 1993 as a Florida corporation and subsequently its reverse merger with Alkan Corp., a New Jersey Corporation on April 14, 1994, we continued operations and changed our state of incorporation from New Jersey to Florida, effective July 1, 1995. On July 14, 1995, we filed with the United States Securities and Exchange Commission (“SEC”) a Form 10 SB for registration of our securities as a small business issuer. The Form 10 SB was declared effective in September 1995 and our stock began trading on the OTC Bulletin Board (OTC:BB) on September 20, 1995 under the symbol IMDS. We became a fully reporting company under Commission File Number 0-26028 and traded on the OTC:BB and then on the OTC:QB and ultimately on the OTC PINK until September 25, 2014, at which time our registration was revoked by the SEC for failure to timely file our required periodic reports. Our latest quarterly report on Form 10-Q that was filed prior to our filing of our Form 10 registration statement on August 28, 2018, was filed on May 15, 2013, for the quarter ended March 31, 2013. Our last annual report on Form 10-K filed prior to the Form 10, was filed on October 15, 2012, for the year ended June 30, 2012. Copies of our SEC reports through the date of revocation (the “Prior Reports”) are available at www.sec.gov.

 

On August 28, 2018, we filed a Form 10 registration statement to register issued and outstanding shares held by our shareholders and to become a fully reporting company under the Securities Exchange Act of 1934 (the “Exchange Act”). The Form 10 was amended in response to SEC comments on October 5, 2018 and November 14, 2018. On February 7, 2019, the SEC confirmed that it had no further comments on the Form 10. Under the Exchange Act, our registration became effective on October 29, 2018, i.e. 60 days after filing the Form 10. The Form 10 was further amended on September 26, 2019 to correct the classification of the Series L Convertible Preferred Stock from a current liability to temporary equity.

 

As of the date of this quarterly report on Form 10-Q for the nine months ended March 31, 2020, we have had no substantial revenues from our operations and have incurred net losses applicable to common shareholders since inception through March 31, 2020 of $133,943,970 after discounts and dividends on preferred stock. We incurred net losses applicable to common shareholders of $881,364 for the nine months ended March, 2020 and $1,168,609 for the nine months ended March 31, 2019. The Company received marking clearance for the CTLM® from the Chinese FDA (“CFDA”) effective November 16, 2018 to November 15, 2023 as disclosed in the Company’s 8-K report filed December 11, 2018; however we anticipate that substantial losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. We believe that we face substantial delays before receiving marketing clearance through the U.S. Food and Drug Administration (“FDA”). These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities. We have implemented a new business strategy which includes a licensing agreement on June 20, 2017 with Xi’an IDI Laser Imaging Co. Ltd (Xi’an IDI), a related party, to shift manufacturing of the CTLM® for the China and Asian markets to China.

 

The Company’s next regulatory focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval (“PMA”) process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China until the third or fourth quarter of fiscal 2021. No sales in other countries are expected in the near future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance.

 

24

 

 

In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade our Quality Management System, we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid substantial regulatory fees. We will maintain our ISO 13485:2016 certification which will allow us to pursue FDA marketing clearance and the CE Mark in the future.

 

On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s Computed Tomography Laser Mammography (CTLM®) breast imaging device. The details of the Agreement were disclosed on the Form 8-K filed with the SEC on October 29, 2019. As of the date of this report, we believe that Dr. Huabei Jiang has made substantial progress on the image quality, but the efficacy of the improvements will need to be tested once the COVID-19 crisis passes.

 

CRITICAL ACCOUNTING POLICIES

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements:

 

Inventory 

 

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. We periodically review the value of items in inventory and record write-downs or write-offs based on its assessment of slow moving or obsolete inventory. We maintain a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.

 

Stock-Based Compensation

 

We rely on the guidance provided by ASC 718, (“Share Based Payments”). ASC 718 requires companies to expense the value of employee stock options and similar awards and applies to all outstanding and vested stock-based awards.

 

In computing the impact, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, we analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If our actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. During the nine months ended March 31, 2020, the Company granted options to purchase 2,098,188 shares with an exercise price of $.51 per share to an employee and consultant. During the nine months ended March 31, 2019, no stock options were granted to employees or consultants. Those options are being expensed pursuant to ASC 718.

 

25

 

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite service period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model.

 

RESULTS OF OPERATIONS

 

Sales and Cost of Sales

 

Revenues during the three months ended March 31, 2020, were $0, representing a decrease of $12,715 or 100% from $12,715 during the three months ended March 31, 2019.

 

The Cost of Sales during the three months ended March 31, 2020, was $0, representing a decrease of $7,442 or 100% from $7,442 during the three months ended March 31, 2019. The Company has booked a reserve for the inventory other than the inventory purchased recently and sold to Xi’an IDI. The reserve was booked due to the age of the inventory, lack of demand for parts and lack of sales. The $7,442 of cost of sales during the three months ended March 31, 2019 was a result of recently purchased inventory that was subsequently sold to Xi’an IDI.

 

Revenues during the nine months ended March 31, 2020, were $0, representing a decrease of $161,781 or 100% from $161,781 during the nine months ended March 31, 2019.

 

The Cost of Sales during the nine months ended March 31, 2020, was $0, representing a decrease of $72,176 or 100% from $72,176 during the nine months ended March 31, 2019. The Company has booked a reserve for the inventory other than the inventory purchased recently and sold to Xi’an IDI. The reserve was booked due to the age of the inventory, lack of demand for parts and lack of sales. The $72,176 of cost of sales during the nine months ended March 31, 2019 was a result of recently purchased inventory that was subsequently sold to Xi’an IDI.

 

GENERAL AND ADMINISTRATIVE

 

Our general and administrative expenses include travel/subsistence related to general and administrative activities, property and casualty insurance, professional fees associated with our corporate and securities attorneys and independent auditors, corporate governance expenses, stockholder expenses, utilities, maintenance, telephones, office supplies and sales and property taxes.

 

General and administrative expenses during the three months ended March 31, 2020, were $46,395 representing a decrease of $63,891 or 58% from $110,286 during the three months ended March 31, 2019.

 

The general and administrative decrease of $63,891 is due primarily to a decrease in legal fees related to relisting the Company with the SEC in 2018 as well as decreases in other operating expenses due to efforts to streamline operations.

 

26

 

 

General and administrative expenses during the nine months ended March 31, 2020, were $214,739 representing a decrease of $192,291 or 47% from $407,030 during the nine months ended March 31, 2019.

 

The general and administrative decrease of $192,291 is due primarily to a decrease in legal fees related to relisting the Company with the SEC and working on a settlement with the IRS in 2018 as well as decreases in other operating expenses due to efforts to streamline operations.

 

We do not expect a material change in our general and administrative expenses until we realize a significant increase in revenue from the sale of our product.

 

SALARIES AND WAGES

 

Our salaries and wages expenses include compensation, related benefits, payroll taxes and other payroll fees for all employees.

 

Salaries and wages expense during the three months ended March 31, 2020, were $68,779 representing a decrease of $72,826 or 51% from $141,605 during the three months ended March 31, 2019.

 

The decrease of $72,826 is primarily the result of the Company’s ongoing efforts to scale back on its workforce to streamline operations as well as a shift of certain roles and responsibilities to Xi’an IDI.

 

Salaries and wages expense during the nine months ended March 31, 2020, were $210,781 representing a decrease of $211,350 or 50% from $422,131 during the nine months ended March 31, 2019.

 

The decrease of $211,350 is primarily the result of the Company’s ongoing efforts to scale back on its workforce to streamline operations as well as a shift of certain roles and responsibilities to Xi’an IDI.

 

RESEARCH AND DEVELOPMENT

 

We incur research and development expenses to develop significant enhancements to our sole product, the CTLM®. These expenses consist primarily of clinical costs, costs of materials and components to make product enhancements, new product research costs, and costs associated with servicing clinical collaboration sites.

 

Research and development expenses during the three months ended March 31, 2020 were $6,709 representing a decrease of $886 or 12% from $7,595 during the three months ended March 31, 2019.

 

The research and development decrease of $886 is not significant for the three months ended March 31, 2020 and 2019.

 

Research and development expenses during the nine months ended March 31, 2020 were $23,849 representing a decrease of $33,214 or 58% from $57,063 during the nine months ended March 31, 2019.

 

The research and development decrease of $33,214 is due primarily to decreases in clinical and regulatory expenses as well as decreases in other research and development expenses due to efforts to streamline operations.

 

After we begin to have revenues from sales of the CTLM® systems in China, we expect a significant increase in our research and development expenses and increased costs associated with conducting the clinical trials and preparing the FDA application for Pre-Market Approval and submitting it to the FDA.  We also expect our consulting expenses and professional fees to increase due to the costs associated with conducting the clinical trials and preparing the FDA application. 

 

27

 

 

SALES AND MARKETING

 

Our sales and marketing expenses consist primarily of expenses associated with advertising and promotion, representative office expense, trade shows, conferences, promotional and training costs related to marketing the CTLM®, commissions, travel/subsistence, patent maintenance fees, consulting, certification expenses, and product liability insurance.

 

Sales and marketing expenses during the three months ended March 31, 2020, were $19,776 representing an increase of $19,551 or 8,689% from $225 during the three months ended March 31, 2019. The increase sales and marketing expense is due primarily to the $19,665 of bad debt expense recorded to reserve the accounts receivable and amounts due from related parties.

 

Sales and marketing expenses during the nine months ended March 31, 2020, were $20,081 representing an increase of $19,238 or 2,282% from $843 during the nine months ended March 31, 2019. The increase sales and marketing expense is due primarily to the $19,665 of bad debt expense recorded to reserve the accounts receivable and amounts due from related parties.

 

We may expect a significant increase in our sales and marketing expenses in the future if we resume implementation of our global commercialization program.  Should that occur, we expect commissions, trade show expenses, advertising and promotion and travel and subsistence costs to increase due to this program.

  

CONSULTING EXPENSES

 

Our consulting expenses consists of all consulting fees paid as well as share-based compensation issued to our consultants. Our share-based compensation expense consists of vested stock options expensed under the Black-Scholes options pricing model.

 

Consulting expenses for the three months ended March 31, 2020, were $175,979 representing an increase of $50,025 or 40% from $125,954 during the three months ended March 31, 2019. The increase of $50,025 is due to the vesting of stock options on January 1, 2020 despite having fewer consultants during the three months ended March 31, 2020.

 

Consulting expenses for the nine months ended March 31, 2020, were $351,678 representing an increase of $3,608 or 1% from $348,070 during the nine months ended March 31, 2019. The increase of $3,608 is due to the vesting of stock options on January 1, 2020 and November 1, 2019 despite having fewer consultants during the nine months ended March 31, 2020.

 

AGGREGATE OPERATING EXPENSES

 

Total operating expenses (general and administrative, salaries and wages, research and development, sales and marketing, depreciation and amortization, and stock options) and cost of sales during the three months ended March 31, 2020, were $318,259, representing a decrease of $76,795 or 19% from $395,054 when compared to the operating expenses during the three months ended March 31, 2019.  The overall decrease in expenses was generally due to cost savings as a result of increased operating efficiency and reducing costs by outsourcing manufacturing.

  

Depreciation and amortization during the three months ended March 31, 2020, was $621 representing a decrease of $1,326 or 68% from $1,947 during the three months ended March 31, 2019.

 

Interest expense during the three months ended March 31, 2020, was $17,112 representing an increase of $2,317 or 16% from $14,795 during the three months ended March 31, 2019. The increase was due to a higher average loan balance outstanding during the three months ended March 31, 2020.

 

Total operating expenses and cost of sales during the nine months ended March 31, 2020, were $825,643, representing a decrease of $487,510 or 37% from $1,313,153 when compared to the operating expenses during the nine months ended March 31, 2019.  The overall decrease in expenses was generally due to cost savings as a result of increased operating efficiency and reducing costs by outsourcing manufacturing.

 

28

 

  

Depreciation and amortization during the nine months ended March 31, 2020, was $4,515 representing a decrease of $1,325 or 23% from $5,840 during the nine months ended March 31, 2019.

 

Interest expense during the nine months ended March 31, 2020, was $42,189 representing an increase of $10,422 or 33% from $31,797 during the nine months ended March 31, 2019. The increase was due to a higher average loan balance outstanding during the nine months ended March 31, 2020.

 

BALANCE SHEET DATA 

 

Our combined cash and cash equivalents totaled $34,743 at March 31, 2020 and $44,615 at June 30, 2019.  We do not expect to generate a positive internal cash flow for at least the next 12 months due to our efforts to generate sales in China and obtain FDA marketing clearance, the expected costs of commercializing our initial product, the CTLM®, and the time required for homologations from certain countries.

 

Our inventory, which consists of raw materials, work in process (including completed units under testing), and finished goods totaled $436,952 at March 31, 2020 and $437,247 at June 30, 2019.  Raw materials used for research and development or other purposes are expensed and not included in inventory. The net inventory is $0 at March 31, 2020 and June 30, 2019 because the Company has recorded an allowance for slow moving and obsolete inventory for the entire value of the inventory due to lack of demand for parts and lack of sales.

 

Our property and equipment, net, totaled $14,876 at March 31, 2020 and $19,391 at June 30, 2019.  The overall decrease of $4,515 is due entirely to depreciation during the nine months ended March 31, 2020.

 

Our operating lease right-of-use assets totaled $84,906 at March 31, 2020 and $0 at June 30, 2019. The increase in operating lease right-of-use assets was a result of the Company’s adoption of ASC 842 on July 1, 2019.

 

Our current liabilities, which consist of accounts payable, accrued payroll taxes and penalties, short term debt, and current portion of lease liabilities, totaled $1,149,863 at March 31, 2020 and $548,962 at June 30, 2019. Accounts payable and accrued expenses totaled $241,866 at March 31, 2020 and $34,943 at June 30, 2019. Accrued payroll taxes and penalties totaled $314,019 at March 31, 2020 and $314,019 at June 30, 2019. Promissory notes totaled $520,000 at March 31, 2020 and $200,000 at June 30, 2019. The current portion of lease liabilities totaled $73,978 at March 31, 2020 and $0 at June 30, 2019. Current liabilities increased because the Company incurred new short term related-party promissory notes during the nine months ended March 31, 2020 of $320,000. Accounts payable increased by $205,058 during the nine months ended March 31, 2020. Also, the Company recorded a lease liability due to the adoption of ASC 842 on July 1, 2019, which resulted in a further increase in current liabilities of $73,978.

 

Our long-term liabilities, which consists of the noncurrent operating lease liabilities totaled $11,250 at March 31, 2020 and $0 at June 30, 2019. The increase in operating lease liabilities was due to the adoption of ASC 842 on July 1, 2019.

 

Our temporary equity, which consists of Convertible Preferred Series L (including accrued dividends), totaled $393,463 at March 31, 2020 and $379,914 at June 30, 2019. The increase of $13,549 is due to dividends for the nine months ended March 31, 2020 that are being included in the total redemption value.

 

29

 

 

LIQUIDITY AND CAPITAL RESOURCES 

 

We are currently a development stage company and our continued existence is dependent upon our ability to resolve our liquidity problems, principally by obtaining additional debt and/or equity financing.  We have yet to generate a positive internal cash flow, and until significant sales of our product occur, we are mostly dependent upon debt and equity funding from Viable and its affiliates and/or outside investors. While Viable has stated its intention to provide, directly or through private investors it procures, the working capital that we need for the next 12 months, there can be no assurance that this funding will be provided. In the event that we are unable to obtain adequate debt or equity financing or are unable to obtain such financing on terms and conditions acceptable to us, we may have to cease or severely curtail our operations.  This would materially impact our ability to continue as a going concern.

 

We have financed our operating and research and development activities through multiple private placements of common stock as well as short term loans from related parties.  During the nine months ended March 31, 2020 and 2019, we raised $130,000 and $960,000 through private placements of common stock, respectively, and $320,000 and $400,000 through short term related party loans, respectively.

 

Net cash used for operating and product development expenses, which include our purchase of additional materials to continue the manufacture of CTLM® Systems in anticipation of receiving orders from our distributors in certain countries where permitted by law was $459,872 for the nine months ended March 31, 2020, compared to net cash used by operating activities and product development of the CTLM® and related software development of $1,129,481 during the nine months ended March 31, 2019.  At March 31, 2020, we had negative working capital of $1,079,229 compared to negative working capital of $473,116 at June 30, 2019. We do not expect to generate a positive internal cash flow for at least the next 12 months due to the time needed to ramp up our sales and marketing plan in China. Implementation of our plan has been severely impeded by the ongoing COVID-19 crisis, and abatement of the crisis is needed in order for our plan to succeed.

 

If and when we receive marketing clearance from the FDA, which cannot be assured, we believe that we will need funding in excess of $5 million above and beyond normal operating expenses over the following year to fully complete all necessary stages in order for us to market the CTLM® in the United States and foreign countries other than China. In China Xi’an IDI will be responsible for all expenses relating to the manufacture, marketing and sale of the CTLM®.  The $5 million will be used to purchase inventory, sub-contracted components, tooling and manufacturing templates and pay non-recurring engineering costs associated with preparation for full capacity manufacturing and assembly and marketing, advertising and promotion, training, ongoing regulatory expenses, and other costs associated with product launch.  We expect to use the proceeds of the sale of restricted common stock through private placements as our preferred choice to raise the additional funds required to continue operations. In the event that we are unable to raise funds through private placements, of common or preferred stock, or debt securities, or combinations thereof; we will be materially adversely affected and may have to cease operations. If additional funds are raised by issuing equity securities, dilution to existing stockholders will result, and future investors may be granted rights superior to those of existing stockholders.

 

Through the date of this report, IDSI has been taking drastic measures as a response to the global COVID-19 crisis to preserve working capital. These measures include salary reductions and deferral of payments to vendors. We are currently in negotiations with our landlord to defer lease payments and have made the decision to furlough all employees from May 1, 2020 until August 1, 2020. We have also applied for the Paycheck Protection Program (“PPP”) and the Economic Injury Disaster Loan (“EIDL”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). As of the date of this report, IDSI has received a $4,000 advance from the EIDL and proceeds of $79,600 under the PPP. We are seeking total funding of $79,600 under PPP and $200,000 under EIDL. There can be no assurance that we will receive this funding.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

30

 

 

Item 4. Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that the information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.  

 

Under the supervision and participation of our Chief Executive Officer and Chief Financial Officer, our management has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2020. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer, or the persons performing similar functions, concluded that our disclosure controls and procedures were effective as of March 31, 2020.

 

We previously had weaknesses and deficiencies in our controls and review policies because they had not been formalized and tested as required by SEC Rule 13a-15(b). Management identified that we did not have sufficient documented procedures to identify and prepare a conclusion on matters involving material accounting issues and to independently review conclusions as to the application of generally accepted accounting principles. In order to address these weaknesses and deficiencies, we had identified certain steps that our management believes are necessary to strengthen our disclosure controls and procedures, in order to evaluate and remedy the deficiencies and to test these procedures and controls on an ongoing basis, we implemented the following:

 

1. We formed a disclosure control committee consisting of the Company’s Chief Executive Officer, Chief Financial Officer, Vice President of Operations and consultant representing our majority shareholder.

 

2. On December 11, 2018 the Board of Directors formally adopted a policy on disclosure controls implementing procedures that enhance the recording, processing, summarizing and reporting of the information which we are required to file within the time periods specified in the Commission’s rules and forms.

 

3. We commenced documenting and formally assessing our accounting and financial reporting policies and procedures and implementing segregation of duties and implementing processes for creating an effective and timely closing process.

 

4. We formally assessed significant accounting transactions and other technical accounting and financial reporting matters, preparing accounting memoranda addressing these matters and maintaining these memoranda in our corporate records.

 

5. We improved the compilation process, documenting and monitoring of our critical accounting estimates.

 

While we believe that these efforts will be sufficient to remediate the identified material weakness and improve our internal control over financial reporting, the implementation of these measures is ongoing and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles. We will continue to monitor the effectiveness of these controls and will make any further changes management determines appropriate.

 

There have been no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recent fiscal year that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

 

31

 

 

PART II

 

OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

At this time, there are no material pending legal proceedings to which the Company is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

 

Item 1A. Risk Factors.

 

Our Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed on September 30, 2019, includes a detailed discussion of our risk factors. The risks described in our Form 10-K Report are not the only risks facing IDSI. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. For the nine months ended March 31, 2020, there were no material changes in risk factors as previously disclosed in our Form 10-K, except for the substantial risks associated with the ongoing global COVID-19 pandemic/economic crisis, which are described throughout this Report.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

In January 2020, the Company issued 117,648 shares of restricted common stock to non-affiliated accredited investors in private transactions pursuant to subscription agreements for $60,000. The price per share was approximately $0.51 per share.

 

The above share issuances were made pursuant to an exemption from registration under Section 4(2) of the Securities Act of 1933.

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. (Mine Safety Disclosures)

 

Not Applicable

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

31.1 Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: May 15, 2020 Imaging Diagnostic Systems, Inc.
     
  By:  /s/ David Fong
    David Fong
    Chief Financial Officer
    (PRINCIPAL ACCOUNTING OFFICER)

 

 

33

 

EX-31.1 2 f10q0320ex31-1_imagingdiag.htm CERTIFCATION

EXHIBIT 31.1

 

CERTIFCATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT SECTIONS 13(a) & 15(d)

AS REQUIRED BY

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Chunming Zhang, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Imaging Diagnostic Systems, Inc.;
   
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  May 15, 2020 /s/ Chunming Zhang
  Chunming Zhang
  Chief Executive Officer

 

EX-31.2 3 f10q0320ex31-2_imagingdiag.htm CERTIFCATION

EXHIBIT 31.2

 

CERTIFCATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO EXCHANGE ACT SECTIONS 13(a) & 15(d)

AS REQUIRED BY

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Fong, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Imaging Diagnostic Systems, Inc.;
   
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2020 /s/ David Fong
  David Fong
   Chief Financial Officer

 

EX-32.1 4 f10q0320ex32-1_imagingdiag.htm CERTIFCATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Imaging Diagnostic Systems, Inc. (the “Company”) on Form 10-Q for the quarter ending March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Chunming Zhang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:  May 15, 2020 /s/ Chunming Zhang
  Chunming Zhang
  Chief Executive Officer

 

 

 

EX-32.1 5 f10q0320ex32-2_imagingdiag.htm CERTIFCATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Imaging Diagnostic Systems, Inc. (the “Company”) on Form 10-Q for the quarter ending March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Fong, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:  May 15, 2020 /s/ David Fong
  David Fong
  Chief Financial Officer

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.INS 7 imds-20200331.xml XBRL INSTANCE FILE 0000790652 2018-07-01 2019-06-30 0000790652 2018-06-30 0000790652 2019-06-30 0000790652 us-gaap:ConvertiblePreferredStockMember 2020-03-31 0000790652 us-gaap:ConvertiblePreferredStockMember 2019-06-30 0000790652 us-gaap:FurnitureAndFixturesMember 2019-06-30 0000790652 us-gaap:ComputerEquipmentMember 2019-06-30 0000790652 imds:ThirdPartySoftwareMember 2019-06-30 0000790652 imds:ClinicalEquipmentMember 2019-06-30 0000790652 us-gaap:FurnitureAndFixturesMember 2018-07-01 2019-06-30 0000790652 us-gaap:ComputerEquipmentMember 2018-07-01 2019-06-30 0000790652 imds:ThirdPartySoftwareMember 2018-07-01 2019-06-30 0000790652 imds:ClinicalEquipmentMember 2018-07-01 2019-06-30 0000790652 imds:XianIDILaserImageLtdMember 2018-03-01 2018-03-22 0000790652 imds:XianIDILaserImageLtdMember 2019-06-30 0000790652 2018-06-27 0000790652 imds:SeriesMConvertiblePreferredStockMember 2018-08-01 2018-08-07 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateOneMember 2019-07-01 2020-03-31 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateTwoMember 2019-07-01 2020-03-31 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateThreeMember 2019-07-01 2020-03-31 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateFourMember 2019-07-01 2020-03-31 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateFiveMember 2019-07-01 2020-03-31 0000790652 imds:SeriesMPreferredStockMember 2019-07-01 2020-03-31 0000790652 imds:SeriesLPreferredStockMember imds:IssuanceDateSixMember 2019-07-01 2020-03-31 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateFourMember 2020-03-31 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateFiveMember 2020-03-31 0000790652 imds:SeriesMPreferredStockMember 2020-03-31 0000790652 imds:SeriesLPreferredStockMember imds:IssuanceDateSixMember 2020-03-31 0000790652 imds:SeriesLPreferredStockMember 2019-07-01 2020-03-31 0000790652 imds:SeriesLPreferredStockMember 2011-01-06 0000790652 imds:SeriesMPreferredStockMember 2015-06-30 0000790652 us-gaap:PreferredStockMember 2018-06-30 0000790652 us-gaap:PreferredStockMember 2019-06-30 0000790652 us-gaap:CommonStockMember 2018-06-30 0000790652 us-gaap:CommonStockMember 2019-06-30 0000790652 us-gaap:RetainedEarningsMember 2018-06-30 0000790652 us-gaap:RetainedEarningsMember 2019-06-30 0000790652 imds:SeriesMPreferredStockMember 2014-06-27 0000790652 imds:SeriesMPreferredStockMember 2015-08-31 0000790652 imds:SeriesMPreferredStockMember 2015-08-01 2015-08-31 0000790652 imds:SeriesMPreferredStockMember 2016-04-22 0000790652 imds:SeriesMPreferredStockMember 2016-04-01 2016-04-22 0000790652 imds:SeriesMPreferredStockMember 2017-11-21 0000790652 imds:SeriesMPreferredStockMember 2017-11-01 2017-11-21 0000790652 imds:SeriesMPreferredStockMember us-gaap:InvestorMember 2017-11-01 2017-11-21 0000790652 imds:SeriesMPreferredStockMember 2017-04-01 2017-04-18 0000790652 imds:SeriesMPreferredStockMember us-gaap:InvestorMember 2017-04-01 2017-04-18 0000790652 imds:SeriesMPreferredStockMember 2018-08-01 2018-08-07 0000790652 imds:SeriesMPreferredStockMember 2018-08-07 0000790652 imds:SeriesMPreferredStockMember 2017-04-18 0000790652 us-gaap:EmployeeStockOptionMember 2018-07-01 2019-06-30 0000790652 imds:EmployeeStockOptionOneMember 2018-07-01 2019-06-30 0000790652 us-gaap:EmployeeStockOptionMember 2018-06-30 0000790652 us-gaap:EmployeeStockOptionMember 2019-06-30 0000790652 imds:EmployeeStockOptionOneMember 2018-06-30 0000790652 imds:EmployeeStockOptionOneMember 2019-06-30 0000790652 imds:DirectorEquityPlanMember 2019-06-30 0000790652 imds:EmployeeOtherPlansMember 2019-06-30 0000790652 imds:DirectorsAndConsultantsOtherPlansMember 2019-06-30 0000790652 2017-01-02 0000790652 2016-12-22 2017-01-02 0000790652 us-gaap:NumberOfEmployeesTotalMember 2016-12-22 2017-01-02 0000790652 imds:ConsultantsTwoMember 2018-04-25 2018-05-01 0000790652 imds:ConsultantsTwoMember 2018-05-01 0000790652 2012-06-30 0000790652 2014-08-01 2014-08-04 0000790652 2014-09-04 0000790652 2018-06-29 0000790652 2014-02-01 2014-02-28 0000790652 us-gaap:CommonStockMember 2018-07-01 2019-03-31 0000790652 us-gaap:CommonStockMember 2018-09-30 0000790652 us-gaap:RetainedEarningsMember 2018-09-30 0000790652 2018-07-01 2019-03-31 0000790652 2018-09-30 0000790652 2018-10-01 2018-10-31 0000790652 imds:SeriesMPreferredStockMember imds:IssuanceDateOneMember 2020-03-31 0000790652 2014-09-25 0000790652 2020-03-31 0000790652 2019-01-06 2019-01-08 0000790652 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000790652 us-gaap:CommonStockMember 2019-03-31 0000790652 imds:SubscriptionDepositsMember 2019-01-01 2019-03-31 0000790652 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000790652 us-gaap:RetainedEarningsMember 2019-03-31 0000790652 2019-01-01 2019-03-31 0000790652 2019-03-31 0000790652 imds:ErhfortLLCMember 2020-03-31 0000790652 imds:ErhfortLLCMember 2019-06-30 0000790652 imds:ErhfortLLCOneMember 2020-03-31 0000790652 imds:ErhfortLLCOneMember 2019-06-30 0000790652 imds:ErhfortLLCMember 2019-07-01 2020-03-31 0000790652 imds:ErhfortLLCOneMember 2019-07-01 2020-03-31 0000790652 imds:ConsultantsSixMember 2016-12-22 2017-01-02 0000790652 imds:ConsultantsOneMember 2019-04-25 2019-05-01 0000790652 imds:ConsultantsOneMember 2019-05-01 0000790652 2018-12-31 0000790652 imds:SeriesLPreferredStockMember 2010-03-31 0000790652 imds:SeriesMPreferredStockMember 2015-06-05 2015-06-30 0000790652 imds:SeriesLPreferredStockMember 2010-03-07 2010-03-31 0000790652 2019-07-01 2020-03-31 0000790652 imds:SalesPartsMember 2019-07-01 2020-03-31 0000790652 imds:SalesPartsMember 2018-07-01 2019-03-31 0000790652 imds:XianIDILaserImageLtdMember 2019-07-01 2020-03-31 0000790652 imds:XianIDILaserImageLtdMember 2018-07-01 2019-03-31 0000790652 imds:XianIDILaserImageLtdMember 2020-03-31 0000790652 us-gaap:FurnitureAndFixturesMember 2020-03-31 0000790652 us-gaap:ComputerEquipmentMember 2020-03-31 0000790652 imds:ThirdPartySoftwareMember 2020-03-31 0000790652 imds:ClinicalEquipmentMember 2020-03-31 0000790652 us-gaap:FurnitureAndFixturesMember 2019-07-01 2020-03-31 0000790652 us-gaap:ComputerEquipmentMember 2019-07-01 2020-03-31 0000790652 imds:ThirdPartySoftwareMember 2019-07-01 2020-03-31 0000790652 imds:ClinicalEquipmentMember 2019-07-01 2020-03-31 0000790652 imds:JMOneHoldingsLLCMember 2020-03-31 0000790652 imds:JMOneHoldingsLLCMember 2019-06-30 0000790652 imds:JMOneHoldingsLLCMember 2019-07-01 2020-03-31 0000790652 imds:ErhfortLLCTwoMember 2020-03-31 0000790652 imds:ErhfortLLCTwoMember 2019-06-30 0000790652 imds:ErhfortLLCTwoMember 2019-07-01 2020-03-31 0000790652 imds:ErhfortMember 2020-03-31 0000790652 us-gaap:EmployeeStockOptionMember 2019-07-01 2020-03-31 0000790652 imds:EmployeeStockOptionOneMember 2019-07-01 2020-03-31 0000790652 us-gaap:EmployeeStockOptionMember 2020-03-31 0000790652 imds:EmployeeStockOptionOneMember 2020-03-31 0000790652 imds:DirectorEquityPlanMember 2020-03-31 0000790652 imds:EmployeeOtherPlansMember 2020-03-31 0000790652 imds:DirectorsAndConsultantsOtherPlansMember 2020-03-31 0000790652 imds:UnvestedMember 2019-07-01 2020-03-31 0000790652 imds:UnvestedMember 2018-07-01 2019-06-30 0000790652 imds:VestedMember 2019-07-01 2020-03-31 0000790652 imds:VestedMember 2018-07-01 2019-06-30 0000790652 imds:UnvestedMember 2018-06-30 0000790652 imds:UnvestedMember 2019-06-30 0000790652 imds:UnvestedMember 2020-03-31 0000790652 imds:VestedMember 2018-06-30 0000790652 imds:VestedMember 2019-06-30 0000790652 imds:VestedMember 2020-03-31 0000790652 srt:MinimumMember 2019-07-01 2020-03-31 0000790652 srt:MaximumMember 2019-07-01 2020-03-31 0000790652 us-gaap:CommonStockMember 2020-03-31 0000790652 us-gaap:RetainedEarningsMember 2020-03-31 0000790652 imds:ConsultantsOneMember 2019-10-25 2019-11-01 0000790652 imds:ErhfortLLCThreeMember 2020-03-31 0000790652 imds:ErhfortLLCThreeMember 2019-06-30 0000790652 imds:ErhfortLLCThreeMember 2019-07-01 2020-03-31 0000790652 2020-01-01 2020-03-31 0000790652 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0000790652 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000790652 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000790652 2018-07-01 2018-09-30 0000790652 us-gaap:CommonStockMember 2018-12-31 0000790652 imds:SubscriptionDepositsMember 2018-12-31 0000790652 us-gaap:RetainedEarningsMember 2018-12-31 0000790652 us-gaap:CommonStockMember 2019-09-30 0000790652 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000790652 us-gaap:RetainedEarningsMember 2019-09-30 0000790652 2019-07-01 2019-09-30 0000790652 2019-09-30 0000790652 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000790652 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000790652 imds:ConsultantsFourMember 2017-12-23 2018-01-02 0000790652 imds:ConsultantsFourMember 2018-01-02 0000790652 imds:ConsultantsFiveMember 2018-12-25 2019-01-02 0000790652 imds:ConsultantsFiveMember 2019-01-02 0000790652 imds:ConsultantsOneMember 2019-11-01 0000790652 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000790652 imds:SubscriptionDepositsMember 2018-10-01 2018-12-31 0000790652 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000790652 2018-10-01 2018-12-31 0000790652 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000790652 us-gaap:CommonStockMember 2019-12-31 0000790652 imds:SubscriptionDepositsMember 2019-12-31 0000790652 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000790652 us-gaap:RetainedEarningsMember 2019-12-31 0000790652 2019-10-01 2019-12-31 0000790652 2019-12-31 0000790652 imds:ErhfortLLCFourMember 2020-03-31 0000790652 imds:ErhfortLLCFourMember 2019-06-30 0000790652 imds:ErhfortLLCFourMember 2019-07-01 2020-03-31 0000790652 us-gaap:SubsequentEventMember 2020-04-02 2020-05-01 0000790652 imds:EmployeesMember 2020-02-17 2020-03-01 0000790652 imds:EmployeesMember 2020-03-01 0000790652 2020-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure imds:Number imds:Agreements IMAGING DIAGNOSTIC SYSTEMS INC /FL/ 0000790652 2020-03-31 --06-30 false Q3 2020 10-Q Non-accelerated Filer true 600 600 200 150 600 35 250 161781 12715 161781 2 P20Y 0.25 0 161781 0.09 0.15 0.15 0.09 0.15 0.15 0.15 0.15 0.15 591 6 3 241 200 150 600 15 5910000 60000 30000 2410000 2000000 1500000 6000000 150000 -1155097 -396982 -867815 -335367 -366765 -833639 7589173 125108179 132228967 -133064117 -133062606 131018179 -131790620 -772441 -1403825 132004884 -132553553 -548669 -933954 132540145 -133943970 131168179 50000 -132152133 132228967 -133322183 -1093216 132359666 -133604128 -1244462 -133062606 -133943970 314019 314019 34943 241866 -1129481 -459872 FL 000-26028 false Yes Yes 1098894 27912 232970 7031 8896 2000000 1500000 6000000 350000 2500000 2017-04-18 2017-11-21 2018-08-07 2018-08-07 2018-08-07 2011-01-06 379914 0 200000 393463 15 147283 250 200 150 591 35 10000 10000 179914 0 193463 150000 100000 2000000 1500000 30000 60000 441848 392157 883696 872787 87044089 3 3 49691 10909 <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Security</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date Issued</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date of Conversion</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of Shares Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Balance</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>3/31/2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left">Series M Cv Pfd</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center">8/1/2014</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center">4/18/2017</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">11/21/2017</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">8/7/2018</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">241</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,410,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series M Cv Pfd</td><td>&#160;</td> <td style="text-align: center">8/31/2015</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">8/7/2018</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Series M Cv Pfd</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">4/22/2016</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">8/7/2018</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total Series M Cv Pfd</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">-0</td><td style="padding-bottom: 4pt; text-align: left">-</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Dividends</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-0</td><td style="padding-bottom: 1.5pt; text-align: left">-</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td colspan="4" style="text-align: center; padding-bottom: 4pt">Total redemption value</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 4pt; text-align: left">-</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series L Cv Pfd</td><td>&#160;</td> <td style="text-align: center">2/10/2010</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">35</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">1/6/2011</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">15</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Dividends</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">193,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td colspan="4" style="text-align: center; padding-bottom: 4pt">Total redemption value</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">393,463</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> false <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(13) CONVERTIBLE PREFERRED STOCK </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of March 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Security</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date Issued</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date of Conversion</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of Shares Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Balance</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>3/31/2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left">Series M Cv Pfd</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center">8/1/2014</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center">4/18/2017</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">11/21/2017</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">8/7/2018</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">241</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,410,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series M Cv Pfd</td><td>&#160;</td> <td style="text-align: center">8/31/2015</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">8/7/2018</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Series M Cv Pfd</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">4/22/2016</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">8/7/2018</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total Series M Cv Pfd</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">-0</td><td style="padding-bottom: 4pt; text-align: left">-</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Dividends</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-0</td><td style="padding-bottom: 1.5pt; text-align: left">-</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td colspan="4" style="text-align: center; padding-bottom: 4pt">Total redemption value</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 4pt; text-align: left">-</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series L Cv Pfd</td><td>&#160;</td> <td style="text-align: center">2/10/2010</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">35</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">1/6/2011</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">15</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Dividends</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">193,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td colspan="4" style="text-align: center; padding-bottom: 4pt">Total redemption value</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">393,463</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Series L Convertible Preferred Stock</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. At March 31, 2020 and June 30, 2019, the balance of cumulative dividends owed to the investor which is included in redemption value was $193,463 and $179,914, respectively. The total presented on the balance sheet as temporary equity is $393,463 as of March 31, 2020 and $379,914 as of June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Series M Convertible Preferred Stock</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, during the fiscal year ending June 30, 2015, sold Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, ("Viable"). Each share of the Series M Preferred Stock was convertible into 147,283 shares of Common Stock. In the event of a liquidation, the holders of the Series M Preferred Stock would have been entitled to receive, prior to any distribution of assets to holders of Common Stock or other class of capital stock or other equity securities of the Corporation, $10,000 per share of Series M Preferred Stock held plus accrued but unpaid dividends. The holders of the Series M Preferred Stock would have had identical voting rights as any holder of Common Stock and would have voted together, not as separate classes. The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. The first tranche of the private placement sale of 250 shares of convertible preferred stock was made pursuant to a Securities Purchase Agreement (the "Agreement") dated June 27, 2014 between the Company and Viable. The Agreement stipulated the payment of a $100,000 non-refundable deposit which was paid on June 27, 2014 and applied to the purchase price on the first closing date, August 4, 2014. At the first closing, $2,400,000 was paid by Viable to purchase 250 shares of convertible preferred stock which provided a 78.9% voting and economic interest in the Company's capital stock representing a change in control of the Company. Because of delays in restructuring the Company and executing its business plan, Viable was unable to convert its Series M Convertible Preferred Stock into Common Stock according to its timeline. On June 1, 2016, Viable presented the Company with a waiver that permanently waived its rights under Section 3 &#8211; Redemption at Holder's Option of the Certificate of Designations of the Series M Preferred Stock. Therefore, the Company reclassified the Series M Preferred Shares to permanent equity from temporary equity on June 1, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Viable, at its option, deviated from the stipulated payment schedules and purchased 200 Series M shares for $2,000,000 on August 31, 2015, and 150 Series M shares for $1,500,000 on April 22, 2016, which completed all of the payments required pursuant to the Agreement. The Series M dividends were payable at the Company's option in cash or common stock. Accordingly, after the reclassification of Series M from temporary equity to permeant equity the Company has continued to accrue the dividend as a charge to retained earnings and a credit to preferred stock Series M in permanent equity. Upon conversion of the remaining 591 Series M shares to common stock on August 7, 2018, the accrued dividends were forfeited and reversed to retained earnings as the Company does not have any further obligations for payment of such accrued dividends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 21, 2017, Viable exercised its right to convert three shares of its Series M Convertible Preferred Stock valued at $30,000 into 441,848 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 392,157 restricted common shares to three accredited investors in China and retained 49,691 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restrictive legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restrictive legend pursuant to Rule 144.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 18, 2017, Viable exercised its right to convert six shares of its Series M Convertible Preferred Stock valued at $60,000 into 883,696 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 872,787 restricted common shares to three accredited investors in China and retained 10,909 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restricted legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restricted legend pursuant to Rule 144.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 7, 2018,&#160;Viable converted its remaining 591 shares Series M Convertible Preferred Stock into 87,044,089 shares of restricted common stock.</p> 10000 At the first closing, $2,400,000 was paid by Viable to purchase 250 shares of convertible preferred stock which provided a 78.9% voting and economic interest in the Company's capital stock representing a change in control of the Company. The private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. 350000 474 <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Sales-parts, related party</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">161,781</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Net sales</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">161,781</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 11965 7700 0 19391 14876 84906 11250 73978 0 193463 0 11965 0 11115 0.24 0.23 0.24 P5Y P4Y P5Y 0.0249 0.0155 0.0249 0.0000 0.0000 0.0000 0.0000 11636777 13447645 11636777 13447645 13 13 15095833 15095833 13 6825181 5730522 4213183 4811596 7717123 10882649 2400000 2400000 2098188 2098188 1598188 1800000 500000 600000 589132 589132 0.31 450000 450000 450000 589132 0.20 0.20 1210 976 0.24 976 0.20 0.51 0.20 6083 0.20 13 13 13 13 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(11) PROMISSORY NOTES &#8211; RELATED PARTY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table is a summary of the outstanding note balances as of March 31, 2020 and June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Noteholder</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest<br /> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity<br /> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Related Party Notes:</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Erhfort, LLC</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">9/30/20</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Erhfort, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">9/30/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">JM One Holdings, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">8/31/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Erhfort, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">9/30/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">9/30/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Erhfort, LLC</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">9/30/20</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total Related Party Notes</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">520,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">200,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of Erhfort, LLC and JM One Holdings, LLC owns Company common stock directly or indirectly. Hence these debts are considered related party debt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended March 31, 2020, the Company received loan proceeds of $300,000 from Erhfort, LLC and $20,000 from JM One Holdings, LLC, both of which are related parties. The loans from Erhfort have an annual interest rate of 15% and interest is being accrued and paid monthly. The loan from JM One Holdings, LLC will accrue interest monthly at an annual rate of 15%, but interest will not be paid until maturity. The maturity dates for all loans with original maturity dates prior to September 30, 2020 from Erhfort were extended to September 30, 2020.</p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Noteholder</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest<br /> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity<br /> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Related Party Notes:</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Erhfort, LLC</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">9/30/20</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Erhfort, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">9/30/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">JM One Holdings, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">8/31/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Erhfort, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">9/30/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">9/30/20</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Erhfort, LLC</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">9/30/20</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total Related Party Notes</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">520,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">200,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> Erhfort, LLC Erhfort, LLC JM One Holdings, LLC Erhfort, LLC Erhfort, LLC Erhfort, LLC 2020-09-30 2020-09-30 2020-08-31 2020-09-30 2020-09-30 2020-09-30 200000 520000 100000 100000 100000 100000 20000 100000 100000 100000 300000 500000000 500000000 2000000 2000000 26705 181178 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(2) GOING CONCERN AND MANAGEMENT'S PLANS </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $133,943,970, a stockholders' deficit of $1,403,825 and a working capital deficiency of $1,098,894. For the nine months ended March 31, 2020, net loss totaled $867,815. The net cash used in operating activities for the nine months ended March 31, 2020 totaled $459,872. These matters raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon increasing sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to increase sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received from the Chinese FDA ("CFDA") marketing clearance for the CTLM&#174; effective November 16, 2018 to November 15, 2023, as disclosed in the Company's Form 8-K filing on December 11, 2018. However, there can be no assurance that we will obtain U.S. Food and Drug Administration ("FDA") marketing or other new international marketing clearances, that the CTLM&#174; will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM&#174; in China or elsewhere to allow us to operate profitably. If our majority shareholder Viable International Investments, LLC ("Viable") fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company's liquidity profile, and management's plans in those regards are discussed in the paragraphs that follow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal year 2020, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM&#174; systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM&#174;, expenses associated with FDA approval processes, and the costs associated with advanced product development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM&#174; Breast Imaging System through the FDA. The premarket approval ("PMA") process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after achieving successful marketing and sales of CTLM&#174; systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China until the third or fourth quarter of fiscal 2021. No sales in other countries are expected in the near future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance, as to which there can be no assurance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company's Quality Management System, we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. We will maintain our ISO 13485:2016 certification which will allow us to pursue FDA marketing clearance and the CE Mark in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 23, 2019, the Company entered into a consulting agreement ("the Agreement") effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI's Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focusing on improving the technical performance and image quality of IDSI's Computed Tomography Laser Mammography (CTLM<sup>&#174;</sup>) breast imaging device. The details of the Agreement were disclosed on the Form 8-K filed with the SEC on October 29, 2019. As of the date of this report, Dr. Huabei Jiang has made progress on the image quality, but the efficacy of the improvements will need to be tested once the COVID-19 crisis passes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's ability to continue as a going concern and its future success is dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. Due to the difficulty of raising additional capital during the current COVID-19 crisis, the Company has been taking aggressive measures to reduce its operating costs in order to preserve cash. The Company has also applied for the Paycheck Protection Program ("PPP") and the Economic Injury Disaster Loan ("EIDL") under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The Company's ability to meet its cash flow requirements throughout fiscal 2020 and continue its development and commercialization efforts will be dependent on the length and severity of the COVID-19 crisis and the Company's ability to secure additional funding through the CARES Act. There can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to execute its plan of operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(4) REVENUE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information about the Company's net sales by reporting segment for the nine months ended March 31, 2020 and 2019 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Sales-parts, related party</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">161,781</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Net sales</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">161,781</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All sales-parts, related party are sales to a customer located in China.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(5) DUE FROM RELATED PARTY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi'an of China, an affiliated Company of IDSI. The agreements are a Know How Transfer Contract and a CTLM Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi'an will pay IDSI a know how transfer fee of 25% of revenue for CTLM product sales in their territory. The Company also sells inventory parts or acquires parts from third parties on behalf of Xi'an. For the nine months ended March 31, 2020 and 2019, such sales totaled $0 and $161,781, respectively. As of March 31, 2020 and June 30, 2019, the Company has receivables from related parties, net of allowance of $0 and $7,700, respectively as a result of sales of inventory parts or acquisition of parts from third parties on behalf of Xi'an. Xi'an and Viable have common ownership hence these transactions are considered related party transactions. During the three months ended March 31, 2020, the Company decided to reserve the full amount of the receivable of $7,700 due to its age as well as the current COVID-19 crisis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, as of March 31, 2020 and June 30, 2019, the Company has amounts due from related parties, net of allowance of $0 and $11,965, respectively. The majority of the amount due is $11,115 due from Xi'an. This was for product that was purchased by Xi'an that IDSI paid for. Xi'an will reimburse IDSI for the amounts paid on their behalf. During the three months ended March 31, 2020, the Company decided to reserve the full amount of the amount due from related parties of $11,965 due to its age as well as the current COVID-19 crisis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(7) INVENTORIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials consisting of purchased parts, components and supplies</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">369,452</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">369,747</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work-in process including units undergoing final inspection and testing</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Inventory</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">436,952</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">437,247</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Inventory Reserve</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(436,952</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(437,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Net Inventory</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the age of the inventory, lack of demand for parts and lack of sales the Company wrote off all inventory during the year ended June 30, 2017 and has booked a reserve for the entire value of its inventory as of March 31. 2020 and June 30, 2019. For the nine months ended March 31, 2020, reduction of inventory represents physical count adjustments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(9) ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2020 and June 30, 2019, accounts payable and accrued expenses totaled $241,866 and $34,943, respectively, which consists of accounts payable of $232,970 and $27,912 and other accrued expenses of $8,896 and $7,031, respectively.</p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials consisting of purchased parts, components and supplies</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">369,452</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">369,747</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work-in process including units undergoing final inspection and testing</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Inventory</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">436,952</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">437,247</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Inventory Reserve</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(436,952</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(437,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Net Inventory</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 7700 11965 -437247 -436952 437247 436952 15000 15000 52500 52500 369747 369452 44615 34743 7700 5000 11566 11226 75846 50969 95237 150751 548962 1149863 548962 1161113 379914 393463 379914 393463 132228967 132540145 95237 150751 0 0 0 0 122876549 122876549 122621646 122621646 161781 12715 72176 7442 89605 5273 407030 110286 214739 46395 422131 141605 210781 68779 57063 7595 23849 6709 843 225 20081 19776 5840 1947 4515 621 348070 125954 351678 175979 1240977 387612 825643 318259 -1151372 -382339 -825643 -318259 99 77 17 4 27943 75 31767 14795 42189 17112 -3725 -14643 -42172 -17108 13512 4438 13549 4475 -1168609 -401420 -881364 -339842 -0.01 -0.01 108930341 121964130 122732306 122758901 591 33597241 122621646 120641250 122523607 122876549 120935373 122621646 122758901 -5910000 5910000 -591 87044089 -80 6 -1679173 1679173 -4438 -4438 -4475 -4537 -4537 -4537 -4537 -4475 -4537 -4537 -4537 -4537 -396982 -396982 -335367 -401139 -401139 -255040 -255040 -335367 -356976 -356976 -277408 -277408 760000 760000 60000 60000 150000 150000 70000 70000 1490195 117648 294117 137255 50000 50000 26705 26705 120479 120479 60699 50000 -50000 98039 -27153 5000 21753 11115 4233 -340 -40487 206923 322 25616 407943 400000 320000 960000 130000 960000 450000 -169481 -9872 271540 44615 34743 102059 31767 40068 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(1) ORGANIZATION AND NATURE OF BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Imaging Diagnostic Systems, Inc. (the "Company" or "IDSI") is a medical technology company that has developed a new, non-invasive CT scanner called CTLM&#174; that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM&#174; will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Basis of presentation and use of estimates</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These unaudited financial statements should be read in conjunction with the Company's audited financial statements for the year ended June 30, 2019,&#160;contained in our General Form for Registration of Securities of Form 10-K as filed with the Securities and Exchange Commission (the "Commission")&#160;on September 30, 2019. The results of operations for the nine months ended March 31, 2020, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) Revenue recognition</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) Allowance for doubtful accounts</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our allowance for doubtful accounts was $19,665 as of March 31, 2020 and $0 as of June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Cash and cash equivalents</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2020 and June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) Concentration of Risk</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company's cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. At March 31, 2020 and June 30, 2019, the Company had $0 in excess of the federally insured limit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not have any revenue for the nine months ended March 31, 2020. For the nine months ended March 31, 2019, all of the revenues were from Xi'an IDI Laser Imaging Co. Ltd.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) Inventory</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) Property and equipment</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h) Research and development</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company's CTLM&#174; device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM&#174; device.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i) Net loss per share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 260, ("Earnings per Share"), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company had 10,882,662 and 7,717,136 options vested as of March 31, 2020 and June 30, 2019, respectively and 4,213,184 and 5,730,522 options not yet vested as of March 31, 2020 and June 30, 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j) Stock-based compensation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2018, the FASB issued ASU 2018-07, Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard. The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. During the nine months ended March 31, 2020, the Board granted options to purchase 2,098,188 shares with an exercise price of $.51 per share to an employee and a consultant. No stock options were granted to employees and consultants during the nine months ended March 31, 2019. Stock options are being expensed pursuant to ASC 718.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (15) Stock Options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k) Long-lived assets</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 360 ("Property, Plant &#38; Equipment"). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2020 and 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l) Income taxes</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for income taxes pursuant to the provisions of ASC 740-10, "Accounting for Income Taxes," which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2016-2019 are still potentially subject to audit by the taxing authorities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m) Warranty reserve</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2020 or June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n) Impact of recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2016, the FASB issued ASU No. 2016-13 and updated in Nov 2018 ASU 2018-19, Financial Instruments &#8211; Credit Losses (Topic 326) ("ASU 2016-13"), which requires the immediate recognition of management's estimates of current and expected credit losses. ASU 2016-13 is effective for fiscal years and interim reporting periods within those years beginning after December 15, 2019. Early adoption is permitted after fiscal years beginning December 15, 2018. The Company is currently evaluating the potential impact of adopting this guidance on our financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted. The Company is currently assessing the impact of this standard on their financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(o) Fair Value of Financial Instruments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company's debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2020 and June 30, 2019, the aggregate fair value of the Company's debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 ("Fair Value Measurements and Disclosures"). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1 - Quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(6) ROYALTY RECEIVABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the nine months ended March 31, 2020 and 2019, there was no royalty income. As of March 31, 2020 and June 30, 2019, the Company had a royalty receivable balance of $0 and $0, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(8) PROPERTY AND EQUIPMENT</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of property and equipment, less accumulated depreciation:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Furniture and Fixtures</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">261,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">261,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computers and Equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">370,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">370,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Third Party Software</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,291</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,291</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Clinical Equipment</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">5 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Property &#38; Equipment</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">657,006</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">657,006</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(642,130</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(637,615</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total Property &#38; Equipment - Net</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,391</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense for the nine months ended March 31, 2020 and 2019 was $4,515 and $5,840 respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(10) ACCRUED PAYROLL TAXES AND PENALTIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2020 and June 30, 2019, the Company owed the IRS $314,019 and $314,019, respectively. Accrued payroll taxes represent outstanding interest and penalties based on prior management's failure to pay payroll taxes commencing with the quarter ending March 31, 2010. As part of new management's restructuring plan, the Company received funds from an accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalty and interest abatement. The amount due at March 31, 2020 of $314,019 represents the interest and penalties. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,019. The Company had a telephone conference on April 18, 2019 with the office of appeals and is waiting for further communications from the appeals officer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(14) COMMON STOCK</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of no par preferred shares authorized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended March 31, 2020, the Company issued 254,903 shares of its common stock to non-affiliated accredited investors pursuant to subscription agreements for $130,000. The price per share was approximately $.51 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended March 31, 2019, the Company issued 87,044,089 shares of its common stock as Viable exercised its right to convert the remaining 591 shares of its Series M Convertible Preferred Stock valued at $5,910,000 into 87,044,089 shares of restricted common stock on August 7, 2018. The Company also issued 1,882,351 shares of its common stock to non-affiliated accredited investors pursuant to subscription agreements for $960,000. The price per share was approximately $.51 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(17) SUBSEQUENT EVENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through the date of this report the Company has been taking drastic measures as a response to the global COVID-19 crisis to preserve working capital. These measures include salary reductions and deferral of payments to vendors. The Company is currently in negotiations with its landlord to defer lease payments and has made the decision to furlough all employees from May 1, 2020 until August 1, 2020. The Company has also applied for the Paycheck Protection Program ("PPP") and the Economic Injury Disaster Loan ("EIDL") under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act As of the date of this report, IDSI has received a $4,000 advance from the EIDL and proceeds of $79,600 under the PPP. The Company is seeking total funding of $79,600 under PPP and $200,000 under EIDL. There can be no assurance that the Company will receive this funding</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Basis of presentation and use of estimates</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These unaudited financial statements should be read in conjunction with the Company's audited financial statements for the year ended June 30, 2019,&#160;contained in our General Form for Registration of Securities of Form 10-K as filed with the Securities and Exchange Commission (the "Commission")&#160;on September 30, 2019. The results of operations for the nine months ended March 31, 2020, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) Revenue recognition</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) Allowance for doubtful accounts</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our allowance for doubtful accounts was $19,665 as of March 31, 2020 and $0 as of June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Cash and cash equivalents</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2020 and June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) Concentration of Risk</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company's cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. At March 31, 2020 and June 30, 2019, the Company had $0 in excess of the federally insured limit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not have any revenue for the nine months ended March 31, 2020. For the nine months ended March 31, 2019, all of the revenues were from Xi'an IDI Laser Imaging Co. Ltd.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) Inventory</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) Property and equipment</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h) Research and development</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company's CTLM&#174; device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM&#174; device.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i) Net loss per share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 260, ("Earnings per Share"), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company had 10,882,662 and 7,717,136 options vested as of March 31, 2020 and June 30, 2019, respectively and 4,213,184 and 5,730,522 options not yet vested as of March 31, 2020 and June 30, 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j) Stock-based compensation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2018, the FASB issued ASU 2018-07, Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard. The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. During the nine months ended March 31, 2020, the Board granted options to purchase 2,098,188 shares with an exercise price of $.51 per share to an employee and a consultant. No stock options were granted to employees and consultants during the nine months ended March 31, 2019. Stock options are being expensed pursuant to ASC 718.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (15) Stock Options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k) Long-lived assets</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 360 ("Property, Plant &#38; Equipment"). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2020 and 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l) Income taxes</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for income taxes pursuant to the provisions of ASC 740-10, "Accounting for Income Taxes," which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2016-2019 are still potentially subject to audit by the taxing authorities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m) Warranty reserve</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2020 or June 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n) Impact of recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2016, the FASB issued ASU No. 2016-13 and updated in Nov 2018 ASU 2018-19, Financial Instruments &#8211; Credit Losses (Topic 326) ("ASU 2016-13"), which requires the immediate recognition of management's estimates of current and expected credit losses. ASU 2016-13 is effective for fiscal years and interim reporting periods within those years beginning after December 15, 2019. Early adoption is permitted after fiscal years beginning December 15, 2018. The Company is currently evaluating the potential impact of adopting this guidance on our financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted. The Company is currently assessing the impact of this standard on their financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(o) Fair Value of Financial Instruments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company's debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2020 and June 30, 2019, the aggregate fair value of the Company's debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 ("Fair Value Measurements and Disclosures"). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1 - Quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful life</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Furniture and Fixtures</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">261,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">261,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computers and Equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">370,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">370,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Third Party Software</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,291</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,291</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Clinical Equipment</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">5 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Property &#38; Equipment</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">657,006</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">657,006</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(642,130</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(637,615</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total Property &#38; Equipment - Net</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,391</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">76,662</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total lease expense</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">76,662</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Cash paid for amounts included in measurement of lease liabilities</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,339</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Right-of-use assets obtained in exchange for new lease obligation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">147,291</td><td style="text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Operating leases</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 4pt; padding-left: 10pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">84,906</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Current portion of operating lease liability</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73,978</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total operating lease liability</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85,228</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.04 Years</font></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Discount Rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td></tr> </table> <p style="margin: 0pt"></p> 0 19665 250000 0 0 7717136 10882662 5730522 4213184 2098188 0.51 The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2020 or June 30, 2019. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. 0 0 657006 261011 370704 10291 15000 657006 261011 370704 10291 15000 637615 642130 P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y 5840 4515 381224 314019 314019 76662 76662 76339 147291 85228 P1Y0M15D 0.15 25661 58546 8427 92634 7406 147000 Our leases have remaining lease terms of 9 to 22 months as of March 31, 2020. 1882351 87044089 254903 87044089 960000 130000 0.51 0.51 3000000 25000 1489640 250 2500000 0.789 250000 20000 314019 The Company leases a commercial building from Isco Properties, LLC for its offices and warehouse in Fort Lauderdale, FL. The term of the lease is five years beginning February 2014 with a monthly base rent beginning at $6,360 and increasing at a rate of 3% per year. The total rent commitment for the five years is $405,031, which has been fully satisfied as of March 31, 2020. Total rent expense for operating leases for offices and manufacturing facilities amounted to $61,153 and $67,197 for the nine months ended March 31, 2020 and the 2019, respectively. The Company extended the lease for two years from February 1, 2019 to January 31, 2021. The monthly base rent is $7,150 for the 1st year and $7,350 for the 2nd year. The lease agreement was amended on August 1, 2019 which changed the total base rent for year 1 to $76,102 and year 2 to $98,452. This was the result of an agreement to reduce the base rent from August through October of 2019 by $6,650 per month and increasing the base rent from November 2019 through April 2020 by $3,417.38 (which includes imputed interest of $92.38 per month) to make up the deficit. The rent commitment before sales tax for the two years is $174,554. On January 8, 2019, the Company entered into an auto lease agreement. The term of the lease is 3 years beginning January 8, 2019 with a monthly lease payment of $1,204 due on the 7th day of each month. The total lease commitment including sales tax for the 3 years is $43,338. Through the date of this report the Company has been taking drastic measures as a response to the global COVID-19 crisis to preserve working capital. These measures include salary reductions and deferral of payments to vendors. The Company is currently in negotiations with its landlord to defer lease payments and has made the decision to furlough all employees from May 1, 2020 until August 1, 2020. The Company has also applied for the Paycheck Protection Program ("PPP") and the Economic Injury Disaster Loan ("EIDL") under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act As of the date of this report, IDSI has received a $4,000 advance from the EIDL and proceeds of $79,600 under the PPP. The Company is seeking total funding of $79,600 under PPP and $200,000 under EIDL. There can be no assurance that the Company will receive this funding. <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,<br /> 2020</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,<br /> 2019</b></p></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23 to 24.00</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">24.00</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected term</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4 to 5 Years</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5 Years</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.55 to 2.49</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.49</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Forfeiture rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br /> Exercise<br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Outstanding at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,636,777</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.20</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(589,132</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,447,645</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.20</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,098,188</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.51</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">15,095,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.24</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br /> Exercise<br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Outstanding at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,210</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(.31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,083</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unvested</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,825,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,811,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,636,777</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,400,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,305,527</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,305,527</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(589,132</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(589,132</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,730,522</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,717,123</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,447,645</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,598,188</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,098,188</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,665,526</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,665,526</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,213,183</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,882,649</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">15,095,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested &#38; Exercisable Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee 2016 Equity Plan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Director 2016 Equity Plan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Employee Other Plans</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Directors and Consultants Other Plans</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 7364136 5498555 500000 1865581 360000 2000000 5000000 2040000 98188 0.20 0.20 0.20 0.20 0.20 0.51 0.51 0.51 0.51 0.51 0.51 The previous five plans through and including the 2012 Non-Statutory Plan have a remaining total of options vested and exercisable to purchase 13 shares at exercise prices from a high of $13,500 to a low of $350 per share. 0.1 -2665526 -2305527 2665526 2305527 122876549 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(12) LEASES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires lessees to recognize a right-of-use (ROU) asset and lease liability in the balance sheet for all leases, including operating leases, with terms of more than twelve months. Recognition, measurement, and presentation of expenses and cash flows from a lease by a lessee have not significantly changed from previous guidance. The amendments also require qualitative disclosures along with specific quantitative disclosures. We adopted this guidance using the cumulative-effect adjustment method on July 1, 2019, meaning we did not restate prior periods. Current year financial information is presented under the guidance in topic 842, while prior year information will continue to be presented under Topic 840. Adoption of the standard resulted in the recognition of an operating ROU asset and lease liability of approximately $147,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets, other current liabilities, and operating lease liabilities in our balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, we apply a portfolio approach to effectively account for the operating lease ROU assets and liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our leases have remaining lease terms of 9 to 22 months as of March 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The components of lease expense were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">76,662</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total lease expense</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">76,662</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental cash flow information related to leases was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Cash paid for amounts included in measurement of lease liabilities</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,339</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Right-of-use assets obtained in exchange for new lease obligation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">147,291</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental balance sheet information related to leases was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Operating leases</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 4pt; padding-left: 10pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">84,906</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Current portion of operating lease liability</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73,978</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total operating lease liability</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85,228</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.04 Years</font></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Discount Rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2020, maturities of lease liabilities were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">Years Ended June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2020</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,661</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">58,546</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,427</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">92,634</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amounts representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Present value of capital lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">85,228</p> </td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">Years Ended June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2020</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,661</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">58,546</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,427</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">92,634</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amounts representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Present value of capital lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">85,228</p> </td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(15) STOCK OPTIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 4, 2016, the Board of Directors adopted the Company's 2016 Equity Incentive Plan (the "2016 Plan") which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company's welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company's behalf and strengthening their desire to remain with the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 1, 2017, the Board granted options to purchase a total of 7,364,136 shares, all with an exercise price and fair value of $0.20 per share. Options were granted to nine employees to purchase 5,498,555 shares and to six consultants to purchase 1,865,581 shares. On January 1, 2018, the Board granted options to purchase 5,000,000 shares all with an exercise price and fair value of $0.20 per share to four consultants. On May 1, 2018, the Board granted an option to purchase 500,000 shares with an exercise price and fair value of $0.20 per share to an additional consultant. On January 1, 2019, the Board granted options to purchase 2,040,000 shares all with an exercise price of $.20 and fair value of $.51 per share to five consultants. On May 1, 2019, the Board granted an option to purchase 360,000 shares with an exercise price of $.20 and fair value of $.51 per share to a consultant. On November 1, 2019, the Board granted an option to purchase 2,000,000 shares with an exercise price of $.51 and fair value of $.51 per share to a consultant. On March 1, 2020, the Board granted an option to purchase 98,188 shares with an exercise price of $.51 and fair value of $.51 to an employee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility of a comparable company; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,<br /> 2020</b></p></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,<br /> 2019</b></p></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23 to 24.00</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">24.00</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected term</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4 to 5 Years</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5 Years</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.55 to 2.49</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.49</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Forfeiture rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes information about all of the stock options granted, exercised and cancelled under the 2016 Plan at March 31, 2020 and June 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br /> Exercise<br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Outstanding at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,636,777</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.20</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(589,132</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,447,645</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.20</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,098,188</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.51</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">15,095,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.24</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes information about vested and unvested options under the 2016 Plan at March 31, 2020 and June 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unvested</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,825,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,811,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,636,777</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,400,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,305,527</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,305,527</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(589,132</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(589,132</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,730,522</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,717,123</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,447,645</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,598,188</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,098,188</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,665,526</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,665,526</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,213,183</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,882,649</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">15,095,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unvested options will be expensed under the Black-Scholes options-pricing model when they vest. As of March 31, 2020, the remaining options to be expensed when vested over the next two and a half years are estimated to be $517,513.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2020, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. The previous five plans through and including the 2012 Non-Statutory Plan have a remaining total of options vested and exercisable to purchase 13 shares at exercise prices from a high of $13,500 to a low of $350 per share. The tables below summarize information about these five plans:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br /> Exercise<br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Outstanding at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,210</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(.31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,083</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested &#38; Exercisable Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee 2016 Equity Plan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Director 2016 Equity Plan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Employee Other Plans</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Directors and Consultants Other Plans</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI's registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company's shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.</p> 517513 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(16) COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. Also, due to the lack of sales, there is currently no risk of claims. The Company is now self-insuring the risk of product liability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From May 2010 to June 2012, claims were made by the IRS for payment of the Company's accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company's capital stock representing a change in control of the Company. New management's tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18<sup>th</sup> of each month until the balance of payroll taxes, interest and penalties are paid in full.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2018, as part of new management's restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019 which is recorded on the balance sheet as of March 31, 2020. The IRS is considering the request.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company leases a commercial building from Isco Properties, LLC for its offices and warehouse in Fort Lauderdale, FL. The term of the lease is five years beginning February 2014 with a monthly base rent beginning at $6,360 and increasing at a rate of 3% per year. The total rent commitment for the five years is $405,031, which has been fully satisfied as of March 31, 2020. Total rent expense for operating leases for offices and manufacturing facilities amounted to $61,153 and $67,197 for the nine months ended March 31, 2020 and the 2019, respectively. On October 31, 2018, the Company extended the lease for two years from February 1, 2019 to January 31, 2021. The monthly base rent is $7,150 for the 1<sup>st</sup> year and $7,350 for the 2<sup>nd</sup> year. The lease agreement was amended on August 1, 2019 which changed the total base rent for year 1 to $76,102 and year 2 to $98,452. This was the result of an agreement to reduce the base rent from August through October of 2019 by $6,650 per month and increasing the base rent from November 2019 through April 2020 by $3,417.38 (which includes imputed interest of $92.38 per month) to make up the deficit. The rent commitment before sales tax for the two years is $174,554. On January 8, 2019, the Company entered into an auto lease agreement. The term of the lease is 3 years beginning January 8, 2019 with a monthly lease payment of $1,204 due on the 7th day of each month. The total lease commitment including sales tax for the 3 years is $43,338.</p> 19665 EX-101.SCH 8 imds-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Changes in Stockholders' Deficit (Unaudited) (USD $) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern and Management's Plans link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Due from Related Party link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Royalty Receivable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Accrued Payroll Taxes and Penalties link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Promissory Notes - Related Party link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Promissory Notes - Related Party (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Convertible Preferred Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Going Concern and Management's Plans (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Due from Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Royalty Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Accrued Payroll Taxes and Penalties (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Promissory Notes - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Promissory Notes - Related Party (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Leases (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Leases (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Convertible Preferred Stock (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Stock Options (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Stock Options (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Stock Options (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Stock Options (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 imds-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 imds-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 11 imds-20200331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Convertible Preferred Stock [Member] Property, Plant and Equipment, Type [Axis] Furniture and Fixtures [Member] Furniture and Fixtures [Member] Third Party Software [Member] Clinical Equipment [Member] Related Party [Axis] Xi'an [Member] Series M Convertible Preferred Stock [Member] Series M Cv Pfd [Member] Award Date [Axis] Issuance Date 1 [Member] Award Type [Axis] Issuance Date 2 [Member] Issuance Date 3 [Member] Issuance Date 4 [Member] Issuance Date 5 [Member] Series L Cv Pfd [Member] Issuance Date 6 [Member] Equity Components [Axis] Preferred Stock Common Stock Retained Earnings / Accumulated Deficit Investor [Member] Employee Stock Option [Member] Employee Stock Option One [Member] Director Equity Plan [Member] Employee Other Plans [Member] Directors And Consultants Other Plans [Member] Concentration Risk Benchmark [Axis] Number of Employees, Total [Member] Consultants Two [Member] Subscription Deposits [Member] Erhfort LLC [Member] Erhfort LLC [Member] Consultants Six [Member] Consultants One [Member] Product and Service [Axis] Sales-parts [Member] JM One Holdings, LLC [Member] Erhfort LLC [Member] Erhfort [Member] Unvested [Member] Vested [Member] Statistical Measurement [Axis] Minimum [Member] Range [Axis] Maximum [Member] Erhfort LLC Three [Member] Subscription Deposits Consultants Four [Member] Consultants Five [Member] Erhfort LLC Four [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Employee [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Filer Category Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity File Number Entity Incorporation State Country Code Statement of Financial Position [Abstract] Assets Current assets: Cash Accounts receivable, related party, net of allowance Due from related party, net of allowance Employee advances Prepaid expenses Total current assets Property and equipment, net Operating lease right-of-use assets Total assets Liabilities and Stockholders' Deficit Current liabilities: Accounts payable and accrued expenses Accrued payroll taxes and penalties Promissory notes, related party Current portion of operating lease liabilities Total current liabilities Long-term liabilities Operating lease liabilities Total liabilities Commitment and Contingencies (Note 16) Temporary equity Convertible Preferred Series L Total temporary equity Stockholders' Deficit: Preferred stock, no par, 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 shares issued and outstanding at March 31, 2020 and June 30, 2019 Common stock, no par value, 500,000,000 authorized, 122,876,549 and 122,621,646  shares issued and outstanding March 31, 2020 and June 30, 2019, respectively Accumulated Deficit Total stockholders' deficit Total liabilities and stockholders' deficit Statement [Table] Statement [Line Items] Series M preferred stock Preferred stock, par value Preferred stock, shares authorized Preferred stock, designated Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sales, related party Total Revenue Cost of Sales Gross Profit Operating Expenses: General and administrative Salaries and wages Research and development Sales and marketing Depreciation and amortization Consulting expenses (including share-based compensation) Total Operating Expenses Operating Loss Other Income (expense) Interest income Other Income Interest expense Total Other Income (Expense) Net Loss Preferred Stock Dividends Net Loss Available to Common Stockholders Net Loss per common share: Basic and diluted Weighted average number of common shares outstanding: Basic and diluted Accumulated Deficit Balance Balance, shares Conversion Viable Series M Cv Preferred to common stock Conversion Viable Series M Cv Preferred to common stock, shares Adjustment to correct number of common shares Adjustment to correct number of common shares, shares Cummulative Dividend on Series M CV Preferred Cummulative Dividend on Series L CV Preferred Stock options expense Shares Issued for Cash Shares Issued for Cash, shares Subscription Deposit Received Subscription deposit converted to common stock Subscription deposit converted to common stock, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock option expense Bad debt expense Changes in assets and liabilities and stockholders deficit: (Increase) decrease in due from related party, net of allowance (Increase) decrease in employee advances (Increase) decrease in royalty receivable (Increase) decrease in other receivables, net of allowance (Increase) decrease in prepaid expenses Increase (decrease) in accounts payable and accrued expenses Change in right of use asset/lease obligation, net Total adjustments Net cash used in operating activities Cash flows from financing activities: Proceeds from promissory notes, related party Proceeds from issuance of common stock Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental Disclosure of cash flow information: Cash paid for interest Cash paid for taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND NATURE OF BUSINESS Going Concern and Management's Plans [Abstract] GOING CONCERN AND MANAGEMENT'S PLANS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue from Contract with Customer [Abstract] REVENUE Related Party Transactions [Abstract] DUE FROM RELATED PARTY Royalty Receivable [Abstract] ROYALTY RECEIVABLE Inventory Disclosure [Abstract] INVENTORIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES ACCRUED PAYROLL TAXES AND PENALTIES Debt Disclosure [Abstract] PROMISSORY NOTES - RELATED PARTY Leases [Abstract] LEASES Equity [Abstract] CONVERTIBLE PREFERRED STOCK COMMON STOCK Share-based Payment Arrangement [Abstract] STOCK OPTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation and use of estimates Revenue recognition Allowance for doubtful accounts Cash and cash equivalents Concentration of Risk Inventory Property and equipment Research and development Net loss per share Stock-based compensation Long-lived assets Income taxes Warranty reserve Impact of recently issued accounting pronouncements Fair Value of Financial Instruments Schedule of net sales by reporting segment Schedule of inventories Schedule of property and equipment, less accumulated depreciation Schedule of outstanding note balances Schedule of components of lease expense Schedule of cash flow information related to leases Schedule of balance sheet information related to leases Schedule of maturities of lease liabilities Schedule of preferred stock 2016 Plan [Member] 2012 Non-Statutory Plan [Member] Schedule of stock option grants fair value of each option Schedule of stock options granted, exercised and cancelled Schedule of vested and unvested options Schedule of vested & exercisable stock options Going Concern and Management's Plans (Textual) Accumulated deficit Stockholders' deficit Working capital deficiency Net cash used in operating activities Summary of Significant Accounting Policies (Textual) Allowance for doubtful accounts Cash equivalents Federal deposit insurance corporation limit Excess of federally insured limit Concentrations of revenue with customers, description Options vested Options non vested Stock options granted to employees and consultants Option exercise price Impairment losses Warranty reserve, description Tax position, description Sales-parts, related party [Member] Net sales Due from Related Party (Textual) Number of agreements Term of contract Percentage of revenue for product sales Sales from related party Receivables from related parties Received payment of settled all invoices Due from related parties Amount due Full amount of the receivable Amount due from related parties Royalty Receivable (Textual) Royalty income Royalty receivable Raw materials consisting of purchased parts, components and supplies Work-in process including units undergoing final inspection and testing Finished goods Total Inventory Inventory Reserve Net Inventory Computers and Equipment [Member] Total Property & Equipment Less: accumulated depreciation Total Property & Equipment - Net Useful life Property and Equipment (Textual) Depreciation expense Accounts Payable and Accrued Expenses (Textual) Accounts payable Warranty reserve Other accrued expenses Write-offs of accounts payable and accrued expenses Accrued salaries Accrued Payroll Taxes and Penalties (Textual) Accrued payroll taxes and penalties Balance of taxes due Amount of interest and penalties Remaining interest and penalties Erhfort, LLC [Member] Erhfort, LLC One [Member] Erhfort, LLC Two [Member] Noteholder Interest Rate Maturity Date Total Related Party Notes Promissory Notes - Related Party (Textual) Proceeds from loan received Total related party debt Interest rate Repayment of debt Maturity date Operating lease expense Total lease expense Cash paid for amounts included in measurement of lease liabilities Operating cash flows from operating leases Right-of-use assets obtained in exchange for new lease obligation Operating leases Operating leases Current portion of operating lease liability Operating lease liability, net of current portion Total operating lease liability Weighted Average Remaining Lease Term Operating leases Weighted Average Discount Rate Operating leases Years Ended June 30, 2020 2021 2022 Total minimum lease payments Less: amounts representing interest Present value of capital lease liabilities Leases (Textual) ROU asset and lease liability Operating lease terms, description 8/1/2014 [Member] 8/1/2014 One [Member] 8/1/2014 Two [Member] 8/31/2015 [Member] 4/22/2016 [Member] 2/10/2010 [Member] No. of shares Amount of designated preferred shares Date of Conversion. No. of Shares Converted Amount Converted Dividends Balance Series L Convertible Preferred Stock [Member] Series M Convertible Preferred Stock [Member] Convertible Preferred Stock (Textual) Converted short term promissory note Convertible preferred stock Original purchase price Annual rate Conversion of preferred stock to common stock Conversion of preferred stock, description Redemption value Total temporary equity Principal value Non-refundable deposit Preferred stock voting rights Issuance of convertible preferred stock Restricted common shares Number of investors Restricted common shares retained Other equity securities Common Stock (Textual) Description of reverse stock split Issued total shares of common stock Convert shares of convertible preferred stock Convert value of convertible preferred stock Convertible preferred stock shares converted into restricted common stock Issued shares pursuant to subscription agreement Issued value pursuant to subscription agreement Issued shares as settlement of company debt Issued value as settlement of company debt Issued shares as settlement of accounts payable and accrued expenses Issued value as settlement of accounts payable and accrued expenses Price per share Issued date Description of convertible terms Values of restricted common stock Expected volatility Expected term Risk-Free interest rate Forfeiture rate Expected dividend rate Options Outstanding Granted Exercised Cancelled Outstanding Wtd. Avg. Exercise Price Outstanding Granted Exercised Cancelled Outstanding Shares Vested Employee 2016 Equity Plan [Member] Director 2016 Equity Plan [Member] Directors and Consultants Other Plans [Member] Vested & Exercisable Stock Options Total Nine employees [Member] Six Consultants [Member] Four consultants [Member] Additional Consultant [Member] One Consultant [Member] Five Consultants [Member] Stock Options (Textual) Granted options to purchase shares Purchase exercise price and fair value Fair value price per share Stock options, description Quoted price Stock options Vested amount Commitments and Contingencies (Textual) Product liability insurance Number of patents scans conducted worldwide Accrued payroll taxes, interest and penalties Purchase of convertible preferred stock Convertible preferred stock value Voting and economic interest percentage Lump sum payment Monthly installment payments Penalties and interest totaling Operating leasing, description Subsequent Events (Textual) Subsequent event, description Accounts Payable and Accrued Expenses (Textual) The entire disclosure for accrued payroll taxes and penalties. Adjustment to correct number of common shares. Adjustment to correct number of common value. Amount of designated preferred shares. The number of preferred shares converted into common shares. Convertible preferred stock shares converted into restricted common stock. Date of stock conversion. Dividends series preferred stock. Excess of federally insured limit. The entire disclosue for going concern and management's plans. The increase (decrease) during the period in the carrying amount royalty receivable. Lump sum payment. Monthly installment payments. Number of agreements. Represents the number of investors. Number of patents scans conducted worldwide. Convertible preferred stock value. Penalties and interest totaling. Percentage of revenue for product sales. Preferred stock shares designated. Product liability insurance carried at the end of the reporting period. Property and Equipment (Textual). Purchase of convertible preferred stock. Quoted price. The amount of remaining interest and penalties. Number of restricted shares retained. The amount of royalty receivable current. Disclosure of royalty receivable. Royalty Receivable (Textual). The estimated measure of the percentage by which a forfeiture rate Number of shares issued pursuant to subscription agreement. Number of issued shares as settlement of accounts payable and accrued expenses. Number of shares issued to settlement of company debt. Value of shares issued pursuant to subscription agreement. Value of shares issued as settlement of accounts payable and accrued expenses. Value of shares issued to settlement of company debt. Stock options granted to employees and consultants. Summary of Significant Accounting Policies (Textual). Term of contract. Voting and economic interest percentage. Warranty reserve balances including in accounts payable and accrued expenses. Description of warranty reserve. Warranty reserve. Working capital deficiency fot he period. Write-offs of accounts payable and accrued expenses. Amount of convertible preferred series. Price of a single share of a number of saleable stocks of a company. Other equity securities. Schedule of vested and unvested options. Amount of lease expenses total. Tabular disclosure of supplemental cash flow information related to leases. Tabular disclosure of supplemental balance sheet information related to leases. Operating lease terms description. Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock. Increase decrease in employee advances. Subscription Deposit Received. ROU asset and lease liability. Subscription deposit converted to common stock value.. Subscription deposit converted to common stock, shares Amount of the cost of bad debt expense Assets, Current Assets [Default Label] Liabilities, Current Liabilities Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Stockholders' Equity Attributable to Parent Liabilities and Equity Revenues Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Net Income (Loss) Attributable to Parent Preferred Stock Dividends and Other Adjustments Net Income (Loss) Available to Common Stockholders, Basic Weighted Average Number of Shares Outstanding, Basic and Diluted Shares, Outstanding Increase (Decrease) Due from Other Related Parties IncreaseDecreaseInEmployeeAdvances IncreaseDecreaseInRoyaltyReceivable Increase (Decrease) in Other Receivables Increase (Decrease) in Prepaid Expense Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash and Cash Equivalents, at Carrying Value Interest Paid, Excluding Capitalized Interest, Operating Activities Research and Development Expense, Policy [Policy Text Block] Accounts Receivable, Allowance for Credit Loss Revenue from Related Parties Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment WarrantyReserveBalancesIncludingInAccountsPayableAndAccruedExpenses TotalLeaseExpense Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Leases, Future Minimum Payments Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Convertible Debt, Current Convertible Preferred Stock, Shares Issued upon Conversion Debt Default, Short-term Debt, Amount ConversionOfPreferredStockToCommonStock Convertible Preferred Stock, Terms of Conversion Preferred Stock, Redemption Amount Convertible Debt Deposits Preferred Stock, Voting Rights Proceeds from Issuance of Convertible Preferred Stock Stock Issued During Period, Shares, Restricted Stock Award, Gross NumberOfInvestors RestrictedCommonSharesRetained StockIssuedDuringPeriodSharesIssuedForPursuantToSubscriptionAgreement Shares Issued, Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price EX-101.PRE 12 imds-20200331_pre.xml XBRL PRESENTATION FILE XML 13 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Convertible Preferred Stock
9 Months Ended
Mar. 31, 2020
Equity [Abstract]  
CONVERTIBLE PREFERRED STOCK

(13) CONVERTIBLE PREFERRED STOCK

 

The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of March 31, 2020:

 

 

Security

  Date Issued  No. of Shares   Amount   Date of Conversion  No. of Shares Converted   Amount Converted  

Balance

3/31/2020

 
Series M Cv Pfd  8/1/2014   250   $2,500,000   4/18/2017   6   $60,000      
                11/21/2017   3    30,000      
                8/7/2018   241    2,410,000      
Series M Cv Pfd  8/31/2015   200    2,000,000   8/7/2018   200    2,000,000      
Series M Cv Pfd  4/22/2016   150    1,500,000   8/7/2018   150    1,500,000      
Total Series M Cv Pfd      600   $6,000,000       600   $6,000,000   $-0-
Dividends                             -0-
                Total redemption value        $0-
                                
Series L Cv Pfd  2/10/2010   35   $350,000   1/6/2011   15   $150,000   $200,000 
Dividends                             193,463 
                Total redemption value        $393,463 

 

Series L Convertible Preferred Stock

 

On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. At March 31, 2020 and June 30, 2019, the balance of cumulative dividends owed to the investor which is included in redemption value was $193,463 and $179,914, respectively. The total presented on the balance sheet as temporary equity is $393,463 as of March 31, 2020 and $379,914 as of June 30, 2019.

 

Series M Convertible Preferred Stock

 

The Company, during the fiscal year ending June 30, 2015, sold Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, ("Viable"). Each share of the Series M Preferred Stock was convertible into 147,283 shares of Common Stock. In the event of a liquidation, the holders of the Series M Preferred Stock would have been entitled to receive, prior to any distribution of assets to holders of Common Stock or other class of capital stock or other equity securities of the Corporation, $10,000 per share of Series M Preferred Stock held plus accrued but unpaid dividends. The holders of the Series M Preferred Stock would have had identical voting rights as any holder of Common Stock and would have voted together, not as separate classes. The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. The first tranche of the private placement sale of 250 shares of convertible preferred stock was made pursuant to a Securities Purchase Agreement (the "Agreement") dated June 27, 2014 between the Company and Viable. The Agreement stipulated the payment of a $100,000 non-refundable deposit which was paid on June 27, 2014 and applied to the purchase price on the first closing date, August 4, 2014. At the first closing, $2,400,000 was paid by Viable to purchase 250 shares of convertible preferred stock which provided a 78.9% voting and economic interest in the Company's capital stock representing a change in control of the Company. Because of delays in restructuring the Company and executing its business plan, Viable was unable to convert its Series M Convertible Preferred Stock into Common Stock according to its timeline. On June 1, 2016, Viable presented the Company with a waiver that permanently waived its rights under Section 3 – Redemption at Holder's Option of the Certificate of Designations of the Series M Preferred Stock. Therefore, the Company reclassified the Series M Preferred Shares to permanent equity from temporary equity on June 1, 2016.

 

Viable, at its option, deviated from the stipulated payment schedules and purchased 200 Series M shares for $2,000,000 on August 31, 2015, and 150 Series M shares for $1,500,000 on April 22, 2016, which completed all of the payments required pursuant to the Agreement. The Series M dividends were payable at the Company's option in cash or common stock. Accordingly, after the reclassification of Series M from temporary equity to permeant equity the Company has continued to accrue the dividend as a charge to retained earnings and a credit to preferred stock Series M in permanent equity. Upon conversion of the remaining 591 Series M shares to common stock on August 7, 2018, the accrued dividends were forfeited and reversed to retained earnings as the Company does not have any further obligations for payment of such accrued dividends.

 

On November 21, 2017, Viable exercised its right to convert three shares of its Series M Convertible Preferred Stock valued at $30,000 into 441,848 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 392,157 restricted common shares to three accredited investors in China and retained 49,691 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restrictive legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restrictive legend pursuant to Rule 144.

 

On April 18, 2017, Viable exercised its right to convert six shares of its Series M Convertible Preferred Stock valued at $60,000 into 883,696 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 872,787 restricted common shares to three accredited investors in China and retained 10,909 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restricted legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restricted legend pursuant to Rule 144.

 

On August 7, 2018, Viable converted its remaining 591 shares Series M Convertible Preferred Stock into 87,044,089 shares of restricted common stock.

XML 14 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Due from Related Party
9 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
DUE FROM RELATED PARTY

(5) DUE FROM RELATED PARTY

 

On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi'an of China, an affiliated Company of IDSI. The agreements are a Know How Transfer Contract and a CTLM Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi'an will pay IDSI a know how transfer fee of 25% of revenue for CTLM product sales in their territory. The Company also sells inventory parts or acquires parts from third parties on behalf of Xi'an. For the nine months ended March 31, 2020 and 2019, such sales totaled $0 and $161,781, respectively. As of March 31, 2020 and June 30, 2019, the Company has receivables from related parties, net of allowance of $0 and $7,700, respectively as a result of sales of inventory parts or acquisition of parts from third parties on behalf of Xi'an. Xi'an and Viable have common ownership hence these transactions are considered related party transactions. During the three months ended March 31, 2020, the Company decided to reserve the full amount of the receivable of $7,700 due to its age as well as the current COVID-19 crisis.

 

Additionally, as of March 31, 2020 and June 30, 2019, the Company has amounts due from related parties, net of allowance of $0 and $11,965, respectively. The majority of the amount due is $11,115 due from Xi'an. This was for product that was purchased by Xi'an that IDSI paid for. Xi'an will reimburse IDSI for the amounts paid on their behalf. During the three months ended March 31, 2020, the Company decided to reserve the full amount of the amount due from related parties of $11,965 due to its age as well as the current COVID-19 crisis.

XML 15 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Accounts Payable and Accrued Expenses
9 Months Ended
Mar. 31, 2020
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

(9) ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

As of March 31, 2020 and June 30, 2019, accounts payable and accrued expenses totaled $241,866 and $34,943, respectively, which consists of accounts payable of $232,970 and $27,912 and other accrued expenses of $8,896 and $7,031, respectively.

XML 16 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - shares
9 Months Ended
Mar. 31, 2020
May 15, 2020
Document and Entity Information [Abstract]    
Entity Registrant Name IMAGING DIAGNOSTIC SYSTEMS INC /FL/  
Entity Central Index Key 0000790652  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Type 10-Q  
Document Period End Date Mar. 31, 2020  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2020  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Interactive Data Current Yes  
Entity Common Stock, Shares Outstanding   122,876,549
Entity File Number 000-26028  
Entity Incorporation State Country Code FL  
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Statements of Changes in Stockholders' Deficit (Unaudited) (USD $) - USD ($)
Preferred Stock
Common Stock
Subscription Deposits
Accumulated Deficit
Total
Balance at Jun. 30, 2018 $ 7,589,173 $ 125,108,179   $ (133,064,117) $ (366,765)
Balance, shares at Jun. 30, 2018 591 33,597,241      
Conversion Viable Series M Cv Preferred to common stock $ (5,910,000) $ 5,910,000      
Conversion Viable Series M Cv Preferred to common stock, shares (591) 87,044,089      
Adjustment to correct number of common shares        
Adjustment to correct number of common shares, shares   (80)      
Cummulative Dividend on Series M CV Preferred   $ (1,679,173)   1,679,173  
Cummulative Dividend on Series L CV Preferred       (4,537) (4,537)
Net loss       (401,139) (401,139)
Balance at Sep. 30, 2018   $ 131,018,179   (131,790,620) (772,441)
Balance, shares at Sep. 30, 2018   120,641,250      
Adjustment to correct number of common shares, shares   6      
Cummulative Dividend on Series L CV Preferred       (4,537) (4,537)
Shares Issued for Cash   $ 150,000     150,000
Shares Issued for Cash, shares   294,117      
Subscription Deposit Received     $ 50,000   50,000
Net loss       (356,976) (356,976)
Balance at Dec. 31, 2018   $ 131,168,179 50,000 (132,152,133) (933,954)
Balance, shares at Dec. 31, 2018   120,935,373      
Cummulative Dividend on Series L CV Preferred       (4,438) (4,438)
Stock options expense   $ 26,705     26,705
Shares Issued for Cash   $ 760,000     760,000
Shares Issued for Cash, shares   1,490,195      
Subscription deposit converted to common stock   $ 50,000 (50,000)    
Subscription deposit converted to common stock, shares   98,039      
Net loss       (396,982) (396,982)
Balance at Mar. 31, 2019   $ 132,004,884   (132,553,553) (548,669)
Balance, shares at Mar. 31, 2019   122,523,607      
Balance at Jun. 30, 2019 $ 132,228,967   (133,062,606) (833,639)
Balance, shares at Jun. 30, 2019 122,621,646      
Cummulative Dividend on Series L CV Preferred       (4,537) (4,537)
Net loss       (255,040) (255,040)
Balance at Sep. 30, 2019   $ 132,228,967   (133,322,183) (1,093,216)
Balance, shares at Sep. 30, 2019   122,621,646      
Cummulative Dividend on Series L CV Preferred       (4,537) (4,537)
Stock options expense   $ 60,699      
Shares Issued for Cash   $ 70,000     70,000
Shares Issued for Cash, shares   137,255      
Net loss       (277,408) (277,408)
Balance at Dec. 31, 2019   $ 132,359,666 (133,604,128) (1,244,462)
Balance, shares at Dec. 31, 2019   122,758,901      
Cummulative Dividend on Series L CV Preferred       (4,475) (4,475)
Stock options expense   $ 120,479     120,479
Shares Issued for Cash   $ 60,000     60,000
Shares Issued for Cash, shares   117,648      
Net loss       (335,367) (335,367)
Balance at Mar. 31, 2020   $ 132,540,145   $ (133,943,970) $ (1,403,825)
Balance, shares at Mar. 31, 2020   122,876,549      
XML 18 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Royalty Receivable (Details) - USD ($)
9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Jun. 30, 2019
Royalty Receivable (Textual)      
Royalty income  
Royalty receivable $ 0   $ 0
XML 19 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Going Concern and Management's Plans (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Accounting Policies [Abstract]                    
Accumulated deficit $ 133,943,970   $ 133,943,970       $ 133,062,606      
Stockholders' deficit 1,403,825 $ 548,669 1,403,825 $ 548,669 $ 1,244,462 $ 1,093,216 $ 833,639 $ 933,954 $ 772,441 $ 366,765
Working capital deficiency 1,098,894   1,098,894              
Net loss $ (335,367) $ (396,982) (867,815) (1,155,097)            
Net cash used in operating activities     $ 459,872 $ 1,129,481            
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies
9 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

(a) Basis of presentation and use of estimates

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

These unaudited financial statements should be read in conjunction with the Company's audited financial statements for the year ended June 30, 2019, contained in our General Form for Registration of Securities of Form 10-K as filed with the Securities and Exchange Commission (the "Commission") on September 30, 2019. The results of operations for the nine months ended March 31, 2020, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2020.

 

(b) Revenue recognition

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue

 

(c) Allowance for doubtful accounts

 

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

 

Our allowance for doubtful accounts was $19,665 as of March 31, 2020 and $0 as of June 30, 2019.

 

(d) Cash and cash equivalents

 

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2020 and June 30, 2019.

 

(e) Concentration of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company's cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. At March 31, 2020 and June 30, 2019, the Company had $0 in excess of the federally insured limit.

 

The Company did not have any revenue for the nine months ended March 31, 2020. For the nine months ended March 31, 2019, all of the revenues were from Xi'an IDI Laser Imaging Co. Ltd.

 

(f) Inventory

 

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.

 

(g) Property and equipment

 

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

 

(h) Research and development

 

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company's CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

 

(i) Net loss per share

 

The Company relies on the guidance provided by ASC 260, ("Earnings per Share"), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

 

The Company had 10,882,662 and 7,717,136 options vested as of March 31, 2020 and June 30, 2019, respectively and 4,213,184 and 5,730,522 options not yet vested as of March 31, 2020 and June 30, 2019, respectively.

 

(j) Stock-based compensation

 

In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard. The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. During the nine months ended March 31, 2020, the Board granted options to purchase 2,098,188 shares with an exercise price of $.51 per share to an employee and a consultant. No stock options were granted to employees and consultants during the nine months ended March 31, 2019. Stock options are being expensed pursuant to ASC 718.

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (15) Stock Options.

 

(k) Long-lived assets

 

The Company relies on the guidance provided by ASC 360 ("Property, Plant & Equipment"). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

 

The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2020 and 2019.

 

(l) Income taxes

 

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, "Accounting for Income Taxes," which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

 

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. 

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2016-2019 are still potentially subject to audit by the taxing authorities.

 

(m) Warranty reserve

 

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2020 or June 30, 2019.

 

(n) Impact of recently issued accounting pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 and updated in Nov 2018 ASU 2018-19, Financial Instruments – Credit Losses (Topic 326) ("ASU 2016-13"), which requires the immediate recognition of management's estimates of current and expected credit losses. ASU 2016-13 is effective for fiscal years and interim reporting periods within those years beginning after December 15, 2019. Early adoption is permitted after fiscal years beginning December 15, 2018. The Company is currently evaluating the potential impact of adopting this guidance on our financial statements.

 

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted. The Company is currently assessing the impact of this standard on their financial statements.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

 

(o) Fair Value of Financial Instruments

 

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company's debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2020 and June 30, 2019, the aggregate fair value of the Company's debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 ("Fair Value Measurements and Disclosures"). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities

 

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

XML 21 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options (Details 1) - $ / shares
9 Months Ended 12 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Options    
Outstanding 13,447,645 11,636,777
Granted 2,098,188 2,400,000
Cancelled (450,000) (589,132)
Outstanding 15,095,833 13,447,645
2016 Plan [Member]    
Options    
Outstanding 13,447,645 11,636,777
Granted 2,098,188 2,400,000
Exercised
Cancelled (450,000) (589,132)
Outstanding 15,095,833 13,447,645
Wtd. Avg. Exercise Price    
Outstanding $ 0.20 $ 0.20
Granted 0.51 0.20
Exercised
Cancelled 0.20 0.20
Outstanding $ 0.24 $ 0.20
XML 22 R57.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options (Details Textual) - USD ($)
1 Months Ended 9 Months Ended
Nov. 01, 2019
May 01, 2019
Jan. 02, 2019
May 01, 2018
Jan. 02, 2018
Jan. 02, 2017
Mar. 01, 2020
Mar. 31, 2020
Sep. 25, 2014
Stock Options (Textual)                  
Granted options to purchase shares           7,364,136      
Purchase exercise price and fair value           $ 0.20      
Stock options, description               The previous five plans through and including the 2012 Non-Statutory Plan have a remaining total of options vested and exercisable to purchase 13 shares at exercise prices from a high of $13,500 to a low of $350 per share.  
Quoted price                 $ 0.1
Stock options Vested amount               $ 517,513  
Nine employees [Member]                  
Stock Options (Textual)                  
Granted options to purchase shares           5,498,555      
Six Consultants [Member]                  
Stock Options (Textual)                  
Granted options to purchase shares           1,865,581      
Four consultants [Member]                  
Stock Options (Textual)                  
Granted options to purchase shares         5,000,000        
Purchase exercise price and fair value         $ 0.20        
Additional Consultant [Member]                  
Stock Options (Textual)                  
Granted options to purchase shares       500,000          
Purchase exercise price and fair value       $ 0.20          
One Consultant [Member]                  
Stock Options (Textual)                  
Granted options to purchase shares 2,000,000 360,000              
Purchase exercise price and fair value $ 0.51 $ 0.20              
Fair value price per share $ 0.51 $ 0.51              
Five Consultants [Member]                  
Stock Options (Textual)                  
Granted options to purchase shares     2,040,000            
Purchase exercise price and fair value     $ 0.20            
Fair value price per share     $ 0.51            
Employee [Member]                  
Stock Options (Textual)                  
Granted options to purchase shares             98,188    
Purchase exercise price and fair value             $ 0.51    
Fair value price per share             $ 0.51    
EXCEL 23 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Details 2) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Operating leases    
Operating lease right-of-use assets $ 84,906
Current portion of operating lease liability 73,978
Operating lease liability, net of current portion 11,250
Total operating lease liability $ 85,228  
Weighted Average Remaining Lease Term    
Operating leases 1 year 15 days  
Weighted Average Discount Rate    
Operating leases 15.00%  
XML 25 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 26 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Notes - Related Party (Details) - USD ($)
9 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Total Related Party Notes $ 520,000 $ 200,000
Erhfort, LLC [Member]    
Noteholder Erhfort, LLC  
Interest Rate 15.00%  
Maturity Date Sep. 30, 2020  
Total Related Party Notes $ 100,000 100,000
Erhfort, LLC One [Member]    
Noteholder Erhfort, LLC  
Interest Rate 15.00%  
Maturity Date Sep. 30, 2020  
Total Related Party Notes $ 100,000 100,000
JM One Holdings, LLC [Member]    
Noteholder JM One Holdings, LLC  
Interest Rate 15.00%  
Maturity Date Aug. 31, 2020  
Total Related Party Notes $ 20,000
Erhfort, LLC Two [Member]    
Noteholder Erhfort, LLC  
Interest Rate 15.00%  
Maturity Date Sep. 30, 2020  
Total Related Party Notes $ 100,000
Erhfort LLC Three [Member]    
Noteholder Erhfort, LLC  
Interest Rate 15.00%  
Maturity Date Sep. 30, 2020  
Total Related Party Notes $ 100,000
Erhfort LLC Four [Member]    
Noteholder Erhfort, LLC  
Interest Rate 15.00%  
Maturity Date Sep. 30, 2020  
Total Related Party Notes $ 100,000
XML 27 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Events
9 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

(17) SUBSEQUENT EVENTS

 

Through the date of this report the Company has been taking drastic measures as a response to the global COVID-19 crisis to preserve working capital. These measures include salary reductions and deferral of payments to vendors. The Company is currently in negotiations with its landlord to defer lease payments and has made the decision to furlough all employees from May 1, 2020 until August 1, 2020. The Company has also applied for the Paycheck Protection Program ("PPP") and the Economic Injury Disaster Loan ("EIDL") under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act As of the date of this report, IDSI has received a $4,000 advance from the EIDL and proceeds of $79,600 under the PPP. The Company is seeking total funding of $79,600 under PPP and $200,000 under EIDL. There can be no assurance that the Company will receive this funding

XML 28 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Property and Equipment (Tables)
9 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment, less accumulated depreciation

   March 31,
2020
   June 30,
2019
   Useful life
            
Furniture and Fixtures  $261,011   $261,011   5 years
Computers and Equipment   370,704    370,704   5 years
Third Party Software   10,291    10,291   5 years
Clinical Equipment   15,000    15,000   5 years
Total Property & Equipment  $657,006   $657,006    
Less: accumulated depreciation   (642,130)   (637,615)   
Total Property & Equipment - Net  $14,876   $19,391    

XML 29 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Details 3)
Mar. 31, 2020
USD ($)
Years Ended June 30,  
2020 $ 25,661
2021 58,546
2022 8,427
Total minimum lease payments 92,634
Less: amounts representing interest (7,406)
Present value of capital lease liabilities $ 85,228
XML 30 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Notes - Related Party (Details Textual) - USD ($)
9 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Promissory Notes - Related Party (Textual)    
Total related party debt $ 520,000 $ 200,000
JM One Holdings, LLC [Member]    
Promissory Notes - Related Party (Textual)    
Total related party debt $ 20,000
Interest rate 15.00%  
Maturity date Aug. 31, 2020  
Erhfort, LLC [Member]    
Promissory Notes - Related Party (Textual)    
Proceeds from loan received $ 300,000  
Total related party debt $ 100,000 $ 100,000
Interest rate 15.00%  
Maturity date Sep. 30, 2020  
Erhfort [Member]    
Promissory Notes - Related Party (Textual)    
Interest rate 15.00%  
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
9 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

(16) COMMITMENTS AND CONTINGENCIES

 

The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. Also, due to the lack of sales, there is currently no risk of claims. The Company is now self-insuring the risk of product liability.

 

From May 2010 to June 2012, claims were made by the IRS for payment of the Company's accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company's capital stock representing a change in control of the Company. New management's tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18th of each month until the balance of payroll taxes, interest and penalties are paid in full.

 

During fiscal 2018, as part of new management's restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019 which is recorded on the balance sheet as of March 31, 2020. The IRS is considering the request.

 

The Company leases a commercial building from Isco Properties, LLC for its offices and warehouse in Fort Lauderdale, FL. The term of the lease is five years beginning February 2014 with a monthly base rent beginning at $6,360 and increasing at a rate of 3% per year. The total rent commitment for the five years is $405,031, which has been fully satisfied as of March 31, 2020. Total rent expense for operating leases for offices and manufacturing facilities amounted to $61,153 and $67,197 for the nine months ended March 31, 2020 and the 2019, respectively. On October 31, 2018, the Company extended the lease for two years from February 1, 2019 to January 31, 2021. The monthly base rent is $7,150 for the 1st year and $7,350 for the 2nd year. The lease agreement was amended on August 1, 2019 which changed the total base rent for year 1 to $76,102 and year 2 to $98,452. This was the result of an agreement to reduce the base rent from August through October of 2019 by $6,650 per month and increasing the base rent from November 2019 through April 2020 by $3,417.38 (which includes imputed interest of $92.38 per month) to make up the deficit. The rent commitment before sales tax for the two years is $174,554. On January 8, 2019, the Company entered into an auto lease agreement. The term of the lease is 3 years beginning January 8, 2019 with a monthly lease payment of $1,204 due on the 7th day of each month. The total lease commitment including sales tax for the 3 years is $43,338.

XML 32 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories (Tables)
9 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of inventories

   March 31,
2020
   June 30,
2019
 
         
Raw materials consisting of purchased parts, components and supplies  $369,452   $369,747 
Work-in process including units undergoing final inspection and testing   52,500    52,500 
Finished goods   15,000    15,000 
Total Inventory  $436,952   $437,247 
Inventory Reserve   (436,952)   (437,247)
Net Inventory  $-   $- 

XML 34 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue
9 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
REVENUE

(4) REVENUE

 

The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue. 

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

 

Information about the Company's net sales by reporting segment for the nine months ended March 31, 2020 and 2019 is as follows:

 

   For the nine months ended 
   March 31,   March 31, 
   2020   2019 
Sales-parts, related party  $      -   $161,781 
Net sales  $-   $161,781 

 

All sales-parts, related party are sales to a customer located in China.

XML 35 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Property and Equipment
9 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

(8) PROPERTY AND EQUIPMENT

 

The following is a summary of property and equipment, less accumulated depreciation:

 

   March 31,
2020
   June 30,
2019
   Useful life
            
Furniture and Fixtures  $261,011   $261,011   5 years
Computers and Equipment   370,704    370,704   5 years
Third Party Software   10,291    10,291   5 years
Clinical Equipment   15,000    15,000   5 years
Total Property & Equipment  $657,006   $657,006    
Less: accumulated depreciation   (642,130)   (637,615)   
Total Property & Equipment - Net  $14,876   $19,391    

 

Depreciation expense for the nine months ended March 31, 2020 and 2019 was $4,515 and $5,840 respectively.

XML 36 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Leases
9 Months Ended
Mar. 31, 2020
Leases [Abstract]  
LEASES

(12) LEASES

 

In February 2016, the FASB issued Accounting Standards Update 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires lessees to recognize a right-of-use (ROU) asset and lease liability in the balance sheet for all leases, including operating leases, with terms of more than twelve months. Recognition, measurement, and presentation of expenses and cash flows from a lease by a lessee have not significantly changed from previous guidance. The amendments also require qualitative disclosures along with specific quantitative disclosures. We adopted this guidance using the cumulative-effect adjustment method on July 1, 2019, meaning we did not restate prior periods. Current year financial information is presented under the guidance in topic 842, while prior year information will continue to be presented under Topic 840. Adoption of the standard resulted in the recognition of an operating ROU asset and lease liability of approximately $147,000.

 

We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets, other current liabilities, and operating lease liabilities in our balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our balance sheets.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, we apply a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

 

Our leases have remaining lease terms of 9 to 22 months as of March 31, 2020.

 

The components of lease expense were as follows:

 

   Nine Months Ended 
   March 31,
2020
 
Operating lease expense  $76,662 
Total lease expense  $76,662 

 

Supplemental cash flow information related to leases was as follows:

 

   Nine Months Ended 
   March 31,
2020
 
Cash paid for amounts included in measurement of lease liabilities    
Operating cash flows from operating leases  $76,339 
      
Right-of-use assets obtained in exchange for new lease obligation     
Operating leases  $147,291 

 

Supplemental balance sheet information related to leases was as follows:

 

   March 31,
2020
 
Operating leases    
Operating lease right-of-use assets  $84,906 
      
Current portion of operating lease liability   73,978 
Operating lease liability, net of current portion   11,250 
Total operating lease liability  $85,228 
      
      
Weighted Average Remaining Lease Term     
Operating leases   1.04 Years 
      
Weighted Average Discount Rate     
Operating leases   15%

 

As of March 31, 2020, maturities of lease liabilities were as follows:

 

   Operating 
Years Ended June 30,  Leases 
2020  $25,661 
2021   58,546 
2022   8,427 
Total minimum lease payments   92,634 
Less: amounts representing interest   (7,406)
Present value of capital lease liabilities  $

85,228

 
XML 37 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories (Details) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Inventory Disclosure [Abstract]    
Raw materials consisting of purchased parts, components and supplies $ 369,452 $ 369,747
Work-in process including units undergoing final inspection and testing 52,500 52,500
Finished goods 15,000 15,000
Total Inventory 436,952 437,247
Inventory Reserve (436,952) (437,247)
Net Inventory
XML 38 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Details) - USD ($)
9 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Jun. 30, 2019
Summary of Significant Accounting Policies (Textual)      
Allowance for doubtful accounts $ 19,665   $ 0
Cash equivalents  
Federal deposit insurance corporation limit 250,000    
Excess of federally insured limit $ 0   $ 0
Options vested 10,882,662   7,717,136
Options non vested 4,213,184   5,730,522
Stock options granted to employees and consultants 2,098,188    
Option exercise price $ 0.51    
Impairment losses  
Warranty reserve, description The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2020 or June 30, 2019.    
Tax position, description Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.    
XML 39 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Going Concern and Management's Plans
9 Months Ended
Mar. 31, 2020
Going Concern and Management's Plans [Abstract]  
GOING CONCERN AND MANAGEMENT'S PLANS

(2) GOING CONCERN AND MANAGEMENT'S PLANS

 

The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $133,943,970, a stockholders' deficit of $1,403,825 and a working capital deficiency of $1,098,894. For the nine months ended March 31, 2020, net loss totaled $867,815. The net cash used in operating activities for the nine months ended March 31, 2020 totaled $459,872. These matters raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon increasing sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to increase sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received from the Chinese FDA ("CFDA") marketing clearance for the CTLM® effective November 16, 2018 to November 15, 2023, as disclosed in the Company's Form 8-K filing on December 11, 2018. However, there can be no assurance that we will obtain U.S. Food and Drug Administration ("FDA") marketing or other new international marketing clearances, that the CTLM® will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM® in China or elsewhere to allow us to operate profitably. If our majority shareholder Viable International Investments, LLC ("Viable") fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company's liquidity profile, and management's plans in those regards are discussed in the paragraphs that follow.

 

During fiscal year 2020, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities.

 

The Company's next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval ("PMA") process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after achieving successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China until the third or fourth quarter of fiscal 2021. No sales in other countries are expected in the near future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance, as to which there can be no assurance.

 

In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company's Quality Management System, we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. We will maintain our ISO 13485:2016 certification which will allow us to pursue FDA marketing clearance and the CE Mark in the future.

 

On October 23, 2019, the Company entered into a consulting agreement ("the Agreement") effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI's Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focusing on improving the technical performance and image quality of IDSI's Computed Tomography Laser Mammography (CTLM®) breast imaging device. The details of the Agreement were disclosed on the Form 8-K filed with the SEC on October 29, 2019. As of the date of this report, Dr. Huabei Jiang has made progress on the image quality, but the efficacy of the improvements will need to be tested once the COVID-19 crisis passes.

 

The Company's ability to continue as a going concern and its future success is dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. Due to the difficulty of raising additional capital during the current COVID-19 crisis, the Company has been taking aggressive measures to reduce its operating costs in order to preserve cash. The Company has also applied for the Paycheck Protection Program ("PPP") and the Economic Injury Disaster Loan ("EIDL") under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The Company's ability to meet its cash flow requirements throughout fiscal 2020 and continue its development and commercialization efforts will be dependent on the length and severity of the COVID-19 crisis and the Company's ability to secure additional funding through the CARES Act. There can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to execute its plan of operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 40 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]        
Sales, related party $ 12,715 $ 161,781
Total Revenue 12,715 161,781
Cost of Sales 7,442 72,176
Gross Profit 5,273 89,605
Operating Expenses:        
General and administrative 46,395 110,286 214,739 407,030
Salaries and wages 68,779 141,605 210,781 422,131
Research and development 6,709 7,595 23,849 57,063
Sales and marketing 19,776 225 20,081 843
Depreciation and amortization 621 1,947 4,515 5,840
Consulting expenses (including share-based compensation) 175,979 125,954 351,678 348,070
Total Operating Expenses 318,259 387,612 825,643 1,240,977
Operating Loss (318,259) (382,339) (825,643) (1,151,372)
Other Income (expense)        
Interest income 4 77 17 99
Other Income 75 27,943
Interest expense (17,112) (14,795) (42,189) (31,767)
Total Other Income (Expense) (17,108) (14,643) (42,172) (3,725)
Net Loss (335,367) (396,982) (867,815) (1,155,097)
Preferred Stock Dividends (4,475) (4,438) (13,549) (13,512)
Net Loss Available to Common Stockholders $ (339,842) $ (401,420) $ (881,364) $ (1,168,609)
Net Loss per common share:        
Basic and diluted $ (0.01) $ (0.01)
Weighted average number of common shares outstanding:        
Basic and diluted 122,758,901 121,964,130 122,732,306 108,930,341
XML 41 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options (Details)
9 Months Ended 12 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Expected volatility   24.00%
Expected term   5 years
Risk-Free interest rate   2.49%
Forfeiture rate 0.00% 0.00%
Expected dividend rate 0.00% 0.00%
Minimum [Member]    
Expected volatility 23.00%  
Expected term 4 years  
Risk-Free interest rate 1.55%  
Maximum [Member]    
Expected volatility 24.00%  
Expected term 5 years  
Risk-Free interest rate 2.49%  
XML 42 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options (Details 4) - shares
Mar. 31, 2020
Jun. 30, 2019
Vested & Exercisable Stock Options    
Total 13 13
Employee 2016 Equity Plan [Member]    
Vested & Exercisable Stock Options    
Total
Director 2016 Equity Plan [Member]    
Vested & Exercisable Stock Options    
Total
Employee Other Plans [Member]    
Vested & Exercisable Stock Options    
Total 13 13
Directors and Consultants Other Plans [Member]    
Vested & Exercisable Stock Options    
Total
XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 183 340 1 false 45 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StatementsOfOperations Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statements of Changes in Stockholders' Deficit (Unaudited) (USD $) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StatementsOfChangesInStockholdersDeficit Statements of Changes in Stockholders' Deficit (Unaudited) (USD $) Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows (Unaudited) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Nature of Business Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/OrganizationAndNatureOfBusiness Organization and Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern and Management's Plans Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernAndManagementsPlans Going Concern and Management's Plans Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Revenue Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Revenue Revenue Notes 10 false false R11.htm 00000011 - Disclosure - Due from Related Party Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DueFromRelatedParty Due from Related Party Notes 11 false false R12.htm 00000012 - Disclosure - Royalty Receivable Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivable Royalty Receivable Notes 12 false false R13.htm 00000013 - Disclosure - Inventories Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories Inventories Notes 13 false false R14.htm 00000014 - Disclosure - Property and Equipment Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyAndEquipment Property and Equipment Notes 14 false false R15.htm 00000015 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 15 false false R16.htm 00000016 - Disclosure - Accrued Payroll Taxes and Penalties Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesAndPenalties Accrued Payroll Taxes and Penalties Notes 16 false false R17.htm 00000017 - Disclosure - Promissory Notes - Related Party Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotes-RelatedParty Promissory Notes - Related Party Notes 17 false false R18.htm 00000018 - Disclosure - Leases Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Leases Leases Notes 18 false false R19.htm 00000019 - Disclosure - Convertible Preferred Stock Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStock Convertible Preferred Stock Notes 19 false false R20.htm 00000020 - Disclosure - Common Stock Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStock Common Stock Notes 20 false false R21.htm 00000021 - Disclosure - Stock Options Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptions Stock Options Notes 21 false false R22.htm 00000022 - Disclosure - Commitments and Contingencies Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 00000023 - Disclosure - Subsequent Events Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Revenue (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RevenueTables Revenue (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Revenue 25 false false R26.htm 00000026 - Disclosure - Inventories (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables Inventories (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories 26 false false R27.htm 00000027 - Disclosure - Property and Equipment (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyAndEquipment 27 false false R28.htm 00000028 - Disclosure - Promissory Notes - Related Party (Tables) Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotes-RelatedPartyTables Promissory Notes - Related Party (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotes-RelatedParty 28 false false R29.htm 00000029 - Disclosure - Leases (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesTables Leases (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Leases 29 false false R30.htm 00000030 - Disclosure - Convertible Preferred Stock (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables Convertible Preferred Stock (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStock 30 false false R31.htm 00000031 - Disclosure - Stock Options (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables Stock Options (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptions 31 false false R32.htm 00000032 - Disclosure - Going Concern and Management's Plans (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernAndManagementsPlansDetails Going Concern and Management's Plans (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernAndManagementsPlans 32 false false R33.htm 00000033 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryOfSignificantAccountingPoliciesPolicies 33 false false R34.htm 00000034 - Disclosure - Revenue (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RevenueDetails Revenue (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RevenueTables 34 false false R35.htm 00000035 - Disclosure - Due from Related Party (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DueFromRelatedPartyDetails Due from Related Party (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DueFromRelatedParty 35 false false R36.htm 00000036 - Disclosure - Royalty Receivable (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivableDetails Royalty Receivable (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivable 36 false false R37.htm 00000037 - Disclosure - Inventories (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesDetails Inventories (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables 37 false false R38.htm 00000038 - Disclosure - Property and Equipment (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyAndEquipmentTables 38 false false R39.htm 00000039 - Disclosure - Property and Equipment (Details Textual) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyAndEquipmentTables 39 false false R40.htm 00000040 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableAndAccruedExpenses 40 false false R41.htm 00000041 - Disclosure - Accrued Payroll Taxes and Penalties (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesAndPenaltiesDetails Accrued Payroll Taxes and Penalties (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesAndPenalties 41 false false R42.htm 00000042 - Disclosure - Promissory Notes - Related Party (Details) Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotes-RelatedPartyDetails Promissory Notes - Related Party (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotes-RelatedPartyTables 42 false false R43.htm 00000043 - Disclosure - Promissory Notes - Related Party (Details Textual) Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotes-RelatedPartyDetailsTextual Promissory Notes - Related Party (Details Textual) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotes-RelatedPartyTables 43 false false R44.htm 00000044 - Disclosure - Leases (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesDetails Leases (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesTables 44 false false R45.htm 00000045 - Disclosure - Leases (Details 1) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesDetails1 Leases (Details 1) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesTables 45 false false R46.htm 00000046 - Disclosure - Leases (Details 2) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesDetails2 Leases (Details 2) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesTables 46 false false R47.htm 00000047 - Disclosure - Leases (Details 3) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesDetails3 Leases (Details 3) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesTables 47 false false R48.htm 00000048 - Disclosure - Leases (Details Textual) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesDetailsTextual Leases (Details Textual) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - Convertible Preferred Stock (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails Convertible Preferred Stock (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables 49 false false R50.htm 00000050 - Disclosure - Convertible Preferred Stock (Details Textual) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetailsTextual Convertible Preferred Stock (Details Textual) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables 50 false false R51.htm 00000051 - Disclosure - Common Stock (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStockDetails Common Stock (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStock 51 false false R52.htm 00000052 - Disclosure - Stock Options (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails Stock Options (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 52 false false R53.htm 00000053 - Disclosure - Stock Options (Details 1) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails1 Stock Options (Details 1) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 53 false false R54.htm 00000054 - Disclosure - Stock Options (Details 2) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails2 Stock Options (Details 2) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 54 false false R55.htm 00000055 - Disclosure - Stock Options (Details 3) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails3 Stock Options (Details 3) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 55 false false R56.htm 00000056 - Disclosure - Stock Options (Details 4) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails4 Stock Options (Details 4) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 56 false false R57.htm 00000057 - Disclosure - Stock Options (Details Textual) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetailsTextual Stock Options (Details Textual) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 57 false false R58.htm 00000058 - Disclosure - Commitments and Contingencies (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsAndContingencies 58 false false R59.htm 00000059 - Disclosure - Subsequent Events (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEvents 59 false false All Reports Book All Reports imds-20200331.xml imds-20200331.xsd imds-20200331_cal.xml imds-20200331_def.xml imds-20200331_lab.xml imds-20200331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 44 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Details 1)
9 Months Ended
Mar. 31, 2020
USD ($)
Cash paid for amounts included in measurement of lease liabilities  
Operating cash flows from operating leases $ 76,339
Right-of-use assets obtained in exchange for new lease obligation  
Operating leases $ 147,291
XML 45 R41.htm IDEA: XBRL DOCUMENT v3.20.1
Accrued Payroll Taxes and Penalties (Details) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Jun. 27, 2018
Accrued Payroll Taxes and Penalties (Textual)      
Accrued payroll taxes and penalties $ 314,019 $ 314,019  
Balance of taxes due     $ 381,224
Amount of interest and penalties 314,019    
Remaining interest and penalties $ 314,019    
XML 46 R49.htm IDEA: XBRL DOCUMENT v3.20.1
Convertible Preferred Stock (Details) - USD ($)
9 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Dividends $ 0  
Balance $ 393,463 $ 379,914
Series M Cv Pfd [Member]    
No. of shares 600  
Amount of designated preferred shares $ 6,000,000  
No. of Shares Converted 600  
Amount Converted $ 6,000,000  
Dividends 0  
Balance $ 0  
Series M Cv Pfd [Member] | 8/1/2014 One [Member]    
Date of Conversion. Nov. 21, 2017  
No. of Shares Converted 3  
Amount Converted $ 30,000  
Series M Cv Pfd [Member] | 8/1/2014 Two [Member]    
Date of Conversion. Aug. 07, 2018  
No. of Shares Converted 241  
Amount Converted $ 2,410,000  
Series M Cv Pfd [Member] | 8/31/2015 [Member]    
No. of shares 200  
Amount of designated preferred shares $ 2,000,000  
Date of Conversion. Aug. 07, 2018  
No. of Shares Converted 200  
Amount Converted $ 2,000,000  
Series M Cv Pfd [Member] | 4/22/2016 [Member]    
No. of shares 150  
Amount of designated preferred shares $ 1,500,000  
Date of Conversion. Aug. 07, 2018  
No. of Shares Converted 150  
Amount Converted $ 1,500,000  
Series M Cv Pfd [Member] | 8/1/2014 [Member]    
No. of shares 250  
Amount of designated preferred shares $ 2,500,000  
Date of Conversion. Apr. 18, 2017  
No. of Shares Converted 6  
Amount Converted $ 60,000  
Series L Cv Pfd [Member]    
Dividends $ 193,463  
Series L Cv Pfd [Member] | 2/10/2010 [Member]    
No. of shares 35  
Amount of designated preferred shares $ 350,000  
Date of Conversion. Jan. 06, 2011  
No. of Shares Converted 15  
Amount Converted $ 150,000  
Balance $ 200,000  
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Notes - Related Party (Tables)
9 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
Schedule of outstanding note balances

 

Noteholder

  Interest
Rate
   Maturity
Date
  March 31,
2020
   June 30,
2019
 
Related Party Notes:               
Erhfort, LLC   15%  9/30/20  $100,000   $100,000 
Erhfort, LLC   15%  9/30/20   100,000    100,000 
JM One Holdings, LLC   15%  8/31/20   20,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Total Related Party Notes          $520,000   $200,000 

XML 48 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Common Stock
9 Months Ended
Mar. 31, 2020
Equity [Abstract]  
COMMON STOCK

(14) COMMON STOCK

 

The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of no par preferred shares authorized.

 

During the nine months ended March 31, 2020, the Company issued 254,903 shares of its common stock to non-affiliated accredited investors pursuant to subscription agreements for $130,000. The price per share was approximately $.51 per share.

 

During the nine months ended March 31, 2019, the Company issued 87,044,089 shares of its common stock as Viable exercised its right to convert the remaining 591 shares of its Series M Convertible Preferred Stock valued at $5,910,000 into 87,044,089 shares of restricted common stock on August 7, 2018. The Company also issued 1,882,351 shares of its common stock to non-affiliated accredited investors pursuant to subscription agreements for $960,000. The price per share was approximately $.51 per share.

XML 49 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of presentation and use of estimates

(a) Basis of presentation and use of estimates

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

These unaudited financial statements should be read in conjunction with the Company's audited financial statements for the year ended June 30, 2019, contained in our General Form for Registration of Securities of Form 10-K as filed with the Securities and Exchange Commission (the "Commission") on September 30, 2019. The results of operations for the nine months ended March 31, 2020, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2020.

Revenue recognition

(b) Revenue recognition

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue

Allowance for doubtful accounts

(c) Allowance for doubtful accounts

 

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

 

Our allowance for doubtful accounts was $19,665 as of March 31, 2020 and $0 as of June 30, 2019.

Cash and cash equivalents

(d) Cash and cash equivalents

 

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2020 and June 30, 2019.

Concentration of Risk

(e) Concentration of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company's cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. At March 31, 2020 and June 30, 2019, the Company had $0 in excess of the federally insured limit.

 

The Company did not have any revenue for the nine months ended March 31, 2020. For the nine months ended March 31, 2019, all of the revenues were from Xi'an IDI Laser Imaging Co. Ltd.

Inventory

(f) Inventory

 

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.

Property and equipment

(g) Property and equipment

 

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

Research and development

(h) Research and development

 

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company's CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

Net loss per share

(i) Net loss per share

 

The Company relies on the guidance provided by ASC 260, ("Earnings per Share"), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

 

The Company had 10,882,662 and 7,717,136 options vested as of March 31, 2020 and June 30, 2019, respectively and 4,213,184 and 5,730,522 options not yet vested as of March 31, 2020 and June 30, 2019, respectively.

Stock-based compensation

(j) Stock-based compensation

 

In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard. The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. During the nine months ended March 31, 2020, the Board granted options to purchase 2,098,188 shares with an exercise price of $.51 per share to an employee and a consultant. No stock options were granted to employees and consultants during the nine months ended March 31, 2019. Stock options are being expensed pursuant to ASC 718.

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (15) Stock Options.

Long-lived assets

(k) Long-lived assets

 

The Company relies on the guidance provided by ASC 360 ("Property, Plant & Equipment"). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

 

The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2020 and 2019.

Income taxes

(l) Income taxes

 

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, "Accounting for Income Taxes," which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

 

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. 

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2016-2019 are still potentially subject to audit by the taxing authorities.

Warranty reserve

(m) Warranty reserve

 

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2020 or June 30, 2019.

Impact of recently issued accounting pronouncements

(n) Impact of recently issued accounting pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 and updated in Nov 2018 ASU 2018-19, Financial Instruments – Credit Losses (Topic 326) ("ASU 2016-13"), which requires the immediate recognition of management's estimates of current and expected credit losses. ASU 2016-13 is effective for fiscal years and interim reporting periods within those years beginning after December 15, 2019. Early adoption is permitted after fiscal years beginning December 15, 2018. The Company is currently evaluating the potential impact of adopting this guidance on our financial statements.

 

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820. The ASU is effective for the Registrants for fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted. The Company is currently assessing the impact of this standard on their financial statements.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

Fair Value of Financial Instruments

(o) Fair Value of Financial Instruments

 

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company's debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2020 and June 30, 2019, the aggregate fair value of the Company's debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 ("Fair Value Measurements and Disclosures"). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities

 

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Due from Related Party (Details)
1 Months Ended 9 Months Ended
Mar. 22, 2018
Agreements
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2019
USD ($)
Due from Related Party (Textual)        
Receivables from related parties     $ 11,965
Xi'an [Member]        
Due from Related Party (Textual)        
Number of agreements | Agreements 2      
Term of contract 20 years      
Percentage of revenue for product sales 25.00%      
Sales from related party   0 $ 161,781  
Receivables from related parties   0   7,700
Due from related parties   0   $ 11,965
Amount due   11,115    
Full amount of the receivable   7,700    
Amount due from related parties   $ 11,965    
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options (Tables)
9 Months Ended
Mar. 31, 2020
Schedule of stock option grants fair value of each option

   

As of

March 31,
2020

   

As of

June 30,
2019

 
Expected volatility     23 to 24.00 %     24.00 %
Expected term     4 to 5 Years       5 Years  
Risk-Free interest rate     1.55 to 2.49 %     2.49 %
Forfeiture rate     0.00 %     0.00 %
Expected dividend rate     0.00 %     0.00 %

Schedule of vested and unvested options

Employees/Consultants  Unvested   Vested   Total 
Outstanding at June 30, 2018   6,825,181    4,811,596    11,636,777 
Granted   1,800,000    600,000    2,400,000 
Vested   (2,305,527)   2,305,527    - 
Cancelled   (589,132)   -    (589,132)
Outstanding at June 30, 2019   5,730,522    7,717,123    13,447,645 
Granted   1,598,188    500,000    2,098,188 
Vested   (2,665,526)   2,665,526    - 
Cancelled   (450,000)   -    (450,000)
Outstanding at March 31, 2020   4,213,183    10,882,649    15,095,833 

Schedule of vested & exercisable stock options

Vested & Exercisable Stock Options  March 31, 2020   June 30,
2019
 
Employee 2016 Equity Plan   -    - 
Director 2016 Equity Plan   -    - 
Employee Other Plans   13    13 
Directors and Consultants Other Plans   -    - 
Total   13    13 

2016 Plan [Member]  
Schedule of stock options granted, exercised and cancelled

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
 
Outstanding at June 30, 2018   11,636,777   $0.20 
Granted   2,400,000   $0.20 
Exercised   -   $- 
Cancelled   (589,132)  $0.20 
Outstanding at June 30, 2019   13,447,645   $0.20 
Granted   2,098,188   $0.51 
Exercised   -   $- 
Cancelled   (450,000)  $0.20 
Outstanding at March 31, 2020   15,095,833   $0.24 

2012 Non-Statutory Plan [Member]  
Schedule of stock options granted, exercised and cancelled

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
 
Outstanding at June 30, 2018   13   $1,210 
Granted   -   $- 
Exercised   -   $- 
Cancelled   (.31)  $6,083 
Outstanding at June 30, 2019   13   $976 
           
Granted   -   $- 
Exercised   -   $- 
Cancelled   -   $- 
Outstanding at March 31, 2020   13   $976 

XML 52 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Property and Equipment (Details Textual) - USD ($)
9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Property and Equipment (Textual)    
Depreciation expense $ 4,515 $ 5,840
XML 53 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Balance Sheets - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Current assets:    
Cash $ 34,743 $ 44,615
Accounts receivable, related party, net of allowance 7,700
Due from related party, net of allowance 11,965
Employee advances 5,000
Prepaid expenses 11,226 11,566
Total current assets 50,969 75,846
Property and equipment, net 14,876 19,391
Operating lease right-of-use assets 84,906
Total assets 150,751 95,237
Current liabilities:    
Accounts payable and accrued expenses 241,866 34,943
Accrued payroll taxes and penalties 314,019 314,019
Promissory notes, related party 520,000 200,000
Current portion of operating lease liabilities 73,978
Total current liabilities 1,149,863 548,962
Long-term liabilities    
Operating lease liabilities 11,250
Total liabilities 1,161,113 548,962
Commitment and Contingencies (Note 16)
Temporary equity    
Convertible Preferred Series L 393,463 379,914
Total temporary equity 393,463 379,914
Stockholders' Deficit:    
Preferred stock, no par, 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 shares issued and outstanding at March 31, 2020 and June 30, 2019
Common stock, no par value, 500,000,000 authorized, 122,876,549 and 122,621,646  shares issued and outstanding March 31, 2020 and June 30, 2019, respectively 132,540,145 132,228,967
Accumulated Deficit (133,943,970) (133,062,606)
Total stockholders' deficit (1,403,825) (833,639)
Total liabilities and stockholders' deficit $ 150,751 $ 95,237
XML 54 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Statement of Cash Flows [Abstract]    
Net loss $ (867,815) $ (1,155,097)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 4,515 5,840
Stock option expense 181,178 26,705
Bad debt expense 19,665
Changes in assets and liabilities and stockholders deficit:    
(Increase) decrease in due from related party, net of allowance 27,153
(Increase) decrease in employee advances (5,000)  
(Increase) decrease in royalty receivable 21,753
(Increase) decrease in other receivables, net of allowance (11,115)
(Increase) decrease in prepaid expenses 340 (4,233)
Increase (decrease) in accounts payable and accrued expenses 206,923 (40,487)
Change in right of use asset/lease obligation, net 322
Total adjustments 407,943 25,616
Net cash used in operating activities (459,872) (1,129,481)
Cash flows from financing activities:    
Proceeds from promissory notes, related party 320,000 400,000
Proceeds from issuance of common stock 130,000 960,000
Net cash provided by financing activities 450,000 960,000
Net decrease in cash and cash equivalents (9,872) (169,481)
Cash and cash equivalents at beginning of period 44,615 271,540
Cash and cash equivalents at end of period 34,743 102,059
Supplemental Disclosure of cash flow information:    
Cash paid for interest 40,068 31,767
Cash paid for taxes
XML 55 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Royalty Receivable
9 Months Ended
Mar. 31, 2020
Royalty Receivable [Abstract]  
ROYALTY RECEIVABLE

(6) ROYALTY RECEIVABLE

 

On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the nine months ended March 31, 2020 and 2019, there was no royalty income. As of March 31, 2020 and June 30, 2019, the Company had a royalty receivable balance of $0 and $0, respectively.

XML 56 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Accrued Payroll Taxes and Penalties
9 Months Ended
Mar. 31, 2020
Payables and Accruals [Abstract]  
ACCRUED PAYROLL TAXES AND PENALTIES

(10) ACCRUED PAYROLL TAXES AND PENALTIES

 

As of March 31, 2020 and June 30, 2019, the Company owed the IRS $314,019 and $314,019, respectively. Accrued payroll taxes represent outstanding interest and penalties based on prior management's failure to pay payroll taxes commencing with the quarter ending March 31, 2010. As part of new management's restructuring plan, the Company received funds from an accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalty and interest abatement. The amount due at March 31, 2020 of $314,019 represents the interest and penalties. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,019. The Company had a telephone conference on April 18, 2019 with the office of appeals and is waiting for further communications from the appeals officer.

XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Details)
1 Months Ended 9 Months Ended
Jan. 08, 2019
Aug. 04, 2014
USD ($)
shares
Oct. 31, 2018
Feb. 28, 2014
Mar. 31, 2020
USD ($)
Jun. 29, 2018
USD ($)
Jun. 27, 2018
USD ($)
Sep. 04, 2014
USD ($)
Jun. 30, 2012
USD ($)
Commitments and Contingencies (Textual)                  
Product liability insurance         $ 3,000,000        
Number of patents scans conducted worldwide         25,000        
Accrued payroll taxes, interest and penalties                 $ 1,489,640
Purchase of convertible preferred stock | shares   250              
Convertible preferred stock value   $ 2,500,000              
Voting and economic interest percentage   78.90%              
Lump sum payment               $ 250,000  
Monthly installment payments               $ 20,000  
Balance of taxes due             $ 381,224    
Penalties and interest totaling           $ 314,019      
Operating leasing, description On January 8, 2019, the Company entered into an auto lease agreement. The term of the lease is 3 years beginning January 8, 2019 with a monthly lease payment of $1,204 due on the 7th day of each month. The total lease commitment including sales tax for the 3 years is $43,338.   The Company extended the lease for two years from February 1, 2019 to January 31, 2021. The monthly base rent is $7,150 for the 1st year and $7,350 for the 2nd year. The lease agreement was amended on August 1, 2019 which changed the total base rent for year 1 to $76,102 and year 2 to $98,452. This was the result of an agreement to reduce the base rent from August through October of 2019 by $6,650 per month and increasing the base rent from November 2019 through April 2020 by $3,417.38 (which includes imputed interest of $92.38 per month) to make up the deficit. The rent commitment before sales tax for the two years is $174,554. The Company leases a commercial building from Isco Properties, LLC for its offices and warehouse in Fort Lauderdale, FL. The term of the lease is five years beginning February 2014 with a monthly base rent beginning at $6,360 and increasing at a rate of 3% per year. The total rent commitment for the five years is $405,031, which has been fully satisfied as of March 31, 2020. Total rent expense for operating leases for offices and manufacturing facilities amounted to $61,153 and $67,197 for the nine months ended March 31, 2020 and the 2019, respectively.          
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.20.1
Convertible Preferred Stock (Details Textual)
1 Months Ended
Aug. 07, 2018
shares
Nov. 21, 2017
USD ($)
Number
shares
Apr. 18, 2017
USD ($)
Number
shares
Apr. 22, 2016
USD ($)
shares
Aug. 31, 2015
USD ($)
shares
Jun. 30, 2015
USD ($)
$ / shares
shares
Mar. 31, 2010
USD ($)
shares
Mar. 31, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 27, 2014
USD ($)
shares
Jan. 06, 2011
USD ($)
shares
Convertible Preferred Stock (Textual)                      
Redemption value               $ 193,463 $ 179,914    
Total temporary equity               393,463 $ 379,914    
Series L Convertible Preferred Stock [Member]                      
Convertible Preferred Stock (Textual)                      
Converted short term promissory note             $ 350,000        
Convertible preferred stock | shares             35       15
Original purchase price             $ 10,000        
Annual rate             9.00%        
Conversion of preferred stock to common stock | shares             474        
Conversion of preferred stock, description             The private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time.        
Principal value                     $ 150,000
Series M Convertible Preferred Stock [Member]                      
Convertible Preferred Stock (Textual)                      
Convertible preferred stock | shares 591     150 200 147,283       250  
Original purchase price           $ 10,000          
Annual rate           9.00%          
Redemption value               0      
Total temporary equity               $ 0      
Non-refundable deposit                   $ 100,000  
Preferred stock voting rights           At the first closing, $2,400,000 was paid by Viable to purchase 250 shares of convertible preferred stock which provided a 78.9% voting and economic interest in the Company's capital stock representing a change in control of the Company.          
Issuance of convertible preferred stock   $ 30,000 $ 60,000 $ 1,500,000 $ 2,000,000            
Restricted common shares | shares 87,044,089 441,848 883,696                
Number of investors | Number   3 3                
Restricted common shares retained | shares   49,691 10,909                
Other equity securities | $ / shares           $ 10,000          
Series M Convertible Preferred Stock [Member] | Investor [Member]                      
Convertible Preferred Stock (Textual)                      
Restricted common shares | shares   392,157 872,787                
XML 60 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options (Details 2) - shares
9 Months Ended 12 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Shares    
Outstanding 13,447,645 11,636,777
Granted 2,098,188 2,400,000
Vested
Cancelled (450,000) (589,132)
Outstanding 15,095,833 13,447,645
Unvested [Member]    
Shares    
Outstanding 5,730,522 6,825,181
Granted 1,598,188 1,800,000
Vested (2,665,526) (2,305,527)
Cancelled (450,000) (589,132)
Outstanding 4,213,183 5,730,522
Vested [Member]    
Shares    
Outstanding 7,717,123 4,811,596
Granted 500,000 600,000
Vested 2,665,526 2,305,527
Cancelled
Outstanding 10,882,649 7,717,123
XML 61 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Property and Equipment (Details) - USD ($)
9 Months Ended 12 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Total Property & Equipment $ 657,006 $ 657,006
Less: accumulated depreciation (642,130) (637,615)
Total Property & Equipment - Net 14,876 19,391
Furniture and Fixtures [Member]    
Total Property & Equipment $ 261,011 $ 261,011
Useful life 5 years 5 years
Computers and Equipment [Member]    
Total Property & Equipment $ 370,704 $ 370,704
Useful life 5 years 5 years
Third Party Software [Member]    
Total Property & Equipment $ 10,291 $ 10,291
Useful life 5 years 5 years
Clinical Equipment [Member]    
Total Property & Equipment $ 15,000 $ 15,000
Useful life 5 years 5 years
XML 62 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2020
Jun. 30, 2019
Preferred stock, par value
Preferred stock, shares authorized 2,000,000 2,000,000
Common stock, par value
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 122,876,549 122,876,549
Common stock, shares outstanding 122,621,646 122,621,646
Series M preferred stock    
Preferred stock, designated 600 600
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 63 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Nature of Business
9 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND NATURE OF BUSINESS

(1) ORGANIZATION AND NATURE OF BUSINESS

 

Imaging Diagnostic Systems, Inc. (the "Company" or "IDSI") is a medical technology company that has developed a new, non-invasive CT scanner called CTLM® that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.

XML 64 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Net sales $ 12,715 $ 161,781
Sales-parts, related party [Member]        
Net sales     $ 161,781
XML 65 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Convertible Preferred Stock (Tables)
9 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Schedule of preferred stock

 

Security

  Date Issued  No. of Shares   Amount   Date of Conversion  No. of Shares Converted   Amount Converted  

Balance

3/31/2020

 
Series M Cv Pfd  8/1/2014   250   $2,500,000   4/18/2017   6   $60,000      
                11/21/2017   3    30,000      
                8/7/2018   241    2,410,000      
Series M Cv Pfd  8/31/2015   200    2,000,000   8/7/2018   200    2,000,000      
Series M Cv Pfd  4/22/2016   150    1,500,000   8/7/2018   150    1,500,000      
Total Series M Cv Pfd      600   $6,000,000       600   $6,000,000   $-0-
Dividends                             -0-
                Total redemption value        $0-
                                
Series L Cv Pfd  2/10/2010   35   $350,000   1/6/2011   15   $150,000   $200,000 
Dividends                             193,463 
                Total redemption value        $393,463 

XML 66 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories
9 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORIES

(7) INVENTORIES

 

Inventories consisted of the following:

 

   March 31,
2020
   June 30,
2019
 
         
Raw materials consisting of purchased parts, components and supplies  $369,452   $369,747 
Work-in process including units undergoing final inspection and testing   52,500    52,500 
Finished goods   15,000    15,000 
Total Inventory  $436,952   $437,247 
Inventory Reserve   (436,952)   (437,247)
Net Inventory  $-   $- 

  

Due to the age of the inventory, lack of demand for parts and lack of sales the Company wrote off all inventory during the year ended June 30, 2017 and has booked a reserve for the entire value of its inventory as of March 31. 2020 and June 30, 2019. For the nine months ended March 31, 2020, reduction of inventory represents physical count adjustments.

XML 67 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Notes - Related Party
9 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
PROMISSORY NOTES - RELATED PARTY

(11) PROMISSORY NOTES – RELATED PARTY

 

The following table is a summary of the outstanding note balances as of March 31, 2020 and June 30, 2019.

 

 

Noteholder

  Interest
Rate
   Maturity
Date
  March 31,
2020
   June 30,
2019
 
Related Party Notes:               
Erhfort, LLC   15%  9/30/20  $100,000   $100,000 
Erhfort, LLC   15%  9/30/20   100,000    100,000 
JM One Holdings, LLC   15%  8/31/20   20,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Erhfort, LLC   15%  9/30/20   100,000    - 
Total Related Party Notes          $520,000   $200,000 

 

Each of Erhfort, LLC and JM One Holdings, LLC owns Company common stock directly or indirectly. Hence these debts are considered related party debt.

 

During the nine months ended March 31, 2020, the Company received loan proceeds of $300,000 from Erhfort, LLC and $20,000 from JM One Holdings, LLC, both of which are related parties. The loans from Erhfort have an annual interest rate of 15% and interest is being accrued and paid monthly. The loan from JM One Holdings, LLC will accrue interest monthly at an annual rate of 15%, but interest will not be paid until maturity. The maturity dates for all loans with original maturity dates prior to September 30, 2020 from Erhfort were extended to September 30, 2020.

XML 68 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Common Stock (Details) - USD ($)
9 Months Ended
Aug. 07, 2018
Mar. 31, 2020
Mar. 31, 2019
Jun. 30, 2019
Common Stock (Textual)        
Common stock, par value    
Common stock, shares authorized   500,000,000   500,000,000
Preferred stock, par value    
Preferred stock, shares authorized   2,000,000   2,000,000
Issued total shares of common stock   254,903 87,044,089  
Issued value pursuant to subscription agreement   $ 130,000 $ 960,000  
Price per share   $ 0.51 $ 0.51  
Series M Convertible Preferred Stock [Member]        
Common Stock (Textual)        
Convert shares of convertible preferred stock 591      
Convert value of convertible preferred stock $ 5,910,000      
Convertible preferred stock shares converted into restricted common stock 87,044,089      
Common Stock        
Common Stock (Textual)        
Issued total shares of common stock     1,882,351  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options (Details 3) - $ / shares
9 Months Ended 12 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Options    
Outstanding 13,447,645 11,636,777
Granted 2,098,188 2,400,000
Cancelled (450,000) (589,132)
Outstanding 15,095,833 13,447,645
2012 Non-Statutory Plan [Member]    
Options    
Outstanding 13 13
Granted
Exercised
Cancelled (0.31)
Outstanding 13 13
Wtd. Avg. Exercise Price    
Outstanding $ 976 $ 1,210
Granted
Exercised
Cancelled 6,083
Outstanding $ 976 $ 976
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Events (Details)
1 Months Ended
May 01, 2020
Subsequent Event [Member]  
Subsequent Events (Textual)  
Subsequent event, description Through the date of this report the Company has been taking drastic measures as a response to the global COVID-19 crisis to preserve working capital. These measures include salary reductions and deferral of payments to vendors. The Company is currently in negotiations with its landlord to defer lease payments and has made the decision to furlough all employees from May 1, 2020 until August 1, 2020. The Company has also applied for the Paycheck Protection Program ("PPP") and the Economic Injury Disaster Loan ("EIDL") under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act As of the date of this report, IDSI has received a $4,000 advance from the EIDL and proceeds of $79,600 under the PPP. The Company is seeking total funding of $79,600 under PPP and $200,000 under EIDL. There can be no assurance that the Company will receive this funding.
ZIP 71 0001213900-20-012538-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-012538-xbrl.zip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

[\IB^8> MQ'3(FI#*0;=MY9_RV8O[N72*OQ>UD'6]V&4K/9R3<>JMEA$5+](RDS:'YIBX MG0H-?P]F:@/8+\BXEAA\:MEK-29$@S?F;-'>C(A9X227_0L''!'&^53\_CS+ MKZL::,:!6";A M' ;M2+^E99EP&'#>O-Y$Z8LBVFT?!>(@OFO%)TX FM)> =4=JV"V]5%!BE:] MWI5# 63)2O#+;SYT]TAOQ_)"LWM2M6WD=BH,-;>GU,!HOA$QVS!>9PO^%$QQ M';U D.0L7;+?Y!4\#;.A::%.:WF0SX0>!_MHI!ULO_4;J$?-'BHV<9Z(ZF+A MW2T>W@OO6T2B9$+KHK%,(/L<93M])?0@VT,3;3\%O>XAMGN]IDU77@;8GL[P M>M;G&JZ^7T-Z$O8[W4F27M[KB9T-]N"@3B>,PT7D"E-Q06?!MKHT%X8>!Y]& M5_E[2>)U:5"-&KX39%B@&](M],6#&T-WC!K#MMQ#'H5#$*IW,"#=?CZG$;Q$ MZM043N6$(]^$:NHIZ5 (4J*Z([>$SO3/2OD[7#@X?1LEM#X'9A4KXB5_,2Q+ M;^B"QD\\W\E='J5%M%"\^K9M(5ZGYZTJ.)BS)Y6 AL=;P1Z3F"]7"Q'Z=9!3 MS3TN'=]'!3_0A34MK^DL9_5[X$OA]R^=2/TP-+]3MM MJ.?G+&'%P N+D/['M%(Z])>]+V?]-*6T,#[L9_&,3&]U'0_G1I@\M=*(!O"] MO4GNIS0)3-BZI?XA/^A]N!ZTX:11>I"OX1J:I@N,1U@GM960AG!2;2;]YE,?W M#G/XW5<[*9J:\>"[R_Y'@X]4WS75KF*7M>S7,'+GHAGF55F44;J$7%)9DC#K M!'_<=P=8/O8JQJA3@^UE8!J_]/I'HTOUI&0"0N>K&W,BQ\OA6[CYSBL=:<-F M.M @$Q_QFW96A*:545Y:0Q8.4$EIE'5R7\=(^\ $R^(B%?%)QBQKA_C2:QIM MAJ;:YWA3?.:KF='T=1L/-"Z)Y6%E8\ L_^.\63+3?!$74D:P70I"DW_"6%'G M?!3*4O 0?%OH\HZH_CL2!N\X<#N?3#%+(28U%N$$[5@^D,%P^.YKFD*:1P^TF=)XN#M\&\_X,K\9 $[N"!PD![DN;9]&9- M7G P^FV)21[/6FH26NF%^#BEA#8:01>_O07<;?Q%L])5">'I"CM$R=$4?QFL M7)%TP#EK%7L/=%)XNT"!460@!1;)]P]9_8^:(7P=H$,<=P#L^4RALDE M2GJ# 4LWS%-J[X96"&\WR!"E@Q,V%^!K__/XR:$#.BF\/:# *-DB)C)Y0MCU ME8]Z97='OY15E&A\"79QO^]NF$$/']!0RP9?DCL"E-8,_6TQ^;96^B.2#;+I M@NC ?7[-FO"1;3*XFTZW6=FV-#27@NU5=KX9K"\J.)/W@U\3:DJRFNIE!N]% M)-OQQ%3@!6$5Q+A[Z.=!D MV28!,[V_8Y3T-D6:H;:SHUHL.!WLV*1U4]OW-2&0O;:SM=>M]T[&OAUZ@Z)? MA;]7T1A[\>7VR@W._0-41KV K&?5([+L% YD./^SRLKZJ2S52!_\V9N)5(!J M[6+O;\$)H0$T[E0A(:P?(IMW;V?PO?&DH0D_;J>#O;]98/W M@>5;P8>,IPH:[2JIC[6C-;PP>2##RJJUCDM^#T@$T91LST7314Q=O#E3M+V9 MY>E5ZKD#756#,W0[O-+]BJZ )@:J*V)_GB$-^:[S;%DMRLLXNN=OY5RD197# MC0]570W"WJAE!=PR22N)@S@V>/(#I%R>)(T"B1N- W&C.8R^CDI@Y^TB2@O& M3D!!E[]F>;)\CI=*HKAJ>F/-M*JT%')3P\&G25BE$ *N#(_@;80Z*4 ?3E1% M >2Y*0''NK1^.)K-]ZQ5DKOH"RU.JCR'N3]=7C$VB']HUA3.VCY7C1.KU%\$ M.JH&)^IV>*63YOIM[XU0)R7H'W5/U< LRA:*45+&![O_T_@PF\=2^:NGUTR# M,N1+OH@4#G.EZ7=7]C>O3JU0-\^Z:@:GWU9PM=[KT8NWFZ:(_;P:JN.=V. 8 MP"OK[*#ECVG.5>@H9E5!PBU7G/(F0$ND@YZ&?,Y@KP&!H*S7LG6\:!X'8[OE M!:M)]*!2/4A$JTC'+0P4$I=Z!22#[7Y+,AK76[.7+3:A^(69?5>G-; MK1N'#'>@J.JGEO/&'1/,EBPJ(1SL," ;TP%$25&M8=D$P@?J]X]96CXFL)LM MHR2!#]7@E"LAD[0W#M@AMTS0B^+@@Q7?F!6U O@2&HV&( =;.C=+4=BHI:RT_:GF2, 7VOS[.NV^K^X+^ MHV*&\.P)K*%+9*U-Q5]TK1OX+L+6+!^:V A\<5&NE@[/+&:*!6Q0TG.W2H<;];+& +4#!5GUP^YK-[;6S%"YZIH7] M^'5J ;\MLX6WOF/?JF!E&BD&QR[H%0YF7@RIR^'KG<;KW!3E9D8.V-%C#SJK M;;M".XV+19(554X!Y/M$Y52;7@2ZSMX.OW2=^9$2]J$XIV39*I%5EI-(==(P M/%_X+DCO+_^[*GC,P%UVDN600J4Y_H-P@BS5N.H=]9#U\R30\K7$1ANN'BR$ M/DG;\\X%+Z*^BH"S,WF\TO2^Y&JOK"O[F+?L2>XN#].1W/TV7[%U0_R01CS6 ML_']:\:C30-9]SG"E7J.ZT$?+5O-_C%'N+$GSET*5M_Y:GA0 P3EQD5Y(.6H MAZO[IH%6S9+=8!OW7G,42KEC*$-@5BVGNR<-W@L&]X:R]6 ,<2[V3M^A1(QT MV+TZ4\XRU63)V]);WH!T$-J<,N/4G-\6HZVL4@!7IVK026GWF!@,8]$KBU8\ M3)/'3_&2ILOBEN9L16V)!3!*(^L,!ZAR0L1:AQ1<:3R$@O30V9<%+8KYZIPN M:1XEB0A6I!W+/@2C-*X>-_@'+)0A3,=_KKMN@_L,$( MA0?IWXMTD8O3$O&_%^E-]A(EY'R,V)SDXD-L+=)\*4@W;Q^/@JHC#0AM M<2E!FGT_(2"HNL"*<4G5GR"*X.D&+3W\!(VI%@S;Z!=L2 M%)"86]OFK03.)A_#&[?X#64KZX(?")<#UT;<* 9M_\/<5$+94TZ8=[BQ%*0? M#Q/ECJK_G/%.CG8/TV-["_##U4MVI!,#_0+U3A.P/E_=0+!%1<^SO+X4>QLE MJHM)5A5L/>6(5^ZO1A'L82Y4^79V4U\:+D [3+\I7,O=^9'<9T9Q9/WE@E6^ MQJWTB'<'8X%Z:?=;]*E-E$-LS@QYQNLIP'I@KG M0JB^8U\O7^".T#^J>,./URUA7@XZZ/K3$;"B9[DFG\M:W2YZ*TR?>;AMBZO_ M)L+>\M9MD,YT34*&JD-D8*9D9$':]8:NHSAEUK59MO;#^Z26-DKC:GL7J"H' M=]3&T>1-"9JL!X'Z:Q0DP ?T#2T95,52SRR.K<<J83IJ M?*AR(J<6,0HBZQPS2LM(DLY]2)U]!$?7Z ]N]:+(N\=V.-M%;JL["$_'F);8 M-H57T$GVQ76M1CJ]P OKK3/NMHDA9T51K47ZQ_,L7]&X9$2\83MSJ8/) )W5UTNR9E6$/*97DX0 MOP>'7I47500A\'!]K+DMUIX0RC3;1ZG("+7'*NE77?52*^;EP:L3O#2X/%#T MRNL.7,,8+*>FN*5EF5!QVF*]Y+8E@R9]XS7R:9L*ZME5TZHF603QFDWQ_!B_ MN4.XZ=TA;.Z3T?HCKX1Q8/6C].64WF]KG32EO786R55QM49@A 9\68BBR)*5 MA8\6?!+?]]SE6.@K(LFT&DD)N_C3)Z]\XN*5..R\M<,G7@67=J^?([->_Z2E M;ZHMYBRGPEXY@^PSEH8K2">L^I&'^I6YNZQ].%LDXV^>X%13P%$989=/0VY^ MX^*A?J&/]7#WB#@,_$574)@.KM;K*'^9KV[CAS1>Q0N&I+: P/0LB5T>E-BJ M%&1=OD,5Y)0UO"P8P;W22%<<:BZ@YWP%NFT W2=;]&X'\%EWU!\R?Z/DH@6*FX2!=)M>1GR],7 MW'LH$U?7[Z]"8VHT)P0DH7 M+W)W: 21=809I=0%0IPLA#S;\C4*9)65I+U;&Z9K\KBDV6I5;.-AFJ*,K NG M(Y>Z%8HXAC)P^WZ4$:,\.8;4GWI17+UGQ:E/H:6)?N7*0;IGMV?*476+$:,< M6 YOE,/((9"3FG4']YB)WW372>'J#1]//$!9#+7&>1:DO^;E(\TA$+Y\N:6+ MBAF!N,WVY'!+<9HZKO[="KN4C1P*(927PL9=4TP8%]GBD2ZKA,Y7XJ5:9OL_ M\>O+M'G^5O:'655P]9DS7LG352O"B'NJW_%E4UI5*S?^SS#.+;A*R;/?UW.T M[-\:2^#J%1T\_;R5\-0LS4)"7"8-/&9.HN+Q/,F>+])5EJ]Y76]H$G&/.J]; M<6<.P=V^*%R]N7,]).=F=%\E4=[/IPQ38;79B ,DMHE8L"^1%?L4B;MOL4T> M_Q@<1G#"A#:KM <]6$M9Z;=I%MRWE0 57;SGCU4_5FRANUDK\ MQW&.CF6;HW))%VS<0K*5N'SDP=DP+OG@[8(%XI#Y7.64<8\WBJ3)EP==U<0 D*A6#AWOTP^A.Z6;K(A+<=U$<:?030U7]TW" MK'J!ICW"J%5(HQ/HHE0U*]CH9_LT/E^T*1BDSM)*XNH?&TSI3M3\$XE @9M0 M,?NU:240#J8VT?<@"[SZT8FM2\+5I;M6PS@*E_4H[)*<]_+A]W)^C)01ZZEQ,PS_CZBHE-OV*E6?TS0K^\WVT MY$&IC:_)<\LWC\GQ.:-0W*Q7"OSV/9I7\-2XI+;G4D>DE@O:R/K61=>LEO8D M?S^EJZA*2G()VO\5J%F;)0ZWUE'KH.L)A;-G>WJUW;#J( M1JLS5(.M;I,FEB^!.JE.A*LTMLW??OL!3:-+D.2T\T(@4'-^R+.BN,ZS5:Q< MTO7^C(C)*E3C=N4R1 @%:MOVR$L5;JH50M3.>FSZT[U&-'2;L]5 MJ:7C 3& M5N_$,+:[ IV^Y84P^1;$?;]!WB!OEE0*%Y-&!%&SZY#)QV3UC:^SH XEMIK- MAD0QM+I6&%'[VS%*V51Z&BW_:Z500^ *HE],MF<@@&BIHL8E-3DMAY8&UQI> M$^+ %KP\3+=[,US9->[:B(;-%J#UCQ"(5 #=HZ.PWAB.(G#+IGW=,86[-J+1M@5H;3S=MZ?M [2G\!(3*Z>>5>N22%W4UQ,1 M&7Z\346JZSV]*H[>VL^[SVC[2P_5WF&2+A+S>9'69J3!Y60V92W$YM( UL5, MQFEK(-L"T'0>VRY!'+S1R6760=UQ&JB.W59K!W:.]7:K=]D-)&M:Q D=;*+8 MWBDJ'J_S#/:ZR_ ;3*&?&J^_<\ M3ME*<-O^56@CL@5;@)[8OVU1X?L74$*N5/8_$-[P%"5@GD3VW/$,J>KA*?J( M^G@KV-+SW=##X!CB/_3*.2*B)*)8*J#JYUG91)-)UUPF*2*RSM/P3NC2J.Q" M[W@A@8^:K]EBD]D9TU%S+8)HW.F0:8^:0?"(K:F;$,.3#^N);YBT6 MU;KB2$[I)J>+.*KO)R:4Q]&GR]D: MS_R7_?/&=^G4 2^-YKZ,IAN*>R$?7Y MWJND&,K-!TC_"T>D_08WX?VO')'F.^PG^-+1\+5Y!'F$T>0'#[]DWGM5="F+ M=RC[M22E0]*;>F#2Q:*Q9.C 98YE%.K1/A#?9EQZIS+O4\M 9,:WAJZ/A^;" M1T0*!:W?IEBA?G%;Q2_)%Q2BU.U&\I1%6TGVQ%;^K8X(J((4I=!FD(@M";4 MS4%:%)0.:]JF!?J4+FORP73.YOU"W%A5=>]6!2'J[-WP2Q6E]MU8]O-LB MCTB_4")*K6\$A_(P=_GV(&.)(5^"6A+!$LH1H.0T[F6B!_G0R1.TF0_[+_A^ MVF2I$"Q&>3EW* ;1B-P%O:F#1U<&CIJ885$@J5B)I"LR$ . A74"E=M'MCV' MI*/P.[T!-FL@ZE='H/(+1_RE*06NS%=#H@[N.$A; M4$<]!%9U*[CJ(6C5QV9Q>9)@_@3B-H96TD8T#K< /%6K"NR1:4+@LX7X5E M/AQB-!.[J:9F44 MIXI7#LSB6/K $:4B3LZ@%CA]OFP+Q._/L_RZRL&VEW=9/T'X["&G=!R>L[]2 ML?3U?BNCM)Z[EAXT?8$ J7T@U2J,:6:T8E2G-:AG/PB5@G=3F9:8^4+VR_NH MX&8& D%X(-<, G<>.%_>OW0B]9$CGY#K1R=[.1K$%*+MSWU^!,%X/WS=E/PY MOH=R2/];I/#5.B,9R,0^JGLR^;..I,(^'(*3UH]@,E9>Z'I*P/10BIK3#P6]?V8N_\WM_G7Y/)/D"M MM^%YX4IT@:WJ_A!:=]"VHWY_5]=LI_8KYM?L?\ M!/:;_P]02P,$% @ RG2O4&&S,, ^.0 $18$ !4 !I;61S+3(P,C P M,S,Q7W!R92YX;6SM?>MSXSB2Y_>+N/]!UWN[,?>ANLKUZ.GJF;D-E1]UOG-9 M/MO5/7M?.F@)LKE%$6H^;*O_^@/XD"B2 !)\*),N;FSTN&PDB,P?$D@D,A-_ M__?GE3=Y9$'HO-J^G-\?GY#Y,P,'G__P[__SO_Z7B?B_O_^W5Z\F9R[S%K],3OC\U;F_Y'^;7#HK]LOD,_-9 MX$0\^-OD5\>+Y6_X/S]=7XA_II_[9?+AQW?.Y-4K0&>_,G_!@Z_7Y]O.'J)H M_?OFS;MW1S\^ M+\6@3YQ(_$G^3OSIS0?QGZ,/MT<__?+^Z)/+_)_B\E M_[OG^M]^D?^Y/'U\G?\V;5EH^WP5>_HUWK_/A;'L6?W4U[0LC"=U? MPF1X%WSN1,F,,GYFHFPA__4J;_9*_NK5T=M7$IYP\4,N_$2" ??8-5M.Y/^* M.;+]ZOF7Z>?SR\\GY]//E[.;V_/CF_^XN3W]JU;/Q: !:OF!]-_<6I M'[G11J(7K)+!"X:2WA\"MOS'#W*.O-K-D'#Q+Q#::+,6&A.ZJ[4G!/2ZHU%_ MPNQHIZPI3MW(YNQ0_HY #=.^'#F\2(^AGG++AW?/?/!&"AYY=B.0_8;/DI#EV?A<81 \G[&?MG+C;Q8R[4*I ? M_^+XSGTJOBNA;,:Q \E[FA_Q:N4$F]GRQKWW73$A';'.SN<\%@NM?W_%/3%% MF7G"6/72#R?7[)'Y,3,-M=2LG[&K?/,0C&$ M*^:+Z0>8#4#RWF;(R@U#'FPN><3"5S9+ (2VGU%?, [=)8&-3$AS./H$-U$QY^/T2/')@#WWNG;"QUK4]\#X*&RB0O/_]"S9<-07* MB?^$18[KM3WXEWK!W$. ##7JK-<=!#CP^M8'\PT 1VFF/)"G "I5 UWO>S1P MG&J*P^W2P*$"2 \^YEOV',7FFP=X#TA>$2 $MOV@^$C@O%CT(!KB65/?5JU0/G7-C[ N(ZL!G9TP)&]M1K9VP..[)W5R-X=<&1 #='1'/@L M!50/*#W.Z(%BM^RF=V\K6/8JBO[/KM!3DYKD8&,TKJ0ZFH.-TKBJZF@.-DKC M"JNC.=@HWS<8Y?N#CQ*X.)DI#WZG8;$^P7HXS T'V-.C)=.-=1VP4) DH3H7 MXA=[) (TYB_8(N](CK'C*$/Q:]EG%A]Z-'DUR:F*/SK^8I)V,2GVD7&2\^+Q M^=[P/1F.R0.3].1O?M>-=7H71H$SW\8)>,X=\Y+N?Y>T,-+7308K11T*62<1 MHB&;_WC/'U\OF/OZ[9NCC_*'5_*'5V^.LOC0?Q&_^CT=Q#6[=^6W_4C&Y-8, M732M;UD>:7&*3(/YA <+%@C(\CZ=8+XW,:HAK5F+U^LDPO'5_,'UMG-J*8Y8 MMK+,Y,8-C!3%*X9P> R.!2>!XYT+'7K^/VRC Z'2%(C"$3T8%%RCX# 57"PD M)V>>\_F!.<^@N945 O>G5K( KO M**%@XAT%D)R76]%O/0C[+8""?T])\'4\H@K[B@4N7VBGOJ(I4/P?*(J_EFM4 M'%)53,=U)GX7ZK&H:0[$XR>*>"BY)X")7![!B!0: _'X*UT\*IQCVJ?ICG7- MUCR0)]TT;T]KIBHH@+C\3 D7B P0P3ES/18-YY:2E.@1*#<%'-WH0U+*,"<$#\[QCOEH[OE8']MM! 2!X>*YC&%'^ MIRL6W(M5\7/ GZ(' ! * B@BI([5 !$@0G/N1TP.W'UDPN!VLGU,AXV* @H. MJ=,V1 B8IM7NIO/F0<@@G,514DU"S"2M@:6E@R)%ZG@.%PBRM749K^Y8H$.G MV J*!:FSNHI9U'5LS@-A?"=#3W+=CV5$7R!FS$)[;V$@A.)#ZNQN(9(:R/[^ MNL+IA?C%P2[\ZFMN[-WPO9V\FFP+&HB?,Y))1M-T[N53;^F$=PE<N;X8D^MX5SQT#1> &3F,NK%JM6=O&H9"OF9& MRNVP+@.MY+JO1@I.NEOHND(CLU:@H%2:HUT1ZB5,F)*$\RC]7?))(9+:9:'Z\)*S#^T [>*P 4Z64J$!937M"8*?G@KM MTK$!:!#^:2 U73Q*TRJ\Y=/ETO7<^KO(7 1UC=%N(YLHDYI;&G! MDE%C%,W1+B0;0*+EF 8H>^P #3#$6\@F>E''84'XZSQ]X"+E6CG"9'@1CQPO M:8FL2VGVHLS,CHHIC)=,JU(Z*K0K3!MK&L(X#FSE1$/S"J,&^X%T-'@WK$UA4*)(VEFD+#A09<#LS@!U M@G<]"X>FWK%A(2,RX)8K,$"P5-+@W=>V@,X@ 1I(W3SP(+IEP>H3#P+^)(PM MC153VQCO_K8I-AJ>:8"R;_CF_&V,*F2BP[O*;0H53!(T4+/9N-KL3[VY0ZS1 M 6U#0S\S7')_WL"PK".#(MR;;Z0[VU(M%1K*J%@X=L.V7D6+I% @>_.?P) MK:55D=! L, B2.$L[I;IJ]=+64_.PM 097/4;6_]NV4J& MS@4;J)=,20"%C*I+Q2")MG I*FG4EJ9B0;WF2 H= 12"WGP?)AER&!^$%>38 M"8*-T.7I2OILSOVY%R^2^L!!(N0H"MR[.))^G%LN]URA^=(U()HDP?G/I-#)/Z[BE@<6U+,CFL\6I$_C2;3N= MS^-5G$00EMZ=K*(#H87BU9N#QAHON$1H(%AET&9+@B/4F^>E@\WGI9@9IEVY M>4"%1?PY49,#*IM.YP"IO+7Z9YCWDMC>:9/8)G_9Z^)_C$EMO;-W6WP 5<-( MULZDI)4IWM.*W#CDJ[-*A4!A^$4_/044 MCCTG#&?+9!&?/KL0,*HD0\2DRD4A%1+S2%88UPE?"0-8Z+S.QXR?)M_GSMA MH,V"9!XO$F_!%0N2HB10KY6:GDJ^?&4'UKJO3/*@<0;?'W-:168:1P\\[VZCY^PT+WWY;11W.V9B+#3ZLVBAW!!74G.PS"V M59"H]B;#2!B[#1[,&X6 MHB"''=Q4S9% M"+8]85]D;/D3A_\L;)K[BDI\[TN7&#O:"5].=M23OWSUG7CABI4>\RI#UD1< ML>T@S;<72@+4.(#D97M90$A&T,KQ_.9&#\=Q&(FQ!MO@+YG(+OY_<>L\ZP(# M&G2&[)\PH%@)$F@L+AIK:,: QO.^:X'MA6@$S8L)/3SF831;?N9\D=Q[L^#1 MG;/PAGM:0T1-@^W8L$/3S#T-??H<\#"\"OA2%S"UUPC;?6&'0PU_0U>L;?96 M5@8,4(-60X+MXK"#T\@[#:VZ84DX^6?FB^%ZLEK#8N7ZR5.:LK!^-GC-[3&0 M'MO/88:#-^*+%):.YP1I\-9OSKW.\JBVQ/9M6..CX)4&$M=">&(,#V)T)\)8 M\GA2I\VH3 8R;!^'+48@*= +%-W,=(O3O"-%9@T+GVU--C.CH;+G89_&CB= M,"')N9O*42S**YDI]>?>J^(U!8AU1-A5!6V1 DB !E2SZ($%.5,:@V^_&7JQ M05L\:MDD@D"9%0NSFT!90&LD5.R^F&-4>@*YX+4O$I:E4&R,7B"P,995EH>. MYB7W^3YWF4S,AV, *7K!0+M3,E@8-%;4<_^1A4DAC'2P>1:V[B9"18%>'Q N M>PYDB1)4R;Z<#M!@?.2-T(L"-@6DAE4:&.0SPWB4JC1$K_K77#EJ6;;?M#ZF MFY;/[F6<#>%MJ\%V1:!N8%-\C6(8O'G"(HB966J&7B6P,9YU[ X=P_T8RQ/W MT5TP/[G>2[:*Z>(_XW0#UP!LTP=Z:<&FZ-L+Z@4LY,49/WUT7"^M+U0(>\JR MOC\YH3L'+@&0CM!K'7:R2,!%-O1E)*_/DZS]YBGRT3A@J1QF!=;MH?>BG%MFCR3L30DYHE,8ICI-,%$R7%/94]NXKMP'KAK*9,3MI;U^4*EJ"6%C@ [ M&\5*X"9F>CDU$2C.;%(D57OLW)0FVJ3G??C8'JAL,WYIJ!XJ]:Y9X'*Q]3E! M1 !(> F"YG4'$,M,J4$N MUJIYE#OC4_M=]2*)I(828Z>3PFH'VHD""X]TVC0%)*?&3B#M")%]8=!8+[=Q M2?L^"?5"J"3 SB %KW &EGM2E>U7TZ?[C.*61 8:[$10F%J &*>A##H[*+DR M;F8J9J38V:"=F(-[8J"/VB5[2O[2T,@OD*,GCW8"7T4>I"%,-\SF&%;HT?-. MNS'#.T=1Y:/>#:+&87O-YLQ]5);HAA*CYX_"MC$[6: DIW(V&(O>EAW)&K1 M'WHR:!>P 21VN.N?^L%H3U#6O: GA@)1:R8=&IM96F=-G^)4;(.>&VI17[W, M&0V)M[N-^?TM@9S0%ACVKG(:#'K-S243 MEU#(*KWEXE#"_;GKL3UFA?TD9"2V;FGP#G2&)43M+CGM7GN.;RV,JVF-' M7!QP7NA%UI/7XI.S.&%WFIH[LE6Y$7;HPR% J>.;T@E9L!HP)V0G+/W? G/' MSMJ-' _T\ FX#^P8B@,JHKUHA[]>EWD^21]322X'KYDGBY%<.8$^HLJF#^P MD 88ZR>)66"8Q6 4JW]5"J>KM<JNER/JM9[N&$CM,I6MDE<)Y>>NZ$%6Z0N6L6JSG=;38(3"=K^-J 0V_ MF%>5UZN K1UW 2BY::)$CZ;I82;42^PN3>43##S/D_HL9SPXN M+;I$#P]J/1-:RY/&M.CR2'V8*P4"04JM)T\?4A]Z[4C!?>MY9M,'>M#4 ;U9 M]K)]H;,I79$M+T2;]$4G_,OJ]KRAS(9_1A9,SQE;A-)_5W#=;:3O7QOPIZ%" M#S]K 6@E1- H'1KV3'&D,D!8VE_;3#U]#AR %#T,K1=$M7*B 2N<[RZ6<0JO M$W0%M+WDAK[U2W:G_D+^CPRE?70\:6*EF39ERUT]6^QZ07_/H,%VWT1.+W-N M3(6*!,%&:(,JK48KL@HY^K,%G1GV90TP&B^#U_EXRZ&LZO+ =<_*E=B?/CG]-0W=NL\LQ :K4M^AL&;7%5L5^C<-CI0;/@WO&SJ&:Q MEUPZ41R(0^:G.'1]%BH2A?XZ>379O>$@_E'L9>+XBTG:CTP;VO:$^&AH873' MW ^YYRYRAJ\*LITMLQ.7X^U2G\Q;2D?=8[ZJVH:#W42X%7/QDZ?UWW3_)>0$ MJ$[G5OD%V)Y@(;@,?>;R7H[[:4:L?+ZUD@M!K;QFC\PON.B*:G?T MIJQV>6O,0OK)".0%E%@.$VA^"LCIE6G:#K) S'BC):RXF@/JHS>O:T\6UE:TSI)@7"#L]'E5$9 M#G&:]ET>VRJ?,1W4= 281S.C?(N',3/7!.?UN2^V2H&KZHQU]*X\HXL4F*[[ M=!2;W=@@Z>D:(M1[B,JX 'N'G@IYLP#@4[F-, N!H )=!7S-Q-8V]1?R;GLM MO2_UFO2^K$DY:>( W!&CQCLF Y+.HZC(D%FU *2X@9SUH[-2.+M>D!40C&4U MEM-:5 35,G.[A%?.)MFW_87X31"S//=2L=M]*.MHWL\DZRC1U:RKR;8OQ)F= M#BO,&70\P+E*2X29/U8"+15S(0M2##A)IB[\:H?6<1Q(O0 HS$JPSF37QR3I M)+EJH.'4E,E*-D=/57O4FIMW=O:OD@!9S?185(IE:KDFJ$E)QK]BJZI$EF2- M\695.@"S0I3;(2I".I39\H*%(6-6*@$@15:.>CQ*2@&6 $'U*#PRJG@X;D]C M*C$C!?K)MH-)V@/>G$S?;3"K4;D=JI.E*'V0/T5!@*PR];*O^$FTW))4E&H^ M;E$UWE;B.E**41>Z>&Y&&K!66XM%%T/0%VN)$-2@0D'M>GOL;24:(R&9Y#2( MQOYV4$EBOO1;)B+*SE/'/(S"Y+69.V$)R",H,*>@;;^H[QH#A_ZI.'3(.:EM MQ]CGJ4[F2N5)Y4ZD37!5D+NDFY9>DDFN/ GV9+XR;/EM)4BDT$/B5=SO S&G M6_#LAO,)&[(2 $K@&T_R K?".=RCGB9_R7_"?.SO!67W"$O,#6?+TN@VZ7\!R@BE'UIVCYU<:!2OR%(B M9&50H43)DU !6[GQ*CQU E\8W,G@U5A"Z;%?YK,&TTXP5,#'P7+6-O&_QAA+S+KZ"_QV<_,;H7,HWIHZC5!EW6 M@>3H#^W9 FXE%B)(RM1OF>"6>%+<\-MQP!9N)'_2'4XU1.@O\5FC9A8!#:RV M\>U@15-3H+^=9XN2B7D:$"ECG\&0P7O ?J_.&D);X=" ]%I(58Q!+NPGPM+S M>#+D+'#;; $!B+%?I6M@V(!%,OP2;]*(%Z*1E6B3VP6P)AL)L=^LL\8=* H: M>KN["BI>%J7WJ&+BGB>;OOO(DCHW)CUNU!GV0W3V14>:BXP&YN>KM>,&2271 MX,0-USQTO-GR@OOW%V+8B^1I)/@QI5EOZ*_.V9M6+:1&!/>\#J6%9:RB0'\5 MKH%IK.>^+4:*O(S?G" 0AMQ&6@/!(V!?E%0F(O27V.#2A[!#24DNV5.!N8#[ MXL=Y5NO-SBUOWQ/Z&VG62M546C2P/A,+>E(3_0MSY#78[I0%!MFB"_RWRVS1 MM98/PUJE-J34K$1%4PT(U&YTJ5E*""W04U/%%E<.YF3^P1>RQV7([PDON MS[.L"0GY_I73:W(XT<<#TI(N= MU\T9B"(JD_5U"EE)/S:F[%/0S1>0N[];_^7@[/?$.BKLK!.;+'X(_P3U+,VS MUFE4)3TY):&@-D/-[)>I15 -41(,)HM?S6U/CN2=*M:\0)6M_;>\,/--3N8V M'6);#WJ!U&= MHB/Y$5398M$*G9;J2U=0T,MCSPG#V3(9UVZD@!.)D1"U4DSV$.)M\56)NG(P M^^U,6E69C[TH%Q"22BV8?5Z*0544H! JR,[%CR$ CD);&I#43R@5 H7A;VUI M7!2F3TZPN!5?F3Z[&@!*S08D^]+("T=2DD9/@GW"/P3>9BG@X]WUJ;1> M9L6CB8SG2X4=AO&J<%RQ.J-V\QWL4C%*.U1Y:NU2OM1\D?4Z6>1M*H[LCVYV M5=UPOMCVC7W3T&J2-!-D[Q7([(G]U^LR"N1LFDP^JR@_3RI%!#(5\HOC.YDYER1#GK#(<3V%7[12K3/I;)+UED0>[OK[-V?-P[^% MDZ3;R5^RCK_[>F2*E=\ BYQ9L>,9WK2U[60PU<::,$=ID[B6D]]GBSSO7' > MK^+D,OR$+07KVNP0,RV:!=8"F'(E!JB$[,^"'].5SY>9&5E;8A7Q=<[U:ELT M0ZXSM-42P$17E1[,@V^2YS1*(9V-S*\MLI!DTBJ;HYE+[7'3,T9IJ;V4$4@QKFJ,>EKJ&3BF. MGNZ13I_G3 8CGC$A),?S-MG'+]Q5K:LIN8?7TZ">D#K! \ D*36J5'/.RI!H M5$E-@GJNZ52=3&*A@=[N43C]C=.=]L;I,I91,-EUM2X$MY>OH=5E[GK.] G& MRYANESR[8S_4C%-^$*V&-+5)9X"DKPB40@C,9UD14MYUYR%ZV7-V8>Q%3N$Y MN/*AW*H+M-K1G=H53<1&>>5(Y]HTCAYXX/[)%E]]@4*!R<0?F84_L*O G;-K M.:UG<10*'A=">)DP?F/N_8.,G1!G3>>>[9%\8O>N+V_[LG3A(]OE!FN4:/6P M#[-&X8)/0RT*I:27YP):_UZFZ*85I,4APHLEFY\Y7SRYGJ>>MY;=X)7<[GIF M-9+?8>H[G[!P'KC)#%5=X6H(\*IJ=[IAF65"1 _SDN"GS\[*]1,QZP',)Z") M$*] =^>Z!I,1P6#$K$2J]BZN\@SJMO0O@8NV[Z+V[[#SLML5]1WSL[%SA ^7 MGQT&40$!\:^R],6O9-'/13R/9L&-V#>%':M(S19-ZUL.0?+*P?>2H&TC=GF4 MSD84*C.K=\.O:XX,@%*V*@CJ>&B9WJSR_3@>"V5ITE";MEIMAG;OKI=2C9M& MP>'P;]"S74ZS#>Q:#"6GL\Q38Y2*#'Z.W87T-] Q@D]2XZ18:%AK$%?>PA = M3*24R^6%2=C'A>K)XL 9.O,TNQ)@&)LH*9A? [6(8:",IC 5@^S@IG!GBOYI M4_R+OHZ131\#0LV&+1H5D/:V(D/]HKJV-,"QGY(:X/JUO/_I.O[YR?F%$[+@ M?.7%Z+B>C5X%?,N"U6R9NSL5PBTW0@V6;B;8>CY[$NH5"V3D MH5BJMF^[G?$@\S\DG@6%H"&$J.'.S80/EP>-J\3"14"!4VWFH(8$-1[:'C S M0[WZ6#">-JIC\SA]%DZ-N)X*-8JZ,>@0233&?<&6KN^203W/DKIR-O)(9HD^ MC!HU+KKQ++"1#(T%NW;>6JHNUJJA$#Q> X MOG$\&:&93S3MK6#E6>Z,?+*C;WDCJ#@65X9I<*-IVG=Y6J]\!N;D,Y-AN?@, MLJN>SZ$2H+%29:--8UDON<_S>C4:TT%-@NHD! N>0]GIU:]5&:[ZF%3+G>VY MJ!\'HJW0]:R0W13R-^Y-%8PJ[\,7"$E$AN3CV=@\/ZTE0LU2R,9U[3Q]$=9% MX#I>$I$6K]>>UM@R4R)?*0%PJJ0CP(1!8]_9CE:6-SSWKP(N*T0 "NUQ[YU M;8%3+>?$T#ES?3=\8 N9,@9!I]0>N_9]"W1J.2>&SN= 6VRSW Z[;GP+-/8X M)8;"=/&?<1BI[M/+G.RU1KO-:H](#=?$<+ED$),F:85VP=0>AP*7!.UFL;N) MXU2TD6\X_!&[:SE?M ;TSV4#.N\A>>9@VP<)6SH?FDS,CXH3-XTTQTY'-0@'Q0PFKO.3(AT+F; M55E:>RR1JR\+>P>1^V?R>R5KVGBICKZ ;4V )T#70K6/8:;V,IR21:T+44^% M;;"T7P_J/8L#+=2AY/)KR):Q=^$N-7XN$#&VH=0>\*HHAN51SD)/ZAW+'RT= MRY.LM]'!#+%[ZU"!1?Z!*)%M*VN/,I@Q2L96T1A03ZS]5J@!?S82YAHFR*YU MI=PA:9C-YT',DO?0_5 ?B_;^37G%R[N;9/TE*U_6XR3ODL;-6CK ,.=81C*9 MESP=49>+G1$6V,IGWPWV,FA&I;@ -A43C=50.?H+U[ES/;=)8J.^$]2UM#%8 MVFQ'B-1(PFV++(U@['Y [!@O6+7X['F"\-S/BM:?^T;N%.ML)SVC%HIHBVMG M4G@IWH D(ZW!>FZB0ZU.T9'VPV33URH0N!'CRV4X6S96=ZLN4$M+=*+7#21& M9LN5@[L1*U&PFV!BU)?ILDW26'V&V'X^D5"?93M#'FU/&BH M[+D?,2';")(*ODW_4))@GU3;PV:41U\9^4P&-B5GX70 Q:$K-D(##?:!L 48 M .[(FIU70@YN&,KT*!ZQ\!7TD8?W;\LVYV37U23I*WD)C=I[#R?L+K))Z%>U MIY#F,LB<(ST 8Z(1L006PHE&XXL.XXL.XXL.34VXT^!AR8/HXN)8&WA?;88= MO0M[O4'%'N:-C!&)F:_//:EMB1U-:8M'ASBC_^XOXTO_BGKRR"TW37-48 MK02HE7#UK/8DWQVBMT\<.&T++:'+2&]AW[;SML)E_W(5[: +PEY;J&Q[J])A M+=LJI[U+]XS' 5"XQ:90V79?X;FA;*M\]B3:2V?%9DMY]'\02Y%2K-5FY//! MZH=-R3$J3]7GOCA+QY*1K5M0,)9PM]@]A:)W=4#[P#8"P2D<]H*A".@7)XH# M5^B[&#(4P'V:P219F1FG =#-@UA>Y?-.GW@0\"=I>6F<0'6-L0UW,"0:5CL^ M3@W &ZY+G7K_KKE3G$(6U>@<'YWCHW-\=(Z/SO'1.=[OP96X<_R0OD-D1SFR M[["?RP" MYXPM0ODNUPE;\]"-9OX%=W15,$'4V)4 ;('A#7BDA.G!/#7]Q/>V1JP/]TW$ M @K9B43=WOU$#+>>"*U\X0/-7RVN4==LG2U>LZ64A68AUU*AABJW7\ !$J&Q M<"/=@?23P=JQ]AHN1EZ",_Z".:;"/>_+_O:4AD2D>3H4LQ.]W XSV3]_T#$9 M4Y9]JQZYHCGR :5>[N74?1VG?16:YI'C&22;%&2NML-V)>EEJAAT6Q,SZ9'P MDG14OR9],*Q)DZ-Q5;(:\K$3/IQY_&FKL]-YY#XFI38N6!@RP$6E11=#6+VL M)4+#GMM?='-' G1_V;7'7@WMQ:_;?,IRH('55/ 1R23(0F$;J+9!:+$=^2 ] M@PN!!FC7[OU#-%M^#5DR\MF=V'!\F=5]^CQ_5MOO_QDLE_>CO9+LVTO+V=D'KV&9 CVB9'CX?L5]W6_ MM%I 39H*&;9E8P9.9\DHI$!C;U0LUN9"A@8Z;$.F'60J.;PT!=WR":F8!R#% MMFLZ0EU;&>]E 6\--_[;8AV!W(LGKI,2IDQN&&PQ%7/'N6?;$CK)\.6%M2%J MQH(>[>H'[$"U%@;%;=7(Q!%4#2$]H18MM<=+IZQPP1&,(2P-7AX>93U7&5A@ MI\'UE$"8_TI&=W4"&(#6%H>?A80TU-K:GH!P=I\_;8N4A;YJ1/:2+^7?U7N0 M_FKR(+T;/4@MU#4\B^4SUE_$!K&*5_GUP4D,\,Q;=S0H;Y.=="BNQ/6#3ZT! M(>C9\DRHE>/]!W,T+X.WZ)*,_\D22OL)H97I<*:&$,:Y?_O$Y>C!-ZF@KLCX MM7J?"K4R'-H4D 5T.IL$A<[(.+H.- TJ-=673RBMM MA?_OJ[_(CB?R196Y:#I=R7_I3-]&W6$[V;J9.JUD:3^1J+WP?G#W>??NN1Y7 MDL$%>6C+U?QL.J@3J$EST..ZPL&9]@U+Y56T)7V0UHR[&R-(]8P$CY-( 1F? M95IMDD<6U.U1DVKULN,@!GH5]/XB)N\3Q/H0S@-WK7C"7%*9B%"S8L$BA[%. MW0CCTG#&?+9#'1EQ+3D P1DRH7- J%%<=E M*A16UY88%JKY54Z'JN&DG[I@-TR^+/ME?S_6UD[24F!?MZBG2]&" C#=D]F: M?OG"6MP*"JBX2T?1%GL)5\R&XGJBY7+X\=Z)!&[%5P"K MT*X9#5V KT*[D1=N7%&+J@G^/CDA6QSSE8Q.SR07R-S(Q+7^:;-KD[G;$TYV M[/B+*\_QY<,:IJ6LGZ_1F .U\[=2PJT/_OM?5$TO0RG:8@<=]#FY52NS[GDI M*H'>>^,U/DZE;(T=8H "K_:%*XH &]_'4C7&#@/ @%?[R!9)=-U'N/86&V-G M8Z"@6Q$6<71OW&[8R7A0@$;@ X[-AN&'%@ /7F/$W_',KW_#M5A#M5F MZ,_&E?F[4\BS: 2VT"0" TC13Q#0I_/ 8B"*6JK#C5"KDJ(? M#!JCIA)#3RN7.O3'?707S%^H]@X((798+FQU@XN DN8DXY6%NHUEA53MT8]7 M=CJB8KC3AR6H1^+I8JP_O&D2D-:1F.;R=Z8J."8ZM&OB#B8$3"8O WN" M#T3W\S1P!W/B0,]#MWX^7&N7I1>W)1'P8[Y:<3_YA]8L U"C>1':H&S%(3:^ M/1L-21D00VR0:>NLZ0.U('U?)H)25L/?'?89O68+MDJJPI@L Q,=VB5^!_, M)I/A8W_@@(U^RMEWI_-=QG"L>>A&[B,]D,'H@F']. !87X[.GK!D:FE<-+L6 M8)<,103+C X?NGTI_,IE1;;DO4 -F#H:O%25SO?8.F&\!,#YG+%%>"8$EZ?; MY%9DC>!TL\"R(^C4(.FI:RBVH9_4$F92-^1)' AUN&*!R[,\D6LF1.;.HXSG M)-7K<\!#;:!2L_[P[KLZF#OMA$@P^.,REG=YLV5^MZ<*>Z]I!P62EB=.P0Q9 M@':3*O,>95,M?2Q=@9:)" H=/?<:3!P$<4SN -/"H#=L+M:.R&5J22APM>T$ MBC,M=UD33I47J?B9#5N?KZZJ\(>C:A*#)!S+"'^'V0D*02HLDC'_@$BL^P7= M_(-T*LF*#]R7-1Z .0CU9$/$IIX3&KD(I;&9@CL5S8FAHIMQ)9 4#)&(ZBQL MWZ; SIJFV$GTVIE5<6DK.*41G3:F4BE3J9 #T\=4JH-41%<>?B"I.D;B067M M $716V3Z=J&$QJ*K"082?6[BF,H>(4;XP#TALC#=^JZ9C*AA:2#NVG,UQU80 M,7(4NA&&&F\U3!XT "QP>.4$LR"-BOS5\6)V)2/HA8A ]I>:&#G$W!) "WF0 M S#US$[CZ($'[I^UKNHJEU4BY!#PYH"I^*$.>YI:'YE$8M M=XGEW\]< 7>-'8G=V52Q%";JXG##HLA+AB.#@U=KQ]\H$ES@&J+L$SN@NOO% MP""^PT*;S+MND05VB1WMW &P5L(CH[+3^5S:I.&5LY&7JU-_(7X3B':GS_+5 M$^7;$+U\"3M4NE_U!HN:BM)W/#=:?0@[%+O7!>)@,Z,CQUQACE^)(PO #ZXA MP0Z^MO7#F9@?>@)4J?A*X7TJC>]&2P1%F(BW#B &GJX/]""KZ%2*..,.5&L MT\\&74%1)>*,:RPL&EC?.![+O(ABI*$K9)M(^IK-F?N8E$0JU G5+,26_4!1 MQO:V-61/"3%V/DS"PBPY[X?:A)BWY828-!,F(R61$;,;7GH6RE]3S"JJ'O,P M"I,M]*[PEF)HSJ!IVR^%,-U!9MQT ^B8H4,UA/JB[PR=,(@*"(A_E:4O?O7[ MM7QJ51&Z+OY>^/,09+P_XEXR:N!25<9"YZ.$QCOW+-E]H=4+-!]J'WDP((E^ M<7UW%:]T,BTU00O6*\NL(M%:7GJQ@&&B=9Z-HMUO@A9(9Q9M'2]$#A>FQZY5 M;UV?.6Z0N+6FXI2<5N<+I<]*WF+_RH4QX'HRFEJLBP;74-\?)Y\_<$AAD)MZ M=V:&[VP8ED=ZC;.JSV]BO\!D-]-Z%3RA"=:51EV[X;>S@+%B2>H#K6SUGT;+ MTT!=V'0P]'5YUN7XSWBP9*YT,BHF4'*+U.<7T2Q0JX2Z PC]!2Y2^6*?J37C'CK^X\AS_TEDQ4Z&5?KY&8P[4SE]; MBZ<1_R1*4IVNUA[?,%8P;$REJ30DZ'Z='M6B7&?,)+CA9RDV-O0S(W<61V'D M^ M9+9][GCA:RC_V<,@R?._%N[5!\A[X&;[*8UIX^R#3*?\4^?6MW0SI;3KN M0]7\H:(T>2!R@FCXJ^-GT3 *S_TT[-WT/D(?'T-WBP]I-FO@(K*RZE)MBGZK MTV<6S-U05\ZE25_HSO*#SJ;&PB8R65H*:W=-$ J#^?1Y[:81Q%L%Z6\I WP: MW94^I(4-#*7]MOTQW;9]=B^=C\/?LC&-S]_?XM=5'=2\KI5@)P;HJ?^RYO)O M3+YEQQ;31Q8X]RS?LI*\/8G3\H '=_!8T.J2(9[J+8%Z&:8&D'_TV8E8;@U_ MIJ%,^>_,GZ#T7=>>4'O2E2X'@5:G;G#ZTCWTW\'MA$EHN5RP5<9R'&B%_5Z< MUC2: -^!XK1U&."8:2V'A5=!<7!Z=8CY,9Y=#CDI+)Q+/=2%?&D*8"'TGOQ1 M!,.D=\SNA4F_!X9)OQW#I,@R3'L.D:PZ0IADDK,E6_^H\L M%$N]]KW+H%%'*-0)YL4=B\? \,-> M(>L#P[]3C^885#[-/RC&,_'LR-\A+RSM>.+I,@@ALO L:+*:(74R]C M3HV72P,[ZX^72^/ETF!G\UBQ:*Q8-%8L&J^:Z$W%\:KI>S ^QZLFPE=-PY[+ M8\6B@9SJQXI%A+-^QXI%8\6BL6+16+%HK%@T$'T9*Q9]YUHS5BP:*Q:-%8O& MBD7CV66L6#16+.HY]/E]?>CS3\#0Y_=CZ/,8^CR&/H^ASV/H,TW9CZ'/8^@S MQ=#G\6'7%_JP:\2"=MX415#\B1NPN6A\^D?L1AO)I#8@7MVLP,B0^SZ($%C&%Y-CBELM?F4_VO7_X>\EI 2+P,MS%"F8/&'8( M'P%Y&[:CB760Z0Q)E2'LV[T57<:.5^_A_2O0PYMU,OIY1S_OZ.<=_;P#]?,* MLWHN!I;>>%^[X;=/FT_,GS^LG.";WO5KIAP00F9F:#B(J^/,1VER]IHI:< % MG9!& ,OLD?#+IM;2;)G[)\);'CF>R36KI\+V!D#G9 DQB"@(NN(*?H@;]UGK MSZEOBIT490N7FI,A8'3&XP *4K$M=KI.2Y2J;-.&Z?:)0U$J-,4.R&\)4H5I MVAB92BW5-T4/TVL)$JDZ28#USGT$HU1L"X6)ZK94Y9L@3EM3!W1[9WO=<]1; MHEX3;!2\]E78ON#DRQQS&C=74HE=1T'^ML+( :EK!EWQD;V BZLXF#\X(4LN M]W3NH(8=HET"0/&RJ-IB%AP1].5H(6D#=HDMW8>A-,2HPEY/2]R9XP:_.EZ< M?DS,A.3+BM5-U1@M_L-2N#H>R$WN)O=K)RR7(H'V]?!'- MN=1"(WL4/<&@ <'HRHW2V]4D]BP2UIMI$KP*^B.?B MB.O?S($YV8"$B[]9Y9N%Q'$@Y"0%< M_D.]AH,[0#U&-@?6ELU^U[_,92,CO?Q'%D3NG2>.NIFG.K'24D>/:CV$TZ.> M %NNC[92Z@NMU*S5#$,%$X 0]8#8$A^P7'H"YE6GAW*MV,1 EZE&M'306DND)FXMXM;Z)5_F1<,7CVMU'MJUOBE:ALKWT M=;SW).XO8H@/GC0A(\?SY&?S"&&%T'4$:+$5[45OE@,I>^W;^"YD?\2B^]-'R;_6S_JQ MDJ2UI9ZDY"1\JV6> (FX2@H*J3J#3*HR@3"F2Q%+QB&<+E6:2^8"64J"(>&A MXH%&3E3-\(R5K]0D1'#1SS,S0*2RGDKC,Z4[*9JC9_";YID>E&UL4$L! A0#% @ RG2O M4*!2U,WY60 &P,% !4 ( !A0 XML 72 R48.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Details Textual)
9 Months Ended
Mar. 31, 2020
USD ($)
Leases (Textual)  
ROU asset and lease liability $ 147,000
Operating lease terms, description Our leases have remaining lease terms of 9 to 22 months as of March 31, 2020.

XML 73 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Details)
9 Months Ended
Mar. 31, 2020
USD ($)
Leases [Abstract]  
Operating lease expense $ 76,662
Total lease expense $ 76,662
XML 74 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Accounts Payable and Accrued Expenses (Details) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Accounts Payable and Accrued Expenses (Textual)    
Accounts payable and accrued expenses $ 241,866 $ 34,943
Accounts payable 232,970 27,912
Other accrued expenses $ 8,896 $ 7,031
XML 75 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Options
9 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
STOCK OPTIONS

(15) STOCK OPTIONS

 

On December 4, 2016, the Board of Directors adopted the Company's 2016 Equity Incentive Plan (the "2016 Plan") which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company's welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company's behalf and strengthening their desire to remain with the Company.

 

On January 1, 2017, the Board granted options to purchase a total of 7,364,136 shares, all with an exercise price and fair value of $0.20 per share. Options were granted to nine employees to purchase 5,498,555 shares and to six consultants to purchase 1,865,581 shares. On January 1, 2018, the Board granted options to purchase 5,000,000 shares all with an exercise price and fair value of $0.20 per share to four consultants. On May 1, 2018, the Board granted an option to purchase 500,000 shares with an exercise price and fair value of $0.20 per share to an additional consultant. On January 1, 2019, the Board granted options to purchase 2,040,000 shares all with an exercise price of $.20 and fair value of $.51 per share to five consultants. On May 1, 2019, the Board granted an option to purchase 360,000 shares with an exercise price of $.20 and fair value of $.51 per share to a consultant. On November 1, 2019, the Board granted an option to purchase 2,000,000 shares with an exercise price of $.51 and fair value of $.51 per share to a consultant. On March 1, 2020, the Board granted an option to purchase 98,188 shares with an exercise price of $.51 and fair value of $.51 to an employee.

 

In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility of a comparable company; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future.

 

In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time.

 

   

As of

March 31,
2020

   

As of

June 30,
2019

 
Expected volatility     23 to 24.00 %     24.00 %
Expected term     4 to 5 Years       5 Years  
Risk-Free interest rate     1.55 to 2.49 %     2.49 %
Forfeiture rate     0.00 %     0.00 %
Expected dividend rate     0.00 %     0.00 %

 

The following table summarizes information about all of the stock options granted, exercised and cancelled under the 2016 Plan at March 31, 2020 and June 30, 2019:

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
 
Outstanding at June 30, 2018   11,636,777   $0.20 
Granted   2,400,000   $0.20 
Exercised   -   $- 
Cancelled   (589,132)  $0.20 
Outstanding at June 30, 2019   13,447,645   $0.20 
Granted   2,098,188   $0.51 
Exercised   -   $- 
Cancelled   (450,000)  $0.20 
Outstanding at March 31, 2020   15,095,833   $0.24 

  

The following table summarizes information about vested and unvested options under the 2016 Plan at March 31, 2020 and June 30, 2019:

 

Employees/Consultants  Unvested   Vested   Total 
Outstanding at June 30, 2018   6,825,181    4,811,596    11,636,777 
Granted   1,800,000    600,000    2,400,000 
Vested   (2,305,527)   2,305,527    - 
Cancelled   (589,132)   -    (589,132)
Outstanding at June 30, 2019   5,730,522    7,717,123    13,447,645 
Granted   1,598,188    500,000    2,098,188 
Vested   (2,665,526)   2,665,526    - 
Cancelled   (450,000)   -    (450,000)
Outstanding at March 31, 2020   4,213,183    10,882,649    15,095,833 

 

Unvested options will be expensed under the Black-Scholes options-pricing model when they vest. As of March 31, 2020, the remaining options to be expensed when vested over the next two and a half years are estimated to be $517,513.

 

At March 31, 2020, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. The previous five plans through and including the 2012 Non-Statutory Plan have a remaining total of options vested and exercisable to purchase 13 shares at exercise prices from a high of $13,500 to a low of $350 per share. The tables below summarize information about these five plans:

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
 
Outstanding at June 30, 2018   13   $1,210 
Granted   -   $- 
Exercised   -   $- 
Cancelled   (.31)  $6,083 
Outstanding at June 30, 2019   13   $976 
           
Granted   -   $- 
Exercised   -   $- 
Cancelled   -   $- 
Outstanding at March 31, 2020   13   $976 

 

Vested & Exercisable Stock Options  March 31, 2020   June 30,
2019
 
Employee 2016 Equity Plan   -    - 
Director 2016 Equity Plan   -    - 
Employee Other Plans   13    13 
Directors and Consultants Other Plans   -    - 
Total   13    13 

 

The Company's common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI's registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company's shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.

XML 76 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue (Tables)
9 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of net sales by reporting segment

   For the nine months ended 
   March 31,   March 31, 
   2020   2019 
Sales-parts, related party  $      -   $161,781 
Net sales  $-   $161,781 

XML 77 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Tables)
9 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Schedule of components of lease expense

   Nine Months Ended 
   March 31,
2020
 
Operating lease expense  $76,662 
Total lease expense  $76,662 

Schedule of cash flow information related to leases

   Nine Months Ended 
   March 31,
2020
 
Cash paid for amounts included in measurement of lease liabilities    
Operating cash flows from operating leases  $76,339 
      
Right-of-use assets obtained in exchange for new lease obligation     
Operating leases  $147,291 

Schedule of balance sheet information related to leases

   March 31,
2020
 
Operating leases    
Operating lease right-of-use assets  $84,906 
      
Current portion of operating lease liability   73,978 
Operating lease liability, net of current portion   11,250 
Total operating lease liability  $85,228 
      
      
Weighted Average Remaining Lease Term     
Operating leases   1.04 Years 
      
Weighted Average Discount Rate     
Operating leases   15%

Schedule of maturities of lease liabilities
   Operating 
Years Ended June 30,  Leases 
2020  $25,661 
2021   58,546 
2022   8,427 
Total minimum lease payments   92,634 
Less: amounts representing interest   (7,406)
Present value of capital lease liabilities  $

85,228